Les cellules dendritiques dans le micro-environnement tumoral des cancers ORL : des mécanismes aux biomarqueurs by Hoffmann, Caroline
HAL Id: tel-02317812
https://tel.archives-ouvertes.fr/tel-02317812
Submitted on 16 Oct 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Dendritic Cells in Head and Neck Cancer
Microenvironment : From Mechanisms to Biomarkers
Caroline Hoffmann
To cite this version:
Caroline Hoffmann. Dendritic Cells in Head and Neck Cancer Microenvironment : From Mechanisms
to Biomarkers. Cellular Biology. Université Paris-Saclay, 2019. English. ￿NNT : 2019SACLS308￿.
￿tel-02317812￿
N
N
T 
: 2
01
9S
A
C
LS
30
8 
 
	
	
	
	
Dendritic Cells in Head and Neck 
Cancer Microenvironment: 
From Mechanisms to Biomarkers 
	
	
	
Thèse de doctorat de l'Université Paris-Saclay 
préparée à l’Université Paris Sud 
	
	
	
École doctorale n°582 CBMS (Cancérologie : biologie – médecine- 
santé) 
Spécialité de doctorat: aspects moléculaires et cellulaires de la biologie 
	
	
	
Thèse présentée et soutenue à Paris, le 08 octobre 2019 par 
	
Caroline Hoffmann 
Composition du Jury : 
Eric Deutsch 
UMR 1030 Radiothérapie moléculaire 
Institut Gustave Roussy, Villejuif Président 
	
Marc Dalod 
U1104 - Centre d'immunologie de Marseille 
LUMINY (CIML)  Statut, Établissement (– Unité de recherche) Rapporteur 
	
Bénédicte Manoury 
INSERM U1151-CNRS UMR 8253 
Institut Necker Enfants Malades, Paris Rapporteur 
	
Marie-Carolyne Dieu-Nosjean 
U1135 - Centre d'immunologie et de maladies infectieuses, 
GH Pitié Salpetrière, Paris Examinateur 
	
Nicolas Manel 
INSERM U932, Institut Curie, Paris Examinateur 
	
Vassili Soumelis 
INSERM U932, Institut Curie, Paris Directeur de thèse 
  
TABLE OF CONTENTS 
 
PREFACE ................................................................................................................... 2 
LIST OF ABBREVIATIONS ........................................................................................ 4 
1. INTRODUCTION .................................................................................................... 7 
1.1 Head and neck squamous cell carcinoma ................................................................ 7 
1.1.1 Epidemiology, Current practice and place of immunotherapy ................................ 7 
1.1.2 Molecular drivers and pharmaceutical targets ........................................................ 9 
1.1.3 Molecular classifications and lack of biomarker .................................................... 10 
1.1.4 Concept of tumor microenvironment ..................................................................... 11 
1.2 Dendritic cells .............................................................................................................. 12 
1.2.1 Basics on dendritic cells and immunology ............................................................ 12 
1.2.1.1 Basic concepts of the immune system ........................................................... 12 
1.2.1.2 Discovery and definition of dendritic cells ...................................................... 12 
1.2.1.3 Dendritic cells functions .................................................................................. 13 
1.2.1.4 DC subsets ..................................................................................................... 15 
(i) Ontogeny ............................................................................................................ 16 
(ii) Subsets markers ................................................................................................ 16 
(iii) cDC ................................................................................................................... 18 
(iv) Mo-DC, CD14+DC and inflammatory DC ......................................................... 20 
(v) pDC ................................................................................................................... 20 
1.2.1.5 Dendritic cells receptors and signaling pathways ........................................... 21 
(i) Pattern-Recognition Receptors .......................................................................... 21 
(ii) Receptors for indirect sensing of infection and inflammation ............................ 28 
1.2.2 DC maturation ....................................................................................................... 30 
1.2.2.1 General concept of maturation ....................................................................... 30 
(i) MHC molecules trafficking and antigen presentation ......................................... 31 
(ii) Membrane-bound costimulatory molecules ....................................................... 31 
(iii) Cytokine and Chemokine production ................................................................ 32 
(iv) Migration and cell shape ................................................................................... 33 
1.2.2.2 Maturation patterns ........................................................................................ 34 
(i) Concept of various maturations .......................................................................... 34 
(ii) Immunogenic DC ............................................................................................... 35 
(iii) Tolerogenic DC ................................................................................................. 36 
1.2.3 DC in cancers .................................................................................................... 39 
1.2.3.1 Tumor-infiltrating DC .................................................................................. 39 
1.2.3.2 cDC in cancer: teammates of the anti-tumor immune response ................ 40 
1	
	
1.2.3.3 cDC in cancer: opponents of the anti-tumor immune response ................. 41 
1.2.3.4 cDC in cancer : 2 sides of the same coin .................................................. 42 
1.2.3.5     DC as therapy ............................................................................................ 43 
2. OBJECTIVES OF THE THESIS ........................................................................... 47 
3. RESULTS ............................................................................................................. 50 
3.1  PDL1 AND ICOSL DISCRIMINATE HUMAN SECRETORY AND HELPER 
DENDRITIC CELLS ........................................................................................................... 50 
3.2  MMP2 AS AN INDEPENDENT PROGNOSTIC STRATIFIER IN ORAL CAVITY 
CANCERS ......................................................................................................................... 92 
4. DISCUSSION AND PROSPECTS ...................................................................... 131 
4.1 Discussion ................................................................................................................. 131 
4.1.1 DC maturation states: towards a novel classification? ........................................ 131 
4.1.2 Translation of DC “Secretory” and “Helper” patterns into a theoretical basis for the 
use of DC modulators in cancer and other diseases ................................................... 134 
4.1.3 What favors a hot versus cold immune microenvironment? ............................... 135 
4.1.4  MMP2: towards a clinical-use biomarker for OCSCC? ...................................... 136 
4.2 PROSPECTS ............................................................................................................ 137 
4.2.1 Redefining tumor infiltrating DC functional subsets: the contribution of 
unsupervised single cell sequencing ........................................................................... 137 
4.2.2 The challenges of translational medicine and the contribution of window-of-
opportunity trials ........................................................................................................... 138 
4.2.3 The role of the tumor draining lymph node in the anti-tumor immune response . 138 
5. ANNEX ............................................................................................................... 141 
5.1 Table of correspondences between mice and human DC subsets ........................... 141 
5.2 Synopsis of ICING, a Phase II trial of M7824 (MSB0011359C), a bifunctional fusion 
protein targeting TGF-β and PDL1, in a pre-operative setting for resectable and untreated 
head and neck squamous cell carcinoma. ...................................................................... 142 
5.3  Plasmacytoid pre-dendritic cells (pDC) from molecular pathways to function and 
disease association. ........................................................................................................ 160 
5.4  Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by 
unleashing both T and NK cells ....................................................................................... 187 
6. SYNTHESE EN FRANÇAIS ............................................................................... 215 
Les cellules dendritiques dans le micro-environnement tumoral des cancers ORL: 
des mécanismes aux biomarqueurs ....................................................................... 215 
7. REFERENCES ................................................................................................... 224 
8. ACKNOWLEDGEMENTS ................................................................................... 248 
 
  
2	
	
PREFACE 
 
 
Why a Head and Neck surgeon studies dendritic cells and tumor microenvironment? 
I have so frequently been asked this question during my PhD that I thought to introduce this 
work with an answer. Precision medicine and immunotherapy were the main axis of research 
and innovation in the last two decades in the field of oncology. Immunotherapy has radically 
changed the prognosis of melanoma patients. The benefit is however limited to a minority of 
patients in most other solid tumors, including head and neck squamous cell carcinomas 
(HNSCC), with only 13 to 15% of overall response rates to PD-1 blockade, the most 
advanced immunotherapy to date (1). The efforts on predictive biomarkers for 
immunotherapy have reached clinical impact with the example of PDL1 companion test for 
PD-1 blockade (2).  However, this is far from precision medicine in which our goal would be 
to have a complete ID of each cancer including its histological features, but also genomic 
alterations and phenotyping of its immune and non-immune microenvironment. This ID would 
allow us to propose a personalized treatment according to tumors aggressiveness and to the 
presence of genomic and immune actionable targets. Technological advances allow us to 
obtain such tumor ID by large screening techniques, but for obvious economic reasons and 
also to impact our patient outcomes we need to identify the best biomarkers to be screened 
and the appropriate combinations of treatment reaching efficacy while limiting toxicity. For 
example, despite theoretical justification, monotherapies targeting a specific genomic 
alteration failed to improve patient’s outcome so far (3).  
Head and neck cancer surgery already offers precision medicine with customized resection 
of tumors for each patient, and is the most efficient treatment to date (4).  This is at cost of 
removing essential anatomical structures leading to functional impairments and their 
important negative impact on patients’ quality of life. Also, adjuvant treatments like 
radiotherapy or chemotherapy are often required and add to the global treatment toxicity. 
Despite those heavy treatments, a non-negligible number of our patients will present early 
and severe recurrences, because of resistance to all those conventional treatments. We are, 
to date, unable to predict such poor outcomes and additionally don’t know how to treat them 
efficiently. This is how a head and neck surgeon enters Vassili Soumelis’ team in the U932 
Immunity and Cancer unit, with the objectives of identifying high-risk patients and better 
understanding dendritic cells (DC) biology to gain insight on how to better exploit the 
therapeutic potential of this key cell type for anti-tumor immune response. 
In this manuscript a short introduction of the head and neck cancer field will be followed by 
the state of the art on DC activation in general and in cancer in particular. The results section 
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will present a paper showing that MMP2 has a great potential to become a clinical-grade 
prognosis biomarker for resectable oral cavity cancers (OCSCC), with the prospect of 
biomarker driven treatment intensification trials, and a second paper giving a new 
perspective on DC activation programs and their functional impact, with the prospect of 
guiding innovation and treatment combinations in immunotherapy. Another great approach to 
decipher cancer biology and the resistance mechanisms to immunotherapy are window-of-
opportunity trials in which pre-and post-treatment samples allow intra-patient comparison of 
treatment effects, in addition to the comparison of responders and non-responders, to 
identify predictive biomarkers. We will be, with Christophe Le Tourneau, the principal 
investigators of such trial with M7824, a bifunctional fusion protein targeting tumor growth 
factor beta (TGF-β) and programmed cell death protein ligand 1 (PDL1), funded by Merck 
and GSK. I prepared the protocol of this investigator sponsored study and will lead its 
translational research. The synopsis of this trial is available in Annex 5.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Art is about opening possibilities, possibilities links to hope, we all need hope. 
The music of strangers: Yo-yo Ma and The Silk Road Ensemble 
Same applies to Science 
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LIST OF ABBREVIATIONS  
 
AIM2    Absent In Melanoma 2  
APC    Antigen presenting cells  
AS DC    Axl+Siglec6+ DC 
CARD    Caspase recruitment domain  
cDC    Conventional dendritic cells, or myeloid dendritic cells 
CDP    Common DC progenitors  
CDS    Cytosolic DNA sensors  
cGAMP   Cyclic-GMP-AMP  
cGAS    cGAMP synthase  
CLR    C-type lectin receptor  
CR    Complement receptors  
CRD    Carbohydrate recognition domain 
CyTOF   cytometry by time of flight  
DAI    DNA-dependent Activator of IFN regulatory factors  
DAMP    Damage associated molecular pattern 
DC    Dendritic Cells 
DC-SIGN   DC-specific ICAM3-grabbing non-integrin  
DNGR-1 or Clec9a  DC NK lectin group receptor-1  
ECM    Extracellular matrix 
ENE    Extradodal extension 
FcR    Fc receptors  
GM-CSF   Granulocyte-Macrophage Colony-Stimulating Factor 
GO    Gene Ontology  
HMBG1   High-mobility Box 1  
HNSCC   Head and neck squamous cell carcinoma 
HPV    Human Papilloma Virus 
HSP    Heat shock proteins  
ICOSL    Inducible T cell costimulatory ligand  
IDO    Indoleamine 2,3-dioxygenase  
IFN    Interferon 
IHC    Immunohistochemistry 
IL    Interleukin 
ITAM    Immune-receptor tyrosine-based activation motifs  
ITIM    Immune-receptor tyrosine based inhibitory motifs  
Jak    Janus kinase  
LPS    Lipopolysaccharide 
LT    Lymphotoxin  
MBL    Mannose-binding-lectin  
MDA5    Melanoma differentiation-associated gene 5  
MHC    Major Histocompatibility Complex 
Mincle    Macrophage-inducible C-type lectin  
MMAC    Mono-macrophages 
Mo-DC    Monocyte derived dendritic cells 
NFkB    Nuclear factor kappa-light chain enhancer of activated B cells 
NLR    NOD-like receptors  
OCSCC   Oral cavity squamous cell carcinoma 
PAMP     Pathogen associated molecular pattern 
PBMCs   Peripheral Blood Mononuclear Cells 
PD1    Programmed cell death protein 1  
pDC    Plasmacytoid dendritic cells 
PDL1    Programmed cell death protein ligand 1  
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PNI    Perineural invasion 
Pre-DC   DC precursors  
PRR    Pattern recognition receptors  
RAGE    Receptor for advanced glycation end products  
RIG    Retinoic acid-inducible  
RLR    RIG-1-like receptors  
RNAseq   RNA sequencing 
SCC    Squamous cell carcinoma 
STAT    Signal transducer and activator of transcription  
STING    Stimulator of interferon genes  
TCGA    The Cancer Genome Atlas 
Tfh    T follicular helper  
TGF    Tumor growth factor 
Th    T helper  
TLR    Toll like receptor 
TMB    Tumor mutational burden  
TME    Tumor microenvironment  
TNF    Tumor Necrosis Factor  
TNFRSF   Tumor Necrosis Factor superfamily receptor 
TNFSF   Tumor Necrosis Factor superfamily 
Treg    Regulatory T cell  
TREM    Triggering receptor expressed on myeloid cells 
TSLP    Thymic stromal lymphopoietin  
UICC     Union for International Cancer Control 
VE    vascular embols   
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1. INTRODUCTION 
 
1.1 Head and neck squamous cell carcinoma  
 
1.1.1 Epidemiology, Current practice and place of immunotherapy   
 
Head and neck cancers represented 64 690 new cases in 2018 in the USA and were 
responsible for 13 740 disease-related deaths (5). The present thesis is limited to the most 
frequent type of head and neck cancers that are Head and Neck squamous cell carcinoma 
(HNSCC). Four main anatomical locations are involved: oral cavity, oropharynx, larynx and 
hypopharynx, which altogether encompass a heterogeneous group with regard to risk 
factors, treatment modalities and prognosis. There are 3 main risk factors for HNSCC: 
tobacco, alcohol and human papilloma virus (HPV). Tobacco and alcohol are risk factors for 
all 4 locations, although with different degrees of importance. This epidemiology explains the 
predominance of males among HNSCC patients (72% in 2018, USA) (5). HPV is a risk factor 
for the occurrence of cancer in the oropharyngeal lymphoid tissues (tonsil and base of 
tongue). HPV-positive oropharyngeal cancers are associated to an increased radio-chemo-
sensitivity and to better prognosis as compared to the other HNSCC (6). Although HPV has 
also been identified in around 10% of the 3 other locations, its role and impact are still 
debated.  
 
Most human cancers are classified according to the TNM stage: “T” describes the primary 
tumor extension and ranges from T1 (smallest) to T4 (largest); “N” describes the regional 
lymph node status and ranges from N0 (no invaded lymph node) to N3 (worse lymph node 
extension); “M” describes the metastatic status as being M0 (no distant metastasis) or M1 
(one or several distant metastasis). The different combinations of TNM stages are gathered 
according to their prognostic value into 4 Union for International Cancer Control (UICC) 
stages ranging from I (earliest cancers) to IV (most advanced cancers). Treatment algorithms 
for HNSCC are rather complicated, because they take into account the tumor precise 
location and size, with detailed analysis going beyond the TNM stage. Here, only the 
treatment algorithm of primary OCSCC will be exposed, for a better understanding of the 
article in the result section 3.2. OCSCC are treated by primary surgery, with the obvious 
exception of unresectable tumors that undergo primary radio-chemotherapy, or 
chemotherapy alone in the case of distant metastasis (7). After surgery, the clinical and 
imaging information gathered in the pre-operative period are analyzed together with the 
histopathological parameters defined on the operative specimen, in order to determine the 
post-operative course. The major risk factors are T3 or T4 stage, N2 or N3 stage, presence 
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of extranodal extension and positive surgical margins. Minor risk factors are N1 stage, the 
presence of perineural invasion and/ vascular embols, the latter being defined by the 
presence of cancer cells in the lumen of vessels (8). HPV status, differentiation index and 
mitotic index are not validated risk factors and do not influence treatment decision. Based on 
their health status, their age and these clinical prognostic parameters, our patients undergo 
close surveillance, adjuvant radiotherapy, adjuvant chemo-radiotherapy or adjuvant 
radiotherapy combined with cetuximab, the only targeted therapy validated to date.  
With this standard of care, around 25% of primary resectable OCSCC patients will present 
with recurrence within 2 years (9), (10), (11). Only 25% to 50% of these recurrences will be 
eligible for a salvage surgery, the best therapeutic option in this setting (12), (13), (14). More 
than 50% of these patients will die within the following 2 years despite treatment for their 
recurrent disease (11), (15). These outcomes, associated to the fact that we are to date 
unable to predict which patient will present with such severe recurrence, were the starting 
point our work on OCSCC biomarkers (Results section 3.2). 
 
Nivolumab and Pembrolizumab are anti-PD1 immunotherapies that are part of the standard 
of care for second line chemo-resistant recurrent and advanced tumors, since 2017 and 
2018 respectively, as a result of the CheckMate-141 (16) and Keynote-040 trials (17). In this 
setting the overall response rates were 13.3% and 14.6%. It is important to mention that 
some unexpected prolonged responses were observed that had never been observed so far 
with chemotherapy or targeted therapy regimens. However, these response rates remain 
limited and way beyond those observed in melanoma, which prompt us to better understand 
how to manipulate patients’ immune system. Immunotherapies are currently under evaluation 
in multiple clinical settings, with various treatment schedules, and with various targets, 
molecules and treatment combinations. Since immunotherapy is expected to initiate or boost 
the anti-tumor immune response, it is likely that it should be more efficient if the treatment is 
initiated in the presence of the tumor, rather than after its removal. Anti-cancer treatments 
given before surgery are defined as neoadjuvant treatments. Specifically, for stage III and IV 
untreated OCSCC, the ongoing worldwide phase III trial KEYNOTE-689 is evaluating the 
benefit of short neoadjuvant pembrolizumab followed by surgery and post-operative 
treatment with pembrolizumab plus radio-chemotherapy. 
 
Neoadjuvant chemotherapy has failed to show benefit in unselected stage III or IV HNSCC, 
possibly to the lack of power in a heterogeneous population undergoing multi-modalities 
treatments (18), (19). If we were able to identify aggressive OCSCC at the time of diagnosis, 
we may be able to evaluate the interest of neoadjuvant treatments in this selected 
population. Our remaining task would be to define which treatment would be the most 
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appropriate, by the mean of predictive biomarkers. The estimation of the expected response 
rate to PD-1 blockade was also one of the questions we tempted to address in this work. 
 
 
1.1.2 Molecular drivers and pharmaceutical targets 
The molecular drivers of HNSCC are separated according to HPV status. HPV proteins 
inhibit the tumor suppressors p53 and pRb and are considered as the molecular events 
initiating HPV-associated cancers. The carcinogenesis of HPV negative cancers include 
molecular events cumulating from benign mucosal hyperplasia, to dysplasia and eventually 
to cancer, which encompass among others losses of heterozygosity at loci 9p21, 3p21, 
17p13 p53 mutation, Cyclin D1 amplification, PIK3CA amplification or mutation, and pTEN 
inactivation (20). Altogether HNSCC are mainly associated to the loss or inhibition of tumor 
suppressor genes, which are more difficult to target than driver oncogenes. This observation 
explains the absence of efficient targeted therapy to date for HNSCC. Ongoing 
developments to target mutant p53 might change the game in the next years (21). Some of 
the different targeted therapies and immunotherapies approved or under evaluation in 
HNSCC are represented in Fig 1.  
 
 
 Fig 1- Selection of targeted therapies and immunotherapies for HNSCC. Color legend: 
Black: approved treatments, Blue: under evaluation, Red: evaluation stopped for absence of 
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efficacy. CAR: chimeric antigen receptor. Chemotherapy and Radiotherapy appear here 
because they may act as adjuvants for the immune system. 
 
 
1.1.3 Molecular classifications and lack of biomarker 
 
The molecular classification of HNSCC is largely ignored by the clinicians, because of the 
absence of a consensus in this field, with 4 to 6 proposed molecular classes, and above all 
because those molecular classes did not have any relevant clinical impact (22), (23), (24), 
(25). De Cecco et al. published the largest analysis to date, based on 1386 tumor and 138 
healthy samples. They identified 6 molecular classes: “classical” HPV-negative, 2 “basal” 
classes, 1 “mesenchymal”, 1 “immuno-reactive”, 1 “atypical HPV-positive” grouped with HPV-
negative “HPV-like” tumors. Interestingly, single cell analysis of OCSCC has recently shown 
that the transcriptome of cancer cells was similar in the mesenchymal and the basal tumors, 
and that it was the frequency of fibroblasts that explained the different signatures identified 
by bulk RNA sequencing. Basal and mesenchymal tumors are respectively poorly and highly 
infiltrated by fibroblasts. 
 
In the absence of prognostic or theragnostic impact of the molecular classifications, many 
individual biomarkers or signatures have been proposed for OCSCC, but again, none of 
them has been implemented in clinical practice (26). One explanation is that many published 
studies did not follow the REMARK criteria (27) that is a checklist of methodological 
requirements aimed at increasing the quality of biomarker studies, to eventually promote 
clinical translation.  Despite hundreds of reports, few have reached a sufficient level of 
evidence by combining multivariate analysis and the presence of a validation cohort. Levels 
of evidence for tumor marker studies range from 1 (highest) to 5 (lowest) (Table 1)  (28) (29). 
Dunkel et al. proposed the CD44lowHIF1ahigh signature quantified by immunohistochemistry 
(IHC) with a level of evidence of 2b, but restricted to stage I OCSCC (30). A study on 
OCSCC data from The Cancer Genome Atlas (TCGA) and 2 independent datasets from 
Gene Expression Omnibus (GEO) identified in multivariate analysis a seven-CpG-based 
methylation signature predicting overall survival (31). However, this signature was not 
confronted to all major clinical and histopathological parameters cited in 1.1.1. The same 
caveat appeared in a study that proposed a histomorphometric-based image classifier of 
nuclear morphology, established in a retrospective cohort of OCSCC patients from a single 
institution, randomly divided in a discovery and a validation cohort (32). 
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Level of evidence Study type 
1a Systematic review of prospective controlled study 
1b Individual prospective controlled study 
2a Systematic review of prospective-retrospective studies 
2b Individual prospective-retrospective using samples banked 
prospectively in the context of a clinical trial or register 
3 Large retrospective studies 
4 Small retrospective studies, Case series 
5 Expert opinion, pilot studies 
 
Table 1 – Levels of evidence according to the study type for biomarker identification 
 
 
1.1.4 Concept of tumor microenvironment  
Tumor microenvironment (TME) is defined as the cellular environment in which tumor cells 
are surrounded by blood vessels, immune cells, fibroblasts, and the extracellular matrix 
(ECM) (33). This concept integrates the work of geneticists, immunologists and biologists 
working on non-immune cells. Concerning the immune microenvironment of tumors, the 
TCGA data was used to propose a pan-cancer classification, by mining immune gene 
expression in bulk RNA sequencing data from tumor samples. Six immune groups of cancer 
have been proposed: C1 “Wound healing”, C2 “INF-γ dominant”, C3 “Inflammatory”, C4 
“Lymphocyte depleted”, C5 “Immunologically quiet” and C6 “TGF-β dominant” (34). HNSCC 
were mainly “INF-γ dominant”, although the classical molecular class, and to a lower 
extended the mesenchymal and the atypical classes, were also found in the “wound-healing” 
group. Almost none of the HNSCC samples were classified in the C3 to C6 groups. This 
classification allows a first level of resolution of the immune landscape of cancers, but lacks 
further resolution for each individual cancer. A study dedicated to HNSCC using 280 TCGA 
samples found that these tumors had the highest regulatory T cell (Treg) to CD8+ T cells 
ratio as compared to other cancers. However this ratio was higher in inflamed “immune high” 
tumors than in the non-inflamed “immune low” tumors suggesting that inflamed tumors might 
also have the highest level of immunosuppression (35). These 2 studies have the interest of 
analyzing large cohorts of patients, but the extrapolation of immune gene expression into 
estimated “real” immune infiltration is imperfect. Chakravarthy et al. showed that the 
deconvolution of methylation data is more accurately correlated to flow cytometry data than 
RNA data (36). They were able to show that inflamed HNSCC were enriched in CD8+T cells, 
B cells and Treg, when non-inflamed tumors were enriched in fibroblast and neutrophils. With 
the idea of understanding the link between cancer cell genomic alteration and the immune 
infiltration of tumors, they compared the driver mutations between inflamed and non-inflamed 
tumors and found few and minor statistically significant differences. This observation 
highlights the complexity of the TME.  
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1.2 Dendritic cells  
1.2.1 Basics on dendritic cells and immunology 
1.2.1.1 Basic concepts of the immune system 
The immune system is aimed at protecting the host from pathogens, while respecting auto-
antigens. It is composed of the two innate and adaptive interplaying systems. The innate 
immune system is composed by cells, such as macrophages and NK cells, which have the 
capacity to defend the host from pathogens recognized rapidly with, in the general case, a 
broad specificity, by pattern recognition receptors (PRR) that recognize non-self conserved 
microbial molecules or altered-self molecules, and have phagocytic or cytotoxic capacities. 
The adaptive immune system provides pathogen-specific responses, such as antibody 
production by B cells or T-cell mediated cytotoxicity, after cell selection via antigen-specific 
receptors among a large repertoire. The efficiency and the specificity of the adaptive immune 
response are at the cost of more complexity, the need of more cell-cell interactions and an 
increased delay in the response.  The adaptive immune system is well known for its capacity 
of developing a memory against those antigens, which is the basis for vaccination. However, 
some innate immune cells such as NK cells may also develop memory, in the context of 
infection or cancer (37). Those 2 systems interplay via the antigen presenting cells (APC), 
which can internalize antigens from their microenvironment, to process them into peptides, to 
link them to major histocompatibility complex (MHC) molecules, and to present the peptide-
MHC complex at the membrane to T cells. Those complexes will be recognized by the CD4+ 
or CD8+ T cells that have a receptor matching each specific combination of peptide-MHC. 
Upon activation CD4+ T cells expand and become effector T helper (Th) cells (38), 
specialized in coordinating the responses of the other adaptive cells that are the antibody-
producing B cells and the cytotoxic CD8+ T cells, which primary function is to kill infected 
cells. 
 
 
1.2.1.2 Discovery and definition of dendritic cells 
 
DC are hematopoietic cells that represent 0,1-0,5% of white blood cells (39) and are also 
found in most tissues, among which the oral and intestinal mucosa (40). DC were first 
described in 1973 by Ralph Steinman when he identified large stellate cells from mouse 
spleen among the cells that were adherent to the glass surfaces in vitro (Fig. 2) (41). He 
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pursued a lifelong research on those cells that he described in 1978 as “100 times more 
effective than other major cell subclasses--i.e., B and T lymphocytes and macrophages” to 
stimulate primary mixed leukocyte reaction in mice, as measured by the increase in cell 
proliferation (42). Their increased capacity to activate T cells as compared to other antigen 
presenting cells was confirmed in humans in 1982 (39). The gross function of DC is now well 
established: DC circulate in blood and patrol into tissues were they constantly sample their 
surrounding environment by endocytosis and a process called macropinocytosis that allows 
them to capture antigens (43). In the presence of some activating signals, which will be 
described in greater details in this thesis, DC become activated and mature, and are able to 
migrate to the T cell-rich paracortex in lymph nodes.  There, they present MHC-peptide 
complex to T cells, as well as membrane-bound costimulatory molecules, they secrete 
soluble modulating molecules, and finally activate the T lymphocytes that bear the matching 
TCR, a process called “T cell priming” (44). DC are described as the most potent cells to 
bridge the innate and adaptive immune responses. 
 
 
Fig 2. Dendritic cell passport, DC picture from Steinman RM (41)  
 
 
 
1.2.1.3 Dendritic cell functions  
In the absence of abnormal antigen or activating signals, cells are loaded with self-antigens. 
They do not induce an adaptive immune response, even by the small fraction of mature T 
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cells that are specific for those antigens and persisted after thymic selection, because of the 
requirement of additional activating signals to eventually activate T cells. This system 
protects the host from autoimmunity. These mechanisms have been summarized by the 
three signal theory required to activate T cells: APC will provide the first signal by presenting 
the peptide-MHC complex, the second signal by membrane bound costimulatory molecules 
such as CD80/CD86 that bind CD28 on T cells, and the third signal by soluble priming 
cytokines (Fig 3) (45).   
 
 
 
Fig 3 – The three signal theory linking the innate and adaptive immune systems (adapted 
from (46) 
 
 
DC main functions are to provide those 3 signals, but they also participate to immune cell 
recruitment by the production of chemokines. Another specificity of DC, as compared to other 
APC, is to migrate from peripheral tissues were they captured antigens to the lymph nodes 
were they activate the T lymphocytes, under the control of the CCR7/CCL19-CCL21 axis 
(47). To deliver the first signal, that is antigen presentation, DCs internalize antigens by 
endocytosis, phagocytosis or micropinocytosis. Endocytosis is mediated by many different 
types of DC-receptors (detailed in section 1.2.1.5), that initiate the formation of clathrin-
coated endocytic vesicles. Phagocytosis is also mediated by specific receptors and allows 
the internalization of particulate antigens, such as pathogens, apoptotic and necrotic bodies. 
Macropinocytosis is dependent on the cytoskeleton and not on receptors. It allows to sample 
large amounts of fluid that contains the soluble antigens (43). The uptaken antigens are 
processed into proteolytic peptides in the endosomes, and are eventually associated to MHC 
class I or MHC class II molecules (48), and presented at the plasma membrane. Peptide-
MHC class I complexes will lead to direct CD8+ T cell activation, a process named “cross-
presentation”, first described by Bevan in 1976 (49). Peptide-MHC class II will lead to CD4+ 
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T helper cell activation. According to the other DC molecules corresponding to signal 2 and 
signal 3 molecules, the CD4+ T cells will fine tune their final function, a process named T 
helper cell polarization, a concept first described by Mosmann in 1987 (50) . Since then, 
many different T helper profiles have been described and are presented in Fig 4 (38), (51), 
(52), (53), (54). The different T helper profiles correspond to different predominant 
transcription factors that induce the production of specific sets of cytokines, appropriate for 
the clearance of specific pathogens (intracellular, extracellular, parasites…), via their effect 
on surrounding immune and non-immune cells. 
 
 
Fig 4 – CD4 T helper cell polarization according to the signals delivered by DC (54)  
 
 
It is now clear that the role of DC and of our immune system in general is not restricted to 
infection and the detection of pathogens, but is also implied in human diseases like auto-
immunity (55), cancer (56), asthma and allergies (57), atherosclerosis  (58), bone diseases 
(59), and in the medicine-induced challenge that is transplantation (60), (61). 
 
 
 
 
1.2.1.4 DC subsets  
 
The identification of DC subsets, their markers, phenotype and function is still an evolving 
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field, which began in 1992 when Vremec and Shortman identified in the spleen and in the 
thymus of mice the CD8+ DC, using DC-enriched cell suspensions and 30 color FACS 
panels (62). Since then, many teams have contributed to the identification of the mice and 
human DC subsets in various tissues, including four recent landmark papers having been 
published between 2017 and 2019, that used the novel single-cell technologies to enrich the 
current knowledge on human blood DC (63) (64) (65) (66). The field will probably further 
evolve in the future by the study of tissue-infiltrating DC both at steady-state and in 
pathological contexts. Mouse DC biology has also bought a lot to the field, and the 
correspondence between mouse and human DC subsets is available in Annex 5.1.    
 
(i) Ontogeny 
 
DC in the periphery arise from a common DC progenitors (CDP) of the bone-marrow. Both in 
humans and mice, CDP differentiates first into plasmacytoid dendritic cells (pDC) or 
conventional (or “myeloid”) DC precursors named “pre-DC”. It was long debated if pDC gave 
rise to pre-DC or if they were two different subsets (67), since pre-DC express most pDC 
markers such as CD123, CD303 and CD304. Pre-DC may now be distinguished by their 
expression of CD33 and CX3CR1 (63). The early separation of pDC and pre-DC has been 
recently confirmed by barcoding technology (68). Pre-DC further differentiate into cDC1 and 
cDC2 the 2 main subsets of conventional DC.  
 
 
(ii) Subsets markers 
 
As mentioned above, peripheral blood DC subsets classification is still a matter of debate. To 
try to clarify the state of knowledge, I performed a comparison of the human DC subsets 
markers presented in table 2, using the markers identified by unsupervised analysis of blood 
DC by single-cell sequencing and confirmed by flow cytometry, or large-scale single-cell 
phenotyping by cytometry by time of flight (63), (64), (65), (66). These four studies have 
consensual data regarding cDC1 and pDC. Villani et al. described a 4 new DC subsets: DC2, 
DC3, DC4 and DC5 (64). The 3 other studies in part redefined the annotation of these 
subsets. DC2 indeed corresponded to cDC2 but require both BDCA1 and CD5 expression 
for their precise identification. DC3 were in fact corresponding to a mix of classical 
monocytes and CD5 negative cDC, referred as cDC3 by Dutertre et al. (65). DC4 were 
corresponding to non-classical monocytes, as shown by Dutertre et al. and Günther et al. 
using different technical approaches (65) (66). The DC5 (or AS-DC for AXL+ SIGLEC6+) 
subset was mainly composed of pre-DC (63), (65), (66).  Most markers are not subsets-
specific or even DC-specific, which explains why multi-marker strategies are required to 
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identify or purify DC and DC subsets (Results section 3.1). The different DC subsets may be 
identified in blood and in peripheral tissues, although with variations in proportions (Fig 5) 
(65). 
 
 
Table 2 – DC subsets markers comparison between the 4 publications of See et al. 
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(63), Villani et al. (64), Dutertre et al. (65), and Günther et al. (66).  Cells in grey are for 
expressed markers (+), cells in light grey are for weakly expressed markers (weak), cells in 
white are for absent markers (-) or undetermined (empty cells). Markers and signs (+/-) in red 
are consistent between See et al. and Villani et al. publications, and those in black have not 
been reported in one or the other publication. Markers in green were reported in the study of 
Dutertre et al. and those in purple in the study of Günther at al.  
 
 
 
  
Fig. 5 Adapted from Dutertre et al. (65). Tissue distribution of monocytic cells and DC 
subsets in the human blood, spleen and tonsil analyzed by cytometry by time of flight.  
 
 
 
(iii) cDC 
 
cDC subsets presentation 
cDC include all DC subsets except pDC and pre-DC. They express high levels of MHC-II 
molecules and CD11c+. The 2 main populations of dendritic cells, now labeled cDC1 and 
cDC2, were identified in 2000 (69) . cDC1 express CLEC9a and BDCA3 and are considered 
as the optimal subset for cross-presentation (70), when cDC2 express BDCA1 and 
preferentially activate CD4 T cells. Since the use of those markers to identify both subsets in 
flow cytometry, most researcher could observe a subset of BDCA3-BDCA1- cells, which was 
in general not further studied, as it is often the case for double-negative populations. Single-
cell sequencing showed recently that they corresponded to a homogenous subset at the 
transcriptomic level in blood, labelled cDC4 by Villani et al. (64). They have also been 
described in benign tonsils and oropharyngeal cancer (71). However, as stated above, those 
cells have the highest similarities with non-classical monocytes (65).  Villani et al. also 
proposed that cDC2 corresponded in fact to 2 subsets, DC2 and DC3, recognizable by their 
differential expression of CD32b (Table 1) (64). However, at the protein level CD32 
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expression appears more as a continuum and CD32b cannot be specifically used for cell 
sorting, in the absence of specific antibody available. Thus, the evidence of the existence of 
those 2 subsets and their differential function was still unclear. The recent papers of Dutertre 
at al. (65) and Günther et al. (66) confirmed that the cDC2 compartment is more 
heterogenous than the cDC1 compartment. Dutertre et al. propose a third class of DC, 
labeled cDC3, expressing BDCA1 but not CD5, and composed of a continuum of cells 
distinguishable by their expression of CD163 and CD14 (Table 2). Langerhans cells are one 
other DC subset and are found in the skin. As we could not identify them in the normal upper 
airway mucosa or in head and neck cancer tissue, they were not part of the scope of the 
present thesis and will not be further detailed. 
 
cDC1 
Human cDC1 or their mouse CD8a+ (blood and lymphoid tissue) or CD103+ (peripheral 
tissue) counterparts appear to be highly effective at performing cross-presentation (72), (73), 
as compared to other DC subsets, and are therefore ideal targets for anti-cancer vaccine, 
among other therapeutic uses. Human cDC1 can be identified by their expression of XCR1 
and CLEC9A, and by their higher expression of BDCA3 as compared to other DC and cell 
types expressing this marker (74), (Results section 3.1). They are not potent inducers of 
regulatory T cells in vitro, which seems to be one of the functional difference with their mouse 
counterpart (75). The main transcription factors involved in cDC1 development and function 
are IRF8 and Batf3 (76). Mouse biology has improved a lot our understanding of cDC1, by 
the mean of cDC1-deficient mice that may be obtained by knock-out of Irf8, Batf3, Nfil3, Id2, 
and Bcl6 (77). Steady-state human and mouse cDC1 express TLR3 at higher levels than 
cDC2 (74), and TLR8 but only mouse and not  human cDC1 express TLR9 (70), (78). The 
high expression of TLR3 is of importance for cross-presentation in response to viral infection 
(79). In the lymph nodes cDC1 are sporadically dispersed in the T cell area, in line with their 
preferential role of direct CD8 T cell activation (80). 
 
cDC2 
On the other hand cDC2 are the main DC subset in the sense that they outnumber cDC1 in 
most tissues (80), (81), (Results section 3.1), (Fig 5). cDC2 are less efficient than cDC1 for 
cross-presentation, but similarly efficient at activating CD4 T cells and inducing the various 
Th polarization described in section 1.2.1.3 (Fig 4) (82). At steady-state, they are considered 
as regulators of the Treg/Th17 homeostasis in the barriers sites that are lung and intestinal 
tissues (83). They express the transcription factors IRF4 and ZEB2 and IRF8, but at lower 
levels than cDC1. Patients with autosomic recessive IRF8 mutations have a complete lack of 
classical and non-classical monocytes, pDC and cDC (76), (84). However, IRF8-deficiency 
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affected cDC1 and pDC but not cDC2 development in a model of human induced pluripotent 
stem cell differentiation (85). They express both the surface and intra-cellular TLR 1 to 8 (86) 
and are able to recognize most pathogens but those recognized by TLR9. cDC2 also 
overexpress ITGAM as compared to cDC1, a molecule implied in phagocytosis (74). In the 
lymph nodes cDC2 are clustered in the interfollicular area, in line with its preferential role of 
direct CD4 T helper cell activation (80).  
 
(iv) Mo-DC, CD14+DC and inflammatory DC 
Beside the cDC subsets presented above, another CD11c+ DC subset derived from CD14+ 
monocytes in humans (in Ly6C+ monocytes in mice) is restricted to secondary lymphoid 
tissues and peripheral tissue (87). This subset is labeled “Mo-DC” for monocyte-derived DC 
or sometimes CD14+DC or inflammatory DC in the cases were they are induced by some 
inflammation, which is not always easy to demonstrate in human (88), (89). They can be 
produced in vitro by stimulating for 5 days monocytes with GM-CSF and IL-4 (90). Mo-DC 
are efficient at promoting an inflammatory microenvironment, at antigen-uptake, antigen-
presentation and cross-presentation (91), but their ability to migrate to lymph nodes is limited 
(81). We may thus hypothesize that in vivo Mo-DC interact with T cells preferentially locally in 
inflammatory peripheral tissues. It is important to mention that the terms CD14+DC and 
inflammatory DC are very confusing. A subset of blood cDC from healthy human expresses 
CD14, is closer to DC than to macrophages at the phenotypic and transcriptomics level, and 
was recently labeled CD14+CD163+ cDC3 (65).  Whether HLA-DR+ CD11c+ BDCA1+ 
CD14+ cells identified in human inflammatory tissues arise from monocytes or are a subset 
of cDC3 remain to be elucidated. A simple flow cytometry approach determining their 
expression of the DC markers FceRIa and HLA-DQ as opposed to the monocyte markers 
CD88 and CD89 could address this question. 
 
(v) pDC 
 
Our team has recently reviewed in detail pDC phenotype and function, and I contributed to 
the chapter describing the state of knowledge on the role of pDC in cancer. This publication 
(92) is available in Annex 5.3. pDC were identified in 1958 by Lennert K and Remmele as a 
cell having the morphological features of a plasma cell, and located in the T cell area in 
lymph nodes (93). It was not until 1997 (94) that they were identified as a DC subset, and 
until 1999 that their main feature, that is a high efficiency at producing type I interferon (IFN) 
after stimulation, was described (95), (96). Their mouse equivalent was discovered in 2001 
(97), and they match most human pDC features, although some differences in markers and 
cytokine production have been observed (92). As shown in the Table 1, steady-state pDC 
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express HLA-DR, CD4, CD303/BDCA2, CD304/BDCA4, CD123 (IL3 receptor), and CD36, 
but they do not express CD11c or CD1c/BDCA1 or AXL. Human pDC express the 
intracellular receptors TLR7 and TLR9 for the detection of single-stranded viral RNA and 
DNA respectively, but do not express TLR3 (98).  They have a functional cyclic-GMP-AMP 
(cGAMP) synthase - Stimulator of IFN genes (cGAS-STING) pathway for cytosolic DNA 
sensing and type I IFN induction. pDC are less efficient than the other DC subsets at 
performing endocytosis or phagocytosis (99). pDC present antigens to CD4 T cells and can 
also perform cross-presentation (100). pDC also express surface receptors, among which 
cytokine-receptors for IL-3, IL-10, GM-CSF, TGF-β or TNF-α, which can induce pDC 
maturation or modulate TLR-induced maturation (92). In summary, pDC is the first subset to 
differentiate from other DC subsets during hematopoiesis and is specialized in the production 
of type I IFN after activation, mostly by viruses. 
 
 
 
1.2.1.5 Dendritic cell receptors and signaling pathways 
DC express at steady-state or upon activation different families of receptors that may be 
separated into 3 groups: PRR that are receptors for the direct recognition of pathogens and 
danger signals, receptors for indirect sensing of infection and inflammation, and the 
remaining receptors that serve the other DC functions and homeostasis. The first two groups 
will be detailed below, since they initiate the maturation process detailed in sections 1.2.2 
and 1.2.3, and because some of their ligands were used in the manuscript presented in the 
result section 3.1.  
 
(i) Pattern-Recognition Receptors 
The direct recognition of pathogens and danger signals occurs via PRR that recognize 
pathogen-associated molecular pattern (PAMP) and damage-associated molecular pattern 
(DAMP) (Table 3). PAMP are small molecular motifs conserved within microbes. DAMP are 
molecules that are undetectable by the immune system at steady-state, but become exposed 
after cell stress or cell death (101). Well-known DAMP include high-mobility Box 1 (HMGB-1) 
and adenosine triphosphate (ATP). The main receptors for PAMP and DAMP recognition, as 
well as their natural or pharmaceutical ligands, are listed in Table 3. PRR include the family 
of Toll-like receptors (TLR), C-type lectin receptor (CLR), Cytosolic sensors that include 
cytosolic DNA sensors (CDS), NOD-like receptors (NLR) and RIG-1-like receptors (RLR), 
and DAMP receptors (Fig 6).  
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Figure 6. Signaling pathways associated to PRR, adapted from Shekarian et al. (102) (in 
particular, the TLR represented by a purple rectangle have been modified from the original 
figure, since they was a typing error so that they were all labelled TLR5) 
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Receptor Ligand Localization Pathway 
PRR agonist in 
clinical trial 
TLR  
TLR1:TLR2 
heterodimer 
Lipomannans (mycobacteria), Lipoproteins 
Lipoteichoic acids (Gram-positive bacteria), 
Cell-wall b-glucans (bacteria & fungi), 
Zymosan (fungi), HKLM, HKSA, PAM3, 
HMGB1 
Plasma 
membrane 
MyD88/MAPK/
NFkB Amplivant 
TLR2:TLR6 
heterodimer 
Lipomannans (mycobacteria), Lipoproteins 
Lipoteichoic acids (Gram-positive bacteria), 
Cell-wall b-glucans (bacteria & fungi), FSL-1 
Plasma 
membrane 
MyD88/MAPK/
NFkB  -  
TLR3 Double-stranded RNA (viruses), Poly I:C Endolysosome 
TRIF/TRAF3/ 
IRF3 
PolyI:C, Rintatolimod, 
Hiltonol 
TLR4 
LPS (Gram-negative bacteria) 
Lipoteichoic acids (Gram-positive bacteria) 
HMGB1 
Plasma 
membrane 
MyD88/MAPK/
NFkB, 
TRAM/TRIF/ 
IRF3 
LPS, GSK1572932A, 
G100, MPL(AS15) 
TLR5 Flagellin (bacteria) 
Plasma 
membrane 
MyD88/MAPK/
NFkB CBLB502 
TLR7 Single-stranded RNA (viruses), Flu Endolysosome 
MyD88/MAPK/
NFkB Imiquimod 
TLR8 Single-stranded RNA (viruses), R848 Endolysosome 
MyD88/MAPK/
NFkB 
Imiquimod, 
Resiquimod, 
MEDI9197, 
Motolimod 
TLR9 
DNA with unmethylated CpG (bacteria and 
herpesviruses) Endolysosome 
MyD88/MAPK/
NFkB 
CpG, CMP-001, 
MGN1703, SD-101, 
1018ISS, Agatolimod 
TLR10 Unknown 
Plasma 
membrane 
MyD88/MAPK/
NFkB  -  
CLR  
Dectin-1 
(CLEC7A) 
Zymosan, b-glucan, HKCA, Curdlan, 
Mycobacteria 
Plasma 
membrane CARD9/NFkB  -  
Dectin-2 
(CLEC6A) a-mannan, Mycobacteria 
Plasma 
membrane CARD9/NFkB  -  
Mincle 
(CLEC4E) 
Carbohydrate patterns (Fungi), trehalose 
dimycolate (Mycobacteria), SAP130 (dead 
cells) 
Plasma 
membrane CARD9/NFkB  -  
DNGR-1 
(CLEC9A) 
Carbohydrate patterns (Fungi), F-actin 
(necrotic cells) 
Plasma 
membrane 
Syk kinases 
and cross-
presentation  -  
Clec2 
(CLEC1B) Podoplanin 
Plasma 
membrane 
Required for 
DC motility  -  
CLECSF8 
(CLEC4D) 
a-mannan, trehalose dimycolate 
(Mycobacteria) 
Plasma 
membrane CARD9/NFkB  -  
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DCIR Carbohydrate patterns (fungi) 
Plasma 
membrane 
ITIM inhibitory 
motif  -  
MICL 
(CLEC12A) 
Carbohydrate patterns (Fungi), uric acid, 
proteinaceous ligands (necrotic cells) 
Plasma 
membrane 
ITIM inhibitory 
motif  -  
DEC-205 Keratin at acid pH only ((103) 
Plasma 
membrane 
Endocytic 
receptor  -  
MMR 
mannose, fucose, N-acetylglucosamine, 
glycolipid antigens (lipoarabinomannan)  
Plasma 
membrane 
Endocytic 
receptor  -  
DC-SIGN fucosylated glycans, mannose structures  
Plasma 
membrane 
ICAM-2 and 
ICAM-3 for T 
cell activation  -  
MBL glycan-associated mannose  Soluble 
 
 -  
Cytosolic sensors  
NOD-like 
receptor 
Peptidoglycans: IE-DAP (NOD1 / gram 
negative bacteria), MDP (bacteria) 
 
RIP2/MAPK/ 
NFkB  -  
AIM2 Cytosolic DNA, Flu Cytoplasm Caspase-1  -  
ZBP1 (or DAI) Cytosolic DNA  
TBK1/IRF3/ 
NFkB  -  
NLRP/NALP 
receptors 
cell damage (eg. by toxins), downstream 
purinergic P2 receptors 
Cytoplasm CARD/ 
Caspase-1  - 
RIG-1-like 
receptors 
Short double-stranded RNA, 5' single-
stranded RNA (RIG-1) (viruses), Long 
double-stranded RNA (MDA5), Flu Cytoplasm 
IPS1/TRAF3/ 
IRF3 BO-112 (MDA5) 
cGAS Cytosolic DNA 
Cytoplasm, 
Endoplasmic 
reticulum 
TBK1/IRF3/ 
NFkB 
MIW815 (ADU-
S100), MK-1454 
Other DAMP receptors 
RAGE HMGB1 
Plasma 
membrane MAPk/NFkB  -  
TREM-1 TREM-1 ligand, soluble TREM-1, HMGB1 
Plasma 
membrane 
ERK/c-Fos/c-
Jun/AP1, NFkB  -  
P2X receptors Extra-cellular ATP 
Plasma 
membrane Inflammasome  -  
 
Table 3. PRR expressed by DC: classification, natural and pharmaceutical ligands, and 
corresponding signaling pathways. NFkB: Nuclear factor kappa-light chain enhancer of 
activated B cells 
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TLR 
Jules Hoffmann was awarded in 2011 the Nobel Prize in Physiology or Medicine for the 
discovery in 1996 of the host-defense role of Toll receptor in adult fly. Similar receptors 
discovered in mammalians were called Toll-like receptors. There are 13 different TLR, but 
only 10 are expressed in humans (TLR1 to TLR10), whereas 12 are expressed in mice (TLR 
1 to TLR 9 and TLR11 to TLR13, that will not be further detailed). Those 10 TLR of a broader 
specificity as compared to the antigen receptors of the adaptive immune response and have 
the advantage of being able to recognize PAMP that cover most pathogenic microbes. TLR3, 
TL7/8 and TLR9 are in the endocytic vesicles, whereas the other TLR1, TLR2, TLR4, TLR5 
and TLR6 are located at the plasma membrane. They are expressed by DC, but also many 
other immune cell types, stromal cells, epithelial cells and even cancer cells. TLR signal 
through 2 main pathways: the MyD88 and the TRIF signaling pathways (104). After ligand 
binding, all TLR but TLR3 engage MyD88 adaptor molecule, that recruits IRAK proteins, 
which in turn recruit TRAF6. Upon phosphorylation, TRAF6 is dissociated from the receptor 
complex and binds TAK1 (TGF-β activated kinase), TAB1 and TAB2 to form a complex in the 
cytosol. This complex phosphorylates the kinases IkB which leads to the translocation of the 
transcription factor NFkB to the nucleus. In parallel TAK1 activates mitogen-activated protein 
(MAP) kinases signaling cascades leading to nuclear translocation of CREB and AP1. AP1 
and NFkB activate the transcription of genes coding for cytokines, chemokines, MHC class II 
and costimulatory molecules. TLR3, but also TLR4, activate the TRIF signaling pathway. 
TRIF recruits TBK1 and TRAF3, and TRAM in the case of TLR4 activation. These complexes 
phosphorylate interferon regulatory factors (IRF) IRF3 and IRF7, which activate together with 
CREB the expression of interferon and a sub-class of interferon-inducible genes such as 
IFN-I, CXCL10 and CCL5. TRIF can also bind TRAF6 and induce cytokine production 
similarly to the MyD88 pathway. Finally, TLR7, TLR8 and TLR9 also induce interferon 
inducible genes via TRAF6 and IRF7, but without TRIF (105) (Fig 7). Eventually, these 
activation pathways are regulated by other autocrine and paracrine molecules, such as IFN-I 
itself (106), (105). 
 
 
 
26	
	
 
Fig 7- TLR signaling pathways (105). 
 
 
 
CLR 
C-type lectin receptors recognize mostly glycan structures of pathogens via their 
carbohydrate recognition domain (CRD). Only CLR having or cooperating with immune-
receptor tyrosine-based activation motifs (ITAM) activate signaling cascade that primarily 
engage Syk kinases to eventually activate NFkB and gene transcription. The ITAM-signaling 
CLR are Dectin-1, Dectin-2, macrophage-inducible C-type lectin (Mincle), DC NK lectin group 
receptor-1 (DNGR-1) (also known as Clec9A), Clec-2 and CLECSF8. DNGR-1 is 
preferentially expressed on cDC1 and does not induce an inflammatory response despite its 
ITAM motif, but rather participates to the process of cross-presentation. Other CLR, such as 
DC immunoreceptor (DCIR) and myeloid inhibitory c-type lectin-like receptor (MICL) have 
immune-receptor tyrosine based inhibitory motifs (ITIM) that inhibit the immune response 
(40), (107). Other CLR are mainly involved in endocytosis and phagocytosis, such as MMR 
(CD206) (108), and DEC-205 (109), (110). DC-specific ICAM3-grabbing non-integrin (DC-
SIGN) is a CLR that activates T cell by via ICAM-3 binding (111). Finally, mannose-binding-
lectin (MBL) is a soluble CLR that undergoes conformational changes upon carbohydrate 
binding. It participates to host defense by direct inhibition of pathogen entry into the cell, 
opsonization, or activation of the complement cascade (112). 
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Cytosolic sensors 
 
In addition to TLR and CLR that are primarily sensors of extracellular pathogens, DC express 
several families of cytosolic sensors of intra-cellular microbial products detailed in Table 2. A 
first family is composed of nucleotide-binding oligomerization domain (NOD)-like receptors 
(NLR), which are also expressed in macrophages and epithelial cells. NLR recognize 
peptidoglycans from bacteria, which have entered the cell by as a result of infection or by 
endocytosis. NLR have a caspase recruitment domain (CARD) for intra-cellular signaling. 
Upon activation, they induce NFkB activation via CARD/RIP2/TAK1/IKK signaling, similarly to 
TLR (113). Absent In Melanoma 2 (AIM2) and Z-DAN-binding protein 1 (ZBP1) also known 
as DNA-dependent Activator of IFN regulatory factors (DAI) are 2 other members of the 
NLR-family and recognize cytosolic DNA. AIM2 signals through caspase-1, to eventually 
induce pyroptosis (114). DAI also activates TBK1, IRF3 and leads to type I IFN production, 
but its knock-down does not significantly reduce the final amount of type I IFN produced 
upon activation (115), (116). 
Another related family is the NLRP family that has a pyrin domain instead of the CARD 
domain. There are 14 NLRP identified in humans. NLRP3 is the best characterized, and its 
signaling leads to the formation of a multiprotein complex labelled the “inflammasome”. It is 
activated upon cell damage such as membrane pores induced by toxins, or by activation of 
the purinergic P2 receptors like P2X7, which are receptors for extra-cellular ATP. Unlike 
NOD-1 and NOD-2, the inflammasome does not activate NFkB, but induces the production of 
inflammatory cytokines and death of infected cells (114).  
A third family is composed of retinoic acid-inducible gene (RIG)-like receptors (RLR). RIG-1 
and melanoma differentiation-associated gene 5 (MDA5) are members of this family and 
recognize respectively short and long double-stranded RNA produced by viruses within the 
cell (as opposed to TLR3, TLR7 and TLR8 that recognize extracellular viral RNAs) (113). 
RLR also harbor CARD domains, which activate the downstream mitochondrial antiviral 
signaling protein (MAVS), TRAF proteins and eventually TBK1 and IRF3, as previously 
described for TLR3. 
The fourth family is composed by the cGAS-STING pathway. At steady-state, host DNA is 
restricted to the nucleus. Cytosolic DNA sensors therefore detect pathogen-derived DNA 
during viral, microbial or protozoan infection or host DNA in pathological conditions like 
cancer. STING is activated by cGAMP upon cytolosic DNA sensing by cGAS. This induces 
STING trafficking from the endoplasmic reticulum to perinuclear vesicles, the recruitment of 
TBK1 and the phosphorylation of IRF3, leading to the transcription of type I IFN (117).  
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Other DAMP receptors  
 
DAMP receptors recognize cell and tissue damage signals, such as ATP, HMGB1, S100 
proteins, heat shock proteins (HSP). Some receptors presented above, such as DNGR-1, 
are DAMP receptors. The purigenic receptors that recognize extra-cellular ATP are part of 
the inflammasome cited above in the cytosolic sensor paragraph. Other DAMP receptors 
include receptor for advanced glycation end products (RAGE) and triggering receptor 
expressed on myeloid cells-1 (TREM-1). Both receptors are located at the plasma membrane 
and recognize HMGB1, which is a DNA chaperone located in the nucleus at steady state, 
released in the extra-cellular compartment after cell death. RAGE also recognizes advanced 
glycation end products, S100 proteins, amyloid beta peptide and beta sheet fibrils. It signals 
with TLR4 to eventually activate MAP kinases and NFkB (101). TREM-1 also binds soluble 
TREM-1, a molecule obtained by alternative splicing or MMP cleavage of TREM-1 transcript, 
and TREM1-ligand, a molecule less characterized. TREM-1 harbors an ITAM motif, and 
activates ERK, c-Fos, c-Jun and NFkB (118). Among other HSP receptors, LDL receptor 
related protein 1 (also named CD91) recognizes HSPgp96 and leads to DC maturation (119). 
 
 
(ii) Receptors for indirect sensing of infection and inflammation 
 
DC may indirectly sense infection and inflammation and undergo a maturation process by the 
stimulation of inflammatory cytokine receptors, Fc receptors by immune complexes, or 
Tumor Necrosis Factor (TNF) superfamily ligands and receptors (TNFSF and TNFRSF). DC 
express receptors for most cytokines spontaneously or upon activation. The cytokines are 
secreted directly by the pathogens or indirectly by surrounding activated immune cells. Many 
inflammatory mediators have been described as DC activators in various contexts, such as 
type I IFN, TNF-α, IL-1β and prostaglandin E2 (PGE2) in infection (48), TNF-α, IL-6, PGE2 
and IFN-β in cancer (120), and TNF-α, IL-1, IL-6, GM-CSF, and thymic stromal 
lymphopoietin (TSLP) in auto-immunity and inflammatory diseases (55). On the other hand, 
DC activation may be downregulated by anti-inflammatory factors such as IL-10, TGF-β, 
VEGF or retinoic acid (121). Cytokine receptors mainly signal through the Janus kinase 
(Jak)–signal transducer and activator of transcription (STAT) pathway (122), although some 
cytokines have other signaling pathways (123). Jak kinases phosphorylate cytokine 
receptors upon activation, and STAT proteins may then bind phosphorylated cytokines 
receptors via their SH2 domain. Phosphorylated STAT may then induce or repress gene 
transcription. There are 4 different JAK kinases and 7 different STAT proteins that permit a 
certain specificity of the cytokine signaling pathways, such as the unique IL-4/STAT6 
pathway. Jak-STAT signaling, and particularly STAT1, STAT3 and STAT5, are of importance 
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in DC development (124). Importantly for the present work on DC activation, STAT proteins 
regulate different transcription programs in differentiated DC. For example, STAT3 and 
STAT5 may collaborate during DC maturation, as shown for TSLP-DC (125) or may 
antagonize each other to regulate the immune response, as shown with the IL-21/STAT3 – 
GM-CSF/STAT5 competition (126). Cytokine receptors may also signal through the MAP 
kinase pathways. Several cytokines signal through the same pathways and still induce 
different effects, suggesting that specificity may be due to a precise combination of the level 
of activation of each pathway (122), or by changes in the STAT sensitive genes in the 
different cell types and states (127). DC also express receptors for growth factors, some of 
which being considered as cytokines, such as GM-CSF, and able to induce DC maturation 
(122).  
 
Beyond receptors for soluble cytokines and growth-factors, DC express several TNFSF and 
the receptor CD40 (TNFRSF5) that are involved cell-cell communication and DC-T cell 
cross-talk in particular, and are upregulated on various cell types during inflammation (128). 
Many of these molecules have been associated with a costimulatory function and have 
entered the field of the targetable positive checkpoints, such as CD40-CD40L, OX40-
OX40L(TNFSF4), CD30-CD30L(TNFSF8), 4-1BB-4-1BBL(TNFSF9), HVEM-
LIGHT(TNFSF14). DC maturation induced by CD40 binding of CD40L expressed on T cells 
was shown in 1994 by Caux et al. using cord blood derived Langherhans cells (129). All DC 
subsets express lymphotoxin beta receptors (LTbR) that binds lymphotoxin beta (LT-β) and 
LIGHT. Since DC also produce LT-β, this interaction is involved in an autocrine loop 
regulating DC proliferation (130).  
 
DC may sense immune complexes or specific antibodies via their Fc receptors (FcR). All DC 
subsets express FcgRI (CD64), FcgRIIA and B (CD32a, CD32b), and FcgRIII (CD16). FcR 
binding induces DC maturation (131). All FcR but FcgRIIB harbor an ITAM motif that has the 
activating properties described above for CLR and induces antibody-dependent 
phagocytosis. FcgRIIB harbors an ITIM inhibitory motif, which activation inhibits the 
production of inflammatory cytokines in DC via downstream signaling through Src kinases 
and phospholipase C gamma (132). FcgRIIA and FcgRIIB counterbalance their opposite 
effect and their expression participates in the regulation of DC maturation (133).  However, 
the role of ITAM and ITIM signaling in DC seems more complex than in other lymphoid cells: 
ITAM-related cytokine secretion inhibition has been described in mouse pDC during murine 
CMV infection (134) or after CpG stimulation (135), and ITIM-dependant IFN-I genes 
expression (136). It remains possible that such paradoxical effect may also occur 
downstream Fc receptors. 
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DC can detect pathogens coated with complement via their complement receptors CR3 and 
CR4. However, most studies on the activating role of complement in DC have been 
conducted with in vitro with Mo-DC, and the observation made on complement-induced 
maturation and CR upregulation during maturation need to be confirmed in primary DC (137).  
 
Finally, chemokine receptors are also part of the indirect sensing of inflammation. Immature 
DC may be recruited from blood into inflammatory sites by the chemokines CCL2 (MCP-1), -
3(MIP1a), -4(MIP-1b), -5(RANTES), -7(MCP-3), -8(MCP-2), -17(TARC), -18, -20(MIP-3a), -
22(MDC)  and CXCL13 (138).  
 
 
 
1.2.2 DC maturation  
1.2.2.1 General concept of maturation 
In the early 1980’s, the ability of DC to activate T cells and the high levels of expression on 
CMH-II by DC were established. Nussenzweig observed that the response of unprimed T 
cells to syngeneic DC mixed leukocyte reaction was 10-times weaker than with allogeneic 
cells (139). This was the first indirect evidence that some variations in DC maturation states 
could have functional consequences on the level of mixed T cell activation. The concept of 
DC maturation was first described in 1985 on Langherhans skin DC (LCs) by Schuler et al.: 
they described that fresh epidermal LCs were poorly efficient at activating T cells, but 
increased this ability by 10 fold after 3 days of in vitro culture without other stimulation, and 
that this “maturation” process was associated to some visible changes such as the 
disappearance of Birbeck granules (140). The same year, the importance of DC in the 
activation of unprimed and memory T helper cells was demonstrated (141). Shortly after the 
first description of T helper polarization (50), the concept of APC costimulatory molecules 
arose in 1988 when Weaver et al. observed that the absence or presence of IL-1 produced 
by macrophages induced Th1 and Th2 helper T cells respectively (142). DC failed to produce 
IL-1 (143), but other costimulatory molecules were identified in the 90’s, such as ICAM-1 
(CD54) (144), and CD80 (145). The receptors initiating DC maturation were described in 
section 1.2.1.5. Maturation is a global process that involves many changes in the 
transcriptomic programs, the expression of surface molecules including MHC molecules 
(146), the secretion of cytokines (147) and chemokines, and changes in cell shape, which 
occur prior or during the migration to the lymph nodes (148), (149), and finally the associated 
changes in function. Steinman stated that he preferred the term “maturation” to “activation”, 
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since the latter seems to reduce the process to a limited number of on-off events, when 
maturation corresponds to a larger scale differentiation process, more comparable to the 
differentiation of blasts of the bone marrow into peripheral blood cells (44). First, we will 
describe the general changes occurring during DC maturation. Secondly, in chapter 1.2.2.2, 
we will overview the different shades of maturation and their functional impact. More details 
on DC states in the context of cancer will be given in chapter 1.2.3. 
 
 
(i) MHC molecules trafficking and antigen presentation 
 
Immature DC present very few MHC II-peptide complexes because they are poorly efficient 
at degrading internalized antigens as a consequence of the low efficiency of proteases and 
cathepsin B (150), (151). In parallel, MHC-II molecules are sequestered in the lysosomes 
and unable to bind peptides (152), (153), because of the presence of the li-chain that 
occupies the peptide binding site, which needs to be degraded by cathepsin S (154), (155). 
In parallel, immature DC have a strong antigen capture capacity that persists until a signal 
initiates the process of maturation. Among the cascade of molecular events occurring upon 
maturation, several participate in the increase of antigen presentation. First, the synthesis of 
MHC class II increases (156). Second, the acidification of the endosomes and lysosomes 
activates the above mentioned enzymes and leads to the formation of CMH-peptide 
complexes (48). Lastly, those complexes traffic to endosomal vesicles, where they colocalize 
with costimulatory molecules and MCH-I before being presented together at the cell surface 
(157). All this machinery occurs rapidly within the first hours of activation, and is limited in 
time to the initial phase of maturation, before a downregulation of these processes (150). 
Conversely, the regulation of MHC-I, involved mainly in self-antigen presentation, but also in 
cross-presentation, seems stable over time (48). In parallel, mature DC lose their high 
antigen-capture capacity (158).   
 
 
(ii) Membrane-bound costimulatory molecules  
 
T cell costimulation corresponds to the 2nd and 3rd signals described in section 1.2.1.3. 
Membrane bound molecules costimulatory molecules deliver the second signal to T cells, as 
opposed to soluble cytokines that deliver the third signal. Upon activating receptors binding, 
DC up-regulate more or less costimulatory molecules, such as the well-known members of 
the B7 family CD80 and CD86, used in most experiments to define DC activation or 
maturation. CD80 and CD86 are ligands for the activation molecule CD28 on T cells (45). 
CD28 binding on naïve CD4 T cells, simultaneously with MHC-II-peptide-TCR binding, 
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promotes T cell proliferation, cytokine production and cell survival. In the last decades, many 
other costimulatory molecules have been described: members of the TNF super family 
described in 1.2.1.5 (CD40, OX40L, CD30L, 4-1BBL, HVEM, LIGHT, GITRL, CD70), other 
members of the B7 family (inducible T cell costimulatory ligand (ICOSL), B7-H6, B7H7), 
members of the SLAM family (CD48, CD150, Ly9, NTBA, CD84) (159), (160), (161). The 
immune activation resulting from the upregulation of costimulatory molecules is regulated in 
two ways: the presence of an inhibitory receptor on T cell for a specific DC costimulatory 
molecule, or the upregulation of co-inhibitory molecules on DC. The first case is illustrated by 
CD80 and CD86 that may bind the inhibitory receptor CTLA-4 on T cells, the latter molecule 
having been the first targeted negative immune-checkpoint in immuno-oncology (162). The 
second case corresponds to the negative-checkpoint ligands expressed on DC, such as 
PDL1, PDL2, B7H3, B7H4, VISTA/B7H5, HVEM, PVR, NECTIN2, CD200 or TIM3 (159), 
(160), (161).  The classification of those molecules as mainly costimulatory or coinhibitory is 
not always trivial, and some difference have been observed in the field between mice and 
human biology, e.g. PDL2 that has a costimulatory role in mice and a coinhibitory role in 
human (163). In 1999 Bleijs et al. also described a costimulatory role for integrins: T cell 
proliferation and polarization was modulated by the level of interaction between the LFA-1 
complex (CD18/CD11a) and the intercellular adhesion molecules (ICAM) ICAM-1 (CD54), 
ICAM-2 (CD102), ICAM-3(CD50) in an antigen-presenting cell-free system (164). The 
costimulatory role of integrins expressed on DC has since then been confirmed (165).    
 
 
(iii) Cytokine and Chemokine production 
 
One of the important effect of the downstream signaling of PRR and the other receptors for 
indirect sensing of inflammation described in chapter 1.2.1.5 is the transcription of genes 
coding for inflammatory cytokines via the transcription factors NFkB, IRF, STAT, CREB or 
AP1 (166).  Simulated DC will produce a certain combination of cytokines, usually classified 
as immunostimulatory (IL-12, IL-6, IL-1β, IFN-a, IFN-β) or immunosuppressive (IL-10, TGF-
β). The various combination of cytokines produced upon DC activation depend on the stimuli 
in vitro, and on the integration of stimuli in in vivo contexts. The cytokines produced by 
activated DC will in turn bind their own receptors in an autocrine manner and allow positive 
or negative feedback loops. For example, IFN-β was essential for TLR3 and TLR4 induced 
upregulation of CD80, CD86 and CD40 (167). In another study, IL-15 together with IFN-a 
and IFN-β induced autocrine DC activation and stimulated in vivo naïve CD8 T cell 
proliferation, but not CD4 T cells (168). Conversely IL-10 may suppress DC maturation in an 
autocrine manner (169). 
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DC cytokines will also act on surrounding cells and provide the 3rd signal to T cells. This third 
signal has been considered as the main regulator of Th polarization. Typically, DC derived 
IL-12 and IFN-γ induce Th1 polarization, IL-4 induces Th2 and IL-10 and TGF-β induce 
regulatory T cells (Treg) (Fig 4) (54). However, IL-4 stimulates DC production of IL-12, 
providing a negative feedback loop in Th2 environment (170). Cytokine production is not only 
controlled by the stimuli but may be influenced by the DC subsets. For example, GM-CSF 
activated mouse cDC1 and cDC2 promote Th1 and Th2 T cell polarization respectively, 
depending on IL-12 levels (171). 
 
 
 
(iv) Migration and cell shape 
Maturation-induced migration and changes in cell shape are important features specific of 
DC as compared to other antigen-presenting cells such as tissue-resident macrophages. 
Upon maturation, tissue-resident DC will migrate by the afferent lymphatics to the draining 
lymph node together with developing cell projections (158). These afferent-lymph derived DC 
are usually labelled “migratory DC”, as opposed to lymphoid tissue resident DC. In the lymph 
node, DC will interact with T cells in the paracortical zone and initiate the adaptive immune 
response. It is assumed that migratory DC do not recirculate in the efferent lymph vessel and 
blood. The migration from the tissue to the lymph node is under the control of the 
CCR7/CCL19-CCL21 axis (47), (172), (173). DC upregulate CCR7 upon maturation, under 
the control of NFkB (174). CCR7+DC will be attracted into the lymphatics by the chemokine 
CCL21, produced by lymphatic endothelial cells, and will follow a gradient of CCL21 to 
eventually get into the lymph node areas (175).  
With regard to subset specificity, all DC have the ability to become migratory DC, although it 
is still debated for mouse Mo-DC and data on human Mo-DC are scarce (176), (177). cDC2 
preferentially migrate in the interfollicular area, as a results of the expression of EBI2 
expression (178).  
Concerning stimuli specificity, under some specific conditions, such as TSLP-induced 
maturation, DC may also upregulate CXCR5 and migrate to B cells zone of lymph nodes 
under the control of CXCL13, were they participate to the activation of follicular helper T cells 
(Tfh) (179), (180). These last examples illustrates how different stimuli induce different 
shades of maturation and here of migration, which will favor DC interaction with a specific 
cell type, which in turn will determine the final functional output.   
Mature DC will develop cell protrusions via actin cytoskeleton modifications that favor DC-T 
interaction in the lymph node (181). The PRR signaling pathways control the cellular pools of 
actin: upon activation the Arp2/3-dependent front pool of actin allowing antigen capture will 
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be downregulated while the mDia1-dependent rear pool of actin allowing cell locomotion will 
be upregulated (158). CCR7 downstream signaling (182) and MHC class II invariant chain 
(183) will also participate to the regulation of the actin cytoskeleton, making a link between 
antigen-presentation and migration. In parallel, trans-endothelial migration itself promotes DC 
maturation (148), (184).   
 
 
1.2.2.2 Maturation patterns 
(i) Concept of various maturations 
All the modifications described in the former chapter are part of DC maturation process. 
However, there are some variations in the quality and quantity of the molecules involved that 
correspond to the various DC maturation states described in literature, such as fully mature, 
TLR-induced, immunogenic, tolerogenic, semi-mature, or homeostatic (Fig 8). Those 
differences in maturations are important to describe because of their functional impact on 
both the innate and the adaptive immune responses. They are therefore implied in the 
physiopathology of many diseases, from autoimmunity to cancer. The role of DC in auto-
immunity was discovered in 1983, when Knight et al. transferred DC from autoimmune 
encephalomyelitis-bearing animals to healthy ones, and observed in the latter the 
appearance of the disease, driven by the induction of auto-reactive T cells (185). This 
experiment illustrates how a specific context of DC maturation, here being encephalomyelitis, 
induces a reproducible effect on the adaptive immune response.  
The main dichotomy found in literature on DC maturation states classifies DC as 
immunogenic if they lead to a predominant effector T cell response or tolerogenic if they lead 
to a predominant regulatory T cell response. This separation happens upon priming, when 
naïve T cells integrate the signals from the combination of membrane-bound and soluble 
costimulatory molecules present at the DC-T immune (186). Grossly, immunogenic DC are 
typically associated to membrane-bound costimulatory molecules and the cytokines IL-12 
and IL-1β, whereas tolerogenic DC are associated to the membrane-bound coinhibitory 
molecules and IL10, TGF-β and TNF, or even no cytokines (187), (188), (189), (190). This is 
of course a simplistic view, omitting other T cell modulating signals, such exosomes (191). 
We will overview so called immunogenic DC and tolerogenic DC, but will not go into details 
about homeostatic maturation, which exists at steady-state and implies self-antigen 
presentation for peripheral self-tolerance (172), (192). Although being a fascinating function 
of DC, homeostatic maturation has no direct link to the inflammation-induced maturation that 
is detailed here in order to better understand the specific context of cancer inflammation. 
It is important to mention that not only the context may induce immunogenic or tolerogenic 
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DC, but also the different DC subsets within the same context (193). For example, in mice 
atherosclerosis, cDC1 promote atheroprotective Treg responses, to the contrary of CCL17+ 
cDC2 that inhibited Treg maintenance (194). The same observation was made in lung were 
CD103+DC become tolerogenic while CD103-DC are immunogenic after allergen or TLR 
ligand stimulation (195).  
 
 
 
Fig 8 – Features of immature and of the different types of mature DC and their impact on the 
immune response, here applied to the anti-tumor immune response. Adapted from Dudek et 
al. (187). 
 
  
(ii) Immunogenic DC 
 
Immunogenic DC are defined by their ability to prime CD4 and eventually CD8 T cells 
towards a cytotoxic effector immune response, and may also include DC that promote Tfh 
and B cells activation towards a humoral immune response. The typical induction of 
immunogenic DC refers to DC stimulated by a “non-self” entity, which will prime T cell 
harboring the specific TCR for this “non-self” antigen, as it is the case for acute infection. 
One of the most broadly corresponding experimental model uses lipopolysaccharide (LPS) to 
stimulate TLR4 on DC. This typically leads to the upregulation of MHC-II, CD80, CD86 and 
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IL12p40 production, which in turn induce naïve CD4 T cell proliferation and IFNg production 
(196). DC IL-12 production may then be increased through CD40L-CD40 DC-T cell 
interaction (197), for up to 16 hours (198). 
Not only the stimuli themselves, but their duration and intensity are important for the 
induction of immunogenic DC (199). Besides the stimuli, the tissue of origin may modulate 
the immunogenic potential of DC. This observation is of major importance for vaccination 
strategies. For example, Stary et al. showed that both R848-based synthetic adjuvants 
particles and a mucosal route, as opposed to a systemic route, where necessary to obtain a 
prolonged immunity after vaccination against Chalmydia Trachomatis (200). The same 
observation was made for anti-cancer vaccine by Sandoval, Tartour et al., in 2 mouse 
models of orthotopic head and neck and lung cancers: tumor growth was inhibited after 
vaccination by intranasal route and not intramuscular route (201).  
 
 
 
(iii) Tolerogenic DC  
 
The concept of tolerogenic DC appeared in 1979 when Mitchison introduced the idea that 
Langherans cells could be exploited to increase host versus graft tolerance to prevent graft 
rejection, which was still a major challenge at that time (202). Since then, the term has been 
used in many different contexts, in vitro, ex vivo and in vivo and is a rather large concept that 
engulfs all cases that eventually induce a predominant regulatory T cell response and 
immunosuppression. It also includes the specific case of self-tolerance, when this regulatory 
response is induced by the presentation of normal self-antigens, as in the thymus (203), the 
mesenteric lymph nodes (204) and even the periphery (205), that will not be further detailed 
in this thesis. Importantly, a regulatory T cell response can also be induced by immature DC, 
further enlarging this field (192), (206), (207), (208), (209). When considering stimulated DC 
that have a tolerogenic function, another term frequently used is “semi-mature” which in 
general corresponds to the presence of some, but not all, features of activation (187). The 
absent features are considered as the cause of this immunosuppressive response. This term 
is confusing because it may be understood as the results of an aborted maturation process, 
whereas it is not the only context lead to tolerogenic DC. It is also questionable, since a 
comprehensive measurement of all DC membrane-bound and secreted molecules is not 
routinely performed: we cannot exclude that DC inducing a tolerogenic output have in fact 
undergone as much change as the immunogenic DC, but qualitatively different. 
 
The main characteristics of tolerogenic DC are a low or intermediate expression of 
costimulatory molecules (210), an increased or predominant secretion of IL-10 (206), and the 
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polarization of CD4 T cells towards a regulatory T cell response (208). IL-10 secretion favors 
Treg polarization (211), but also inhibits antigen presentation by DC though its inhibitory 
effect on proteases in the endosomes (151). Another type of tolerogenic DC corresponds to 
DC expressing the same levels of MHC-II and costimulatory molecules CD80/CD86 than 
control immunogenic DC, but that do not secrete IL-12 not IL-10. This type of DC may be 
induced by paracrine DC stimulation with inflammatory cytokines without PRR stimulation, as 
shown in vitro and in vivo using in chimeric TLR4-/- TLR4+/- chimeric mice (196). In this 
experiment, CD80+/CD86+ semi-mature DC failed to produce IL-12p40 but could induce 
clonal T cell proliferation at a similar level than TLR4+/+ control DC. However, they failed to 
promote INF-γ or IL-4 production by T cells. The regulatory phenotype of expanded T cells 
was not analyzed (196). 
 
Tolerogenic DC can be induced in vitro by siRNA silencing CD80, CD86 (212), CD40 (213) 
or IL-10 (214), or by anti-inflammatory factors such as vitamin A, vitamin D3 (215), 
prostaglandin E2, IDO, IL10 (216), TGF-β (217), retinoids (218), hepatocyte growth factor 
(219), E-cadherin disruption (220), and vasoactive intestinal peptide (221).  For all these 
tolerogenic inducers, the tolerogenic phenotype of DC was experimentally confirmed by the 
observation of a regulatory T cell response. Various mechanisms are engaged in each case 
to eventually obtain the tolerogenic function. For example, Vitamin D3 inhibited NFkB p65 
phosphorylation, skewed the production of CCL17 towards CCL22, a regulatory T cell 
attracting chemokine, down-regulated HLA-DR, CD80, CD86 and CD40 on cDC2, as 
compared to unstimulated DC. The final read-out was that it augmented the suppressive 
effect of CD4 T cells in mixed leukocyte reaction, as shown by the decrease in IFN-γ 
production (215). However, some experiments performed with the tolerogenic inducers listed 
above were not performed with sorted human primary cDC, but with in vitro-generated Mo-
DC, and in some cases the stimuli were given during Mo-DC differentiation, so that their 
effect on cDC remains to be shown. M-CSF is another example of a molecule that induces 
semi-mature DC:  it efficiently induced the upregulation of MCH-II molecules synthesis and 
their presentation at the plasma membrane, but without stabilizing them sufficiently to 
eventually induce T cell activation, thus resulting in a final inhibitory effect (222). 
 
Ex vivo, DC co-culture with murine pulmonary stromal cells also induces a tolerogenic 
phenotype, corresponding to a decreased MCH-II expression, an increase in IL-10 and 
prostaglandin E2 secretion, and a suppression in T proliferation, despite the unchanged 
levels of CD80, CD86 and CD40. In this model, TGF-β is in part responsible for this DC 
phenotype (189).  
Tolerogenic DC have also been observed in vivo. In 3 mouse models of cancer, Gerner et al. 
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showed that tumor infiltrating DC expressed similar levels of costimulatory molecules than 
dermal DC, but that they were poorly efficient at antigen uptake, thus leading to inefficient at 
MHC-II-peptide complex presentation, and poor T cell response in the draining lymph node 
(223). Similarly, in the study of Iliev et al. (224), mouse DC from mesenteric lymph nodes 
induced more Treg differentiation that spleen DC (8.9% vs 3.2%) in the presence of OVA. 
Conditioning spleen DC with intestine epithelial cell-derived supernatant increased the Treg 
polarization up to 9.1%, showing the importance of the soluble microenvironment, and of 
TGF-β and retinoic acid in this case, in the induction of tolerogenic DC.  Another factor 
engaged in the regulatory response is the DC: T cell ratio. In the same study, the authors 
showed that the decrease of DC:T cell ratio from 1:1 to 1:64 dramatically increased the 
induction of CD4+Foxp3+ Treg after co-culture (225).  
The induction of tolerogenic DC upon stimulation is not restricted to specific receptors. TLR 
activation induces mainly immune responses as seen in the previous paragraph 1.2.2.2 (ii), 
but can also induce tolerogenic responses, as seen with Zymosan (226) or Yersinia pestis, 
that signal through TLR2 and Dectin1, and TLR6 respectively (227). Tolerogenic DC may 
also overexpress the inhibitory Fc receptor FcgRIIb (CD32b), as observed in human 
quiescent rheumatoid arthritis (228) and in cancer (71).  
 
Tolerogenic DC play a role in many different diseases. Their presence in cancer TME is 
thought to favor immunosuppression and tumor immune-evasion (188) (see section 1.2.3.3). 
To the contrary, their absence or insufficient effect causes auto-immunity or augments 
atherosclerosis (229). Tolerogenic DC thus have a therapeutic potential in auto-immune and 
inflammatory diseases, and to augment graft lifespan after transplantation. 
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1.2.3 DC in cancers  
 
1.2.3.1 Tumor-infiltrating DC    
 
DC are key players of the anti-tumor immune response. As described for infection, DC will be 
recruited and activated by danger signals occurring upon tumor-induced tissue-damage 
(230). At the initiation of tumor-induced inflammation, DC recruitment from blood into tumor is 
controlled by the chemokines that may be secreted by the epithelial cells and/or the resident 
innate immune cells (117), (231). DAMP present in tumors are released by the tumor cells or 
the normal cells from the underlying tissue that undergo non-apoptotic cell deaths, such as 
necrosis or necroptosis. Necroptosis is a sub-type of regulated cell death in which the 
plasma membrane is irreversibly permeabilized and has been shown to happen during 
treatment by chemotherapy or radiotherapy (232). It is also named “immunogenic cell death” 
because of its potential to initiate anti-tumor response (233), (234). DC will uptake abnormal 
tumor-derived antigens (230), and present them to T cells in the tumor draining lymph node 
after DC maturation and migration (235). As soon as DC have been recruited into the tumor, 
an efficient immune response is therefore possible. The existence of tumors are obvious 
proofs that these responses are insufficient. Deciphering tumor infiltrating DC will add 
knowledge to the complex network of biological events that underlie tumor immune escape.  
 
All main DC subsets described in blood (chapter 1.2.1.4) are found in cancer tissue, to the 
exception of pre-DC / AS-DC (71). Additionally, tumors are inflammatory tissues and are 
infiltrated by CD14+DC / Mo-DC (236), (237). In tonsil SCC, cDC1, cDC2, cDC4 (or BDCA1-
BDCA3-DC) and pDC represent altogether 1.2 +/- 0.8% of CD45+ cells, as compared to 
0.7%+/-0.2% in benign tonsil, and cDC1 was the less frequent DC subset (71). In the same 
study, the proportion of cDC/pDC ratio was increased in the tumor. These data cannot be 
extrapolated to the other locations of HNSCC, because tonsil cancer occur by definition in a 
secondary lymphoid organ and not (or not only) in upper-aero-digestive tract mucosa. In 
early lung adenocarcinoma, cytometry by time of flight (CyTOF) analyses showed that cDC2 
and cDC1 represented 4 % and 0.25% of CD45+ cells respectively. The frequencies of cDC2 
were equivalent to the one observed in paired normal lung, whereas the frequencies of cDC1 
were significantly decreased (237). These variations of proportions are interesting with 
regard to the differential recruitment of subsets, but do not reflect the overall density of cDC 
subsets in tumor tissue, since the frequencies of CD45+ cells are increased in tumors as 
compared to juxtatumors. We will review the evidence of cDC anti- and pro-tumorigenic 
function in cancer. The role of pDC will not be detailed as it is presented in Annex 5.3. 
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1.2.3.2   cDC in cancer: teammates of the anti-tumor immune response 
 
cDC1, the cross-presenting DC subset, are considered as the most efficient cell subset to 
induce an effector CD8 cytotoxic response, since the experiments performed with tumor-
bearing Batf3-deficient mice models (77), (223), (238). This superiority of cDC1 to cross-
present antigens from necrotic cells has been confirmed in human (72) (239) (240). 
Additionally, cDC1 were shown to be, at the RNA level, the main source of the major T cell 
attracting cytokines CXCL9 and CXCL10 in a mice model of melanoma, as compared to 
cDC2, Mo-DC, macrophages, stroma and tumor cells (241). This observation remains to be 
confirmed in human cancer. cDC1 of human malignant tonsil upregulated CXCL10 as 
compared to cDC1 from benign tonsil, but the levels of CXCL10 transcripts were not 
compared across subsets (71). Given the very low number of tumor infiltrating cDC1, it 
seems rather unlikely that CXCL9 and CXCL10 secretion is limited to cDC1 in human 
tumors. Beyond cross-presentation human cDC1 can also produce inflammatory cytokine IL-
12 (72). Finally, in the line with the protective role of cDC1 in the context of cancer, tumor 
highly infiltrated by cDC1 have been associated to good prognosis in multiple cancers, and in 
the TCGA analysis of HNSCC in particular (70).   
 
Cytotoxic anti-tumor CD8+ response is not only due to cDC1 and cross-presentation. First, 
human cDC2 may also cross-present (242). Second, cDC1 and cDC2 prime CD4 T cells, 
whom support to CD8 T cells has been shown essential in B16 and B78 melanoma mice 
models (243), (244), (245), (246). Third, cDC2 overexpress CCL22 and CCL17, two 
chemokines attracting more immature DC and CD4 T cells into tumors (237). Four, they 
secrete inflammatory cytokines, as shown by MARS-seq single-cell transcriptomics of the 
immune infiltrate of an early lung adenocarcinoma and its paired juxtatumor tissue. Two DC 
clusters corresponding to cDC1 and cDC2 were identified. cDC2 were shown to secrete the 
inflammatory cytokines IL-6, IL-8 and IL-1β at a similar level than CD14+ monocytes. The 
same cytokine profile was observed in normal lung tissue, supporting that the immunogenic 
potential of DC was maintained in tumor tissue (237). cDC2 have been also been shown to 
be an important source of IFN-β, a cytokine that promotes cDC1 cross-presentation (247), 
(248). Five, the ability of cDC2 in transporting tumor-antigen to the lymph node was 
confirmed in a mice model of melanoma: the percentages of antigen-positive cDC1 and 
migratory cDC2 in the tumor draining lymph node were of 10-15% and ~3% respectively 
(249). Finally, cDC2 are also important for the anti-tumor immune response occurring locally 
in tertiary lymphoid structures (TLS). Both cDC1 and cDC2 overexpressed LT-β, a cytokine 
associated with TLS (237). The analysis of tumor tissue sections confirmed that DC 
colocalized with TLS and T cells. This observation was in the line with the former analysis by 
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Dieu-Nosjean et al. of mature DC-LAMP+ DC in TLS from 74 early non-small cell carcinomas 
lung cancer (NSCLC) samples (250). High DC-LAMP+/TLS tumors identified patients with a 
better prognosis, supporting the beneficial role of tumor-infiltrating DC in the spontaneous 
anti-tumor response. Since both studies used DC-LAMP to identify DC by immuno-histo-
chemistry (IHC), the presence of DC-LAMP negative cDC2 in other area of the tumor and 
their functional status was not analyzed.  
 
 
1.2.3.3 cDC in cancer: opponents of the anti-tumor immune response 
 
Having described how DC may protect the host against abnormal tumor tissue in a very 
similar manner as in infection, there is also an extensive literature supporting the tolerogenic 
role of tumor infiltrating DC (56). Tolerogenic tumor infiltrating DC are considered as pro-
tumorigenic, either by remaining passive and not initiating an efficient immune response, or 
even by expressing factors that counteract the function of surrounding anti-tumor immune 
cells.  
 
As described in section 1.2.2.2, tolerogenic tumor-infiltrating DC may be recognized by their 
low levels of expression of the costimulatory molecules CD40, CD80 and CD86, their low 
secretion of pro-inflammatory cytokines, and their increased production of IL-10 and TGF-b 
as shown in mice (251), (252) and human DC (253). TGF-β and IL-10 promote Treg 
polarization and anergy of antigen-specific effector T cells (251), (252), (253), (254). IL-10 
blocking was able to restore DC responsiveness (254). In this line, other studies showed that 
IL-10 deficient DC were more immunogenic and able to induce sustained anti-tumor Th1 
responses than control DC (255).   
Tumor DC-derived indoleamine 2,3-dioxygenase (IDO) is another factor responsible for T cell 
immunosuppression (71), (256). IDO is an enzyme that depletes tryptophan available for 
surrounding cells and is recognized as a strong immunosuppressor; in particular mice 
IDO+DC downregulated CD3zeta chain in CD8 T cells, resulting in impaired cytotoxic 
effector function (257).  
Tumor cDC2 have also been categorized as tolerogenic because of their poor ability to 
present MCH-II-tumor-antigen complex to T cells spontaneously; a soluble peptide 
restimulation was required to restore adequate antigen presentation (243), (244).  
The overexpression of negative checkpoints ligands on DC was also reported to inhibit T cell 
response (258), (259), (260). In human tonsil cancer, cDC2 overexpressed the negative 
checkpoints PDL1, PDL2, and LAG, the genes associated to the GOTerm ‘Immune 
response_IL-10 signaling pathway’, and downregulated 2 GOTerms associated to NFkB 
activation as compared to cDC2 from benign tonsil, supporting the idea of tumor-induced 
42	
	
immunosuppression (71). Again, this might be specific to cancers developing in the lymphoid 
organ that is the tonsil.  
 
Given the evidences of the presence of tolerogenic DC in cancer, the next question would be 
to ask which factors are responsible for this phenotype. One mechanism is a DC-Treg loop: 
tolerogenic DC promote Treg that in turn promote tolerogenic DC by downregulating CD80 
and CD86 on DC after TCR engagement via CTLA-4 (261). Also, DC and Treg derived IL-10 
reduce DC expression of MHC-II, costimulatory molecules and secretion of IL-1β, IL-6, IL-12 
and TNF (169). IL-10 is the TME may also be produced by macrophages, and similarly inhibit 
the production of IL-12 by DC, as shown for CD103+ DC in a mice model of mammary 
carcinoma (262). IL-10 exerts its tolerogenic effect on DC by inhibiting TLR, TNF-α, and IFN-
γ signaling in DC (169).  
Besides IL-10, other DC tolerogenic inducers were identified in tumors, such as 
mesenchymal Stromal Cell-Derived Extracellular Vesicles (263), PGE2 (264), VEGF (265), 
CSF-1 (266), GDF-15 (267), RANKL (268).  It is important to mention that Mo-DC and not 
primary DC were used in these 6 studies (263) (264) (265), (266), (267), (268). 
Finally, abnormalities in metabolisms induced by the hypoxic TME is also a factor that may 
promote tolerogenic DC. In vitro experiments using a peptide-pulsed Mo-DC co-cultured with 
CD8+Tcells showed that lactic acid decreased the ability of Mo-DC to produce IL-12, but not 
IL-10, and inhibited CD8+T cell proliferation (269). In a mouse model of ovarian cancer, 
tumor infiltrating DC activation was inhibited by a XBP1-dependant triglyceride biosynthetic 
program induced by the tumor micro-environment (270).  
Altogether, these data support the presence of tolerogenic DC in tumors, but ex vivo data 
from human tumor infiltrating DC compared to normal-tissue resident DC, and on TME-
derived tolerogenic factors are sparse. 
 
 
 
1.2.3.4  cDC in cancer: 2 sides of the same coin 
 
It seems difficult to conciliate the important number of evidences supporting the anti- and 
pro-tumorigenic effect on cDC. NFkB is an important factor in the regulation of DC maturation 
and subsequent function. Although initially associated to the host protection, NFkB may also 
act as a mediator of anti-inflammatory functions, as reviewed by Pires et al. in “NF-kappaB: 
Two sides of the same coin”, hence the title of this paragraph. In human, there are some 
evidence that tumor infiltrating DC harbor simultaneously immunogenic and 
immunosuppressive features. Michea, Noël et al. performed transcriptomic analysis of triple 
negative breast cancer APC and showed that the Gene Ontology (GO) Terms, ‘chemokine 
43	
	
activity’, ‘cytokine activity’, ‘cytokine receptor binding’ and ‘IL-10 signaling’ were shared by 
cDC2s and CD14+, supporting the simultaneous expression of pro and anti-inflammatory 
cytokines (236). Using a similar approach in human tonsil cancer, cDC1 were shown to 
simultaneously upregulate the genes associated to the GO Terms pro-inflammatory ‘Immune 
response_IFN-alpha/beta signaling via JAK/STAT’ and ‘Immune response_T regulatory cell-
mediated modulation’ including the negative immune checkpoint LAG3 (71). 
Similarly, in the same study, BDCA1-BDCA3- DC (cDC4) overexpressed both 
immunostimulatory genes as IRF1 or STAT1 and the immunosuppressive IDO1. IDO that is 
considered as a strong immunosuppressive factor is also in fact required for DC maturation, 
chemokine secretion and chemokine receptor expression, thus moderating the negative role 
of IDO on DC in the TME (271). PGE2 induced tolerogenic DC (264), but was also able to 
rescue the impairment in CCR7/CCL19 upregulation on DC caused by prostate cancer cell 
line-derived factors (272). 
In summary, DC are protective against cancer, but the complex biological network present in 
the TME also limits their full immunogenic potential. Combined therapeutic approaches 
counteracting the different factors inducing tumor tolerance are required and would need to 
be selected on fine analysis of human DC subsets in each specific context.  
 
 
1.2.3.5 DC as therapy 
 
Given their key role in anti-tumor immune response, several approaches using DC as a 
therapeutic tool have been proposed and tested. DC may be used directly as a cell therapy. 
In this case, autologous DC (or monocytes) are obtained by leukapheresis and modulated 
(and/or differentiated), expanded and pulsed or fused with specific targets in vitro, before 
being injected to patients (273). Such treatments have been proposed for cancer and auto-
immune diseases (NCT02618902). One example is the sipuleucel-T vaccine that obtained 
approval for prostate cancer (274). DC cell therapy is limited by its cost, but also by the fact 
that the DC activation phenotype obtained in vitro may not be stable during cell transfer 
limiting the efficacy. A recent meta-analysis including 6 clinical trials testing DC pulsed with 
prostate-specific membrane antigen in metastatic castration-resistant prostate cancer 
patients failed to show a benefit on survival (275). Several trials with combination therapies 
are ongoing with sipuleucel-T (NCT03024216, NCT01818986) and other DC-based vaccines 
in other indications (NCT02479230). Sipuleucel-T is produced with PBMC cultured with 
tumor peptide but does not isolate one or several APC subtypes. To the contrary, other 
phase I trials tested DC vaccination with specific DC subsets, which were injected intra-
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nodally, in HLA-A*0201 patients presenting with metastatic chemo-resistant melanoma 
expressing gp100. A first trial used autologous sorted blood pDC activated overnight with IL-
3 and subsequently with FSME-IMMUN (a vaccine against tick-born encephalitis) and then 
loaded with tumor peptide (276).  Another phase I trial successfully achieved vaccination with 
3 to 10 million sorted autologous CD1c positive primary DC. cDC were cultured overnight in 
X-Vivo with human serum and GM-CSF for maturation, and then loaded with the tumor 
peptide shortly before injection (277). As observed with checkpoint blockade, 4 out of 14 
patients presented prolonged clinical responses in this phase 1. A phase 3 trial is currently 
testing a vaccine made of autologous sorted pDC and cDC in melanoma (NCT02993315). A 
phase 1 trial is currently testing personalized vaccines using autologous DC pulsed with 
autologous whole tumor cell lysate and injected intra-nodally in patients with advanced solid 
tumors and high tumor mutation burden (NCT03671720). 
 
An alternative approach to cell therapy is the DC targeting in vivo via activating receptors and 
pathways. We will only detail here the current clinical use of PRR and TLR agonists, as an 
introduction for the study presented in result section 3.1. However, other activators are being 
used or under evaluation such as cGAS-STING pathway activators (278), (279), (280) 
(NCT02723955), DEC-205 ligands (NCT02166905) (207), DC-SIGN ligands (40), and 
aluminum salts or saponins that activate the NLRP3 inflammasome (281). These activators 
may be used either as adjuvants for peptide-based vaccine or may be applied on or injected 
in tumors. It must be kept it mind that these adjuvants may also interact directly with other 
cells types, such as cGAS-STING activators that have a direct effect on T lymphocytes (282). 
Imiquimod (R848) is a TLR7/8 ligand used routinely for basal cell carcinoma. Salmon et al. 
showed an optimal anti-tumor effect by activating cDC1 with a cocktail FLT3L and Poly I:C 
combined to anti-PDL1 in a B16 melanoma mice models (238). In the same model, Desch et 
al. further showed that Poly I:C activated cDC1 and R848 activated cDC2, and that both 
were able to induce a cytotoxic T cell response (284). A similar approach with intra-target 
lesion injection of FLT3 and Poly I:C, combined with 2Gy radiation therapy, was used in a 
pre-clinical model and in a phase I clinical trial including patients presenting with treatment-
resistant indolent non-Hodgkin's lymphomas (NCT01976585) (283). In both mice and 
human, accumulation of intra-tumoral cDC1 and cDC2 was observed with this in situ 
vaccination strategy. Another study in mouse models of fibrosarcoma, lung carcinoma and 
B16 melanoma, showed that peri-tumoral injections of CpG-ODN controlled tumor growth 
and that this effect was mediated by NK cells and CD8 T cells. The presence of mature 
migratory DC was demonstrated, but the possible role of CD4 T helper cells as an 
intermediate for CD8 T cell activation was not studied (285). In mouse models of colon and 
kidney cancers, weekly peri-tumoral CpG injections associated to radiotherapy could achieve 
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complete cure of established tumors and even induce an abscopal effect on simultaneous 
untreated contralateral tumors (286). That said, CpG is a TLR9 ligand, and TLR9 is not 
expressed on the same DC subsets in mice and in human, limiting the straightforward clinical 
translation of these results. Finally, a study in advanced melanoma patients showed 
promising results and an overall response rate of 38% with TriMixDC-MEL and ipilimumab. 
TriMixDC-MEL combines Mo-DC-based cell therapy with a TLR4 signaling by 
coelectroporating constitutively activated TLR4, CD40L and CD70 (287). 
 
In addition to pharmaceutical TLR agonists, chemotherapy and radiotherapy are also able to 
promote DC recruitment and maturation. In several mice model of solid cancers, Ma et al. 
demonstrated that anthracycline-based chemotherapy induced the recruitment of cDC2 into 
tumors and that it was due to ATP binding on DC purinergic receptors, ATP having been 
released by dying tumor cells (288).  In colon, lung and melanoma mouse models, 
radiotherapy induced the upregulation of CD70 and CD86, but not of MHC-II, on cDC2 and 
induced a CD8+ T cell mediated anti-tumor immune response. CD4+T cell were dispensable 
in this study (289). Radiotherapy was shown to activate the immune system in multiple ways, 
such as the activation of the cGAS-STING pathway, the induction of chemokine production 
and the upregulation of integrins  (290). In this line, dozens of clinical trials are currently 
evaluating various combinations of radiotherapy and immunotherapy in many different 
cancer types (291). However, radiotherapy also has immunosuppressive effects, and in 
particular was shown to down-regulate CD80 and CD86 and DC (292).  
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2. OBJECTIVES OF THE THESIS 
 
DC biology is now a knowledge-rich field, particularly in mouse DC and human blood DC 
biology. As presented in the introduction, some debate remains on DC maturation states. 
Moreover in vivo mouse models and even some clinical trials have shown that DC are a 
highly valuable target for immunotherapy in cancer and other diseases, and that DC 
maturation state is the key for DC-based treatment efficacy. Knowledge on human HNSCC 
tumor infiltrating DC is scarce and does not allow to anticipate how to modulate tumor DC as 
therapy. 
 
The objective of my thesis was to describe in a high-resolution approach the molecular state 
of tumor infiltrating DC and their relation to the tumor microenvironment.   
We wanted to address several questions:  
- Which DC subsets infiltrate HNSCC and in which proportions? 
- What is their expression of maturation marker and of positive and negative immune 
checkpoints? 
- What is the relationship between tumor infiltrating DC frequencies and states and the other 
tumor immune subsets? 
- Which mechanisms shape DC maturation states in the TME? 
- Are there patterns of tumor immune infiltration? 
- What is the association between tumor immune cell infiltration and the soluble TME?  
- Which TME parameters are associated to prognosis? 
- Can we identify potential therapeutic targets and/or theragnostic markers? 
 
To do so, we took advantage of the human clinical samples available at the Institute Curie, 
provided by the surgical oncology and the pathology departments, from surgical specimens 
of willing patients. We analyzed DC subsets, their maturation markers and checkpoint 
expression, other myeloid cell subsets, and T cell subsets in primary HNSCC by flow 
cytometry. In parallel, we completed our biobank of tumor-derived secretome that had been 
initiated several years ago in our team, to obtain multiplex analysis of soluble molecules 
relevant to multiple cancer pathways. I wanted to obtain paired flow cytometry and soluble 
TME data to perform integrated analysis. This joint DC-focused and multiparametric 
approach of the TME was the starting point to understand HNSCC DC in their tumor context.  
 
We developed a multicolor flow cytometry antibody panel optimized for DC subsets and I 
took advantage of the expertise of the clinical immunology team of Olivier Lantz for the T cell 
48	
	
antibody panel. First, I discovered the difficulty of working the limited resource that are fresh 
human tumor samples. Then, I had to handle the analysis of the medium throughput data 
obtained by immuno-monitoring.  For this reason, I trained to use the recent Qlucore 
software, aimed at helping non-bioinformatician researchers to explore sequencing data. I 
thought to apply to my flow cytometry dataset the methods that are usually dedicated to RNA 
sequencing analysis, such as unsupervised analyzes and clustering. With this approach, I 
have been able to identify an important role for the frequency of CD3+ T cell in the “structure” 
of my dataset. With this observation and the extensive literature available on the role of 
tumor infiltrating T cells, I finally selected this parameter for the supervised analyzes. I was 
then able to observe that DC subsets in CD3 high inflamed tumors presented with a constant 
pattern of high PDL1 and very low ICOSL expression. This pattern was opposed to blood DC 
and to DC from non-inflamed tumor, that had an intermediate expression of ICOSL and a low 
expression of PDL1. 
  
This observation lead me to use a valuable resource of the team created by Maximilien 
Grandclaudon aimed at elucidating DC phenotype and T cell modulation after DC exposure 
to many different stimuli in vitro (293). The initial scope of this database was the 
mathematical modelling of cell-cell communication. I approached it in a new way, with the 
perspective of PDL1 and ICOSL, the 2 molecules identified from tumor samples. Doing so, I 
identified 2 opposite patterns of matured DC, which we labelled “secretory” and “helper”. 
Transcriptomic analysis of sorted HNSCC samples allowed us to confirm the relevance of 
this new classification of DC maturation state in human tissue. The corresponding 
manuscript that will soon be submitted is presented in the results section 3.1. 
 
In parallel, I could obtain paired flow cytometry data and soluble data for 18 samples. I was 
able to confirm the expected association of T cell infiltration with the levels of soluble CXCL9 
and CXCL10. This observation was important to validate this original primary-tumor derived 
secretome approach. Comparison of tumor and juxtatumor tissue revealed many deregulated 
proteins that were all candidate biomarkers. I used my medical skills to select the best 
clinical setting to pursue with prognosis biomarker discovery and identified soluble MMP2 as 
a predictive of poor prognosis in oral cavity cancer patients. I designed a large validation 
cohort to confirm this finding. My objective then was not only to validate the value of MMP2, 
but also to evaluate if there was a relation between patients’ prognosis and the expected 
response rates to immunotherapy by measuring genes of a published predictive signature. 
This biomarker study based on an unsupervised analysis of primary tumor secretome has 
been submitted to Clinical Cancer Research and is presented in the results section 3.2. 
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3. RESULTS 
 
3.1  PDL1 AND ICOSL DISCRIMINATE HUMAN SECRETORY AND HELPER 
DENDRITIC CELLS 
 
Article available at https://doi.org/10.1101/721563 
 
Abstract 
  
Dendritic cells (DC) are described as immature at the steady state, with a high antigen 
capture capacity, turning into a mature state with a strong T cell stimulatory capacity upon 
activation. Using 16 different stimuli in vitro (130 observations), we describe two states of 
human activated dendritic cells. PDL1highICOSLlow “secretory DC” produced large amounts 
of inflammatory cytokines and chemokines but induced very low levels of T helper (Th) 
cytokines following DC-T co-culture; conversely PDL1lowICOSLhigh “helper DC” produced 
low levels of secreted factors but induced high levels of Th cytokines characteristic of a 
broad range of Th subsets. Secretory DC were phenotypically identified in T cell inflamed 
primary head and neck squamous cell carcinoma. RNAseq analysis showed that they 
expressed a typical secretory DC signature, including CD40, PVR, IL1B, TNF, and CCL19. 
This novel and universal functional dichotomy of human DC opens broad perspectives for the 
characterization of inflammatory diseases, and for immunotherapy. 
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INTRODUCTION 
 
Dendritic cells (DC) have a key role in initiating and polarizing the immune responses, 
including anti-tumor immunity (1). Immature DC patrol in tissues and have a low expression 
of costimulatory molecules. Following antigen stimulation, they mature and acquire a strong 
T cell stimulatory capacity (2). So far, mature DC have been classified as immunogenic when 
they induced T effectors and secreted IL12 and IL1b, or tolerogenic when they induced 
regulatory T cells and secreted IL-10, TNF and TGFb, or no cytokines (3), (4), (5), (6). In 
cancer, it is considered that factors derived from the tumor microenvironment induce 
tolerogenic DC (7), (8), (9). However, most studies have been realized using a limited 
number of stimuli, mostly in mice models or in vitro with human monocyte-derived DC (10), 
(11), (12).  Furthermore, the phenotype and function of tissue infiltrating DC in human 
remains largely unknown. Our aim was to decipher the mechanisms regulating DC 
phenotypes and to understand their associated function, with a physiopathological relevance 
in human cancer. 
 
 
RESULTS 
 
To determine the phenotypic heterogeneity of DC infiltrating cancer tissue and its relation to 
the other immune cell types, we analyzed by flow cytometry 22 fresh head and neck 
squamous cell carcinoma (HNSCC) samples. Here, we show that the frequencies of tumor 
infiltrating CD3 T cells were positively associated to the frequencies of DC and to PDL1 
expression on CD11c+HLA-DR+ cell subsets, and negatively associated to the frequencies 
of neutrophils and of ICOSL expression on the same cells (Fig1). We used 2 different 
antibody panels analyzing T cell subsets (Fig S1A) and myeloid cells subsets (Fig 1A, 1B). In 
the myeloid panel, CD45+, Lineage- (CD3, CD19, CD56) cells were analyzed by their 
expression of CD11c and HLA-DR. The double positive population was separated into four 
populations by their expression of CD14 and BDCA1, and included the monocytes and 
macrophages (MMAC), the CD14+DC, the cDC2 (BDCA1+CD14-) and the double negative 
population enriched in cDC1 (cDC1e) (Fig S1B). Plasmacytoid DC were gated as CD11c-, 
HLA-DR+, CD123+. We extracted a total of 434 parameters. We found a large variation of 
CD3 infiltration across tumors ranking from 1% to 61% (Fig 1C). In order to identify the 
parameters associated to tumor inflammation, we defined 3 groups of equivalent sizes 
labeled “CD3 High” (n=8), “CD3 Int” (n=6), and “CD3 low” (n=8). To avoid bias, we used a 
sub-list of 81 non-redundant parameters among the 434 measured, meaning that each 
population was expressed only in percentage of its parental population (Table 1). CD3 high 
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tumors were significantly enriched in cDC2, cDC1e, pDC and in PDL1 expressing MMAC 
and cDC1e. Conversely, CD3 low tumors were enriched in Lin-DR- cells (mainly neutrophils, 
see Fig S1C), macrophages, and ICOSL expressing CD11c+HLA-DR+ cells (Fig 1D, 1E, 
1F). The levels of expression of PDL1 and ICOSL in the four CD11c+HLA-DR+ subsets were 
highly correlated in all tumor samples (Fig S1D). CD11c+HLA-DR+ cell subsets in CD3 low 
tumors expressed intermediate levels of PDL1 and ICOSL and were closer to the expression 
observed on their blood counterparts than the same subsets in CD3 high tumors, which 
upregulated PDL1 and downregulated ICOSL (Fig 1E). Thirteen out of the 16 significant 
parameters were obtained from the myeloid cell panel (Fig 1D), showing that there were 
fewer variations in the percentages of the various T cells subsets related to CD3 infiltration 
levels. For example, the proportion of regulatory T cells among the CD4+ T cells were 34%, 
35% and 41% in the CD3 High, Int and Low groups respectively. Finally, to determine if any 
combined parameter, ratio or clinical variable was highly efficient at discriminating the 3 
groups, we performed an elastic net model including the all the 434 parameters and 14 
clinical parameters (Table 2). We found that the intermediate expression of ICOSL on 
CD11c+HLA-DR+ cell subsets was highly characteristic of the CD3 low group (Fig S1E). 
Only parameters directly linked to T cell infiltration (percentages of T cell subsets in live cells) 
were found in the high CD3 group. In summary, we showed that CD3 inflamed tumors were 
more infiltrated by DC subsets that expressed higher levels of PDL1 than in non-inflamed 
tumors, and that PDL1 and ICOSL expressions on DC and macrophages were opposed (Fig 
1D, Fig S1D). 
 
To identify candidate stimuli that could be responsible for the PDL1/ICOSL expression 
patterns and to further understand the subsequent functional implications, we took 
advantage of a DC-T cell dataset from Grandclaudon et al. (13). We used the existing data 
on primary blood CD11c+HLA-DR+ DC and generated supplementary experiments and 
analysis. Briefly, blood DC were activated for 24 hours by 16 different types of perturbators 
and analyzed for their expression of 29 surface markers (n=154 data points), and their 
secretion of 32 chemokines and cytokines (n=130 data points). The remaining cells were co-
cultured with allogenic naïve CD4 T cells for 6 days and we measured the expansion fold. 
After 24h of restimulation by anti CD3/CD28 we measured 17 T helper cytokines (Fig 2A). 
We confirmed the anti-correlation of PDL1 and ICOSL expression (Fig2B).  Three main 
groups of responses were observed: (i) PDL1high and ICOSLlow, like on ex vivo cDC2 from 
inflamed tumors; (ii) PDL1low and ICOSLhigh, and (iii) medium-like PDL1 low and ICOSL 
low (Fig 2B). Co-expression of both PDL1high and ICOSLhigh was a rare profile and was not 
observed for very high expression levels.  ICOSL expression was null when PDL1 
expression reached its highest levels. We used an unsupervised approach by t-SNE of the 
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29 surface markers to verify that PDL1 and ICOSL were relevant markers to discriminate the 
various DC phenotypes observed in vitro. We observed that PDL1 high cells clustered 
together and were distinct from ICOSL high cell clusters and from PDL1 low ICOSL low 
cluster, the latter including most Medium-DC conditions (Fig 2C). The DC perturbators 
inducing a majority of PDL1 high ICOSL low cDC2 were R848, Zymosan, HKSA and HKLM, 
while the ones inducing a majority of ICOSL high PDL1 low cDC2 were TSLP, GM-CSF and 
Flu (Fig 2C, Table 3). To pursue the analysis of the different functions of these DC 
phenotypes, we defined 4 groups of activated DC by their PDL1 and ICOSL expression (Fig 
2B). First, we analyzed the 29 surface markers in these 4 groups and in Medium-DC: PDL1 
High ICOSL low DC co-expressed PVR, PDL2, Nectin2, CD54, and CD40, with Spearman 
correlation coefficients of 0.8, 0.75, 0.66, 0.64 and 0.62 respectively (Fig2D, 3E, Table 4). 
ICOSL high PDL1 low DC did not have any correlated molecule with a Spearman correlation 
coefficient superior to 0,5. 
 
Next, we analyzed the secretion of 32 DC derived cytokines and chemokines, and 17 T 
helper cytokines secreted by naïve CD4 T cells after 6 days of co-culture (Fig 3A, Table 5, 
Table 6). PDL1 high ICOSL low secreted the largest amount of most cytokines measured, 
such as TNF-α, IL-1a, IL-1b, IL1-RA, IL-6, IL-10, IL-12p40, IL-23, IL-27, CCL19, BCA1, 
MIP1a, as compared to both PDL1 low ICOSL high DC and to Medium DC, but they did not 
induce more secretion of T helper cytokines by naïve CD4 T cells than Medium-DC (Fig 3B). 
Conversely, it was the PDL1 low ICOSL high DC that induced the highest activation of T cells 
as measured by the high expression of most CD4 T helper cytokines after co-culture, without 
a clear T helper polarization (Fig 3A, 3B, S3A, S3B). Therefore, we labeled PDL1 high 
ICOSL low DC the “secretory DC” and PDL1 low ICOSL DC the “helper DC”, both being 
different activated profiles, distinct from previously described tolerogenic DC. “Helper” DC 
increased very significantly the secretion of Th2 cytokines, IL-10, IL-3 and IL-9 by the CD4 T 
cells as compared to “secretory” DC, whereas IL-2 and IFNg were only mildly increased. 
There was no significant difference for Th17 cytokines. T cell proliferation was increased by 
both “secretory” and “helper” DC as compared to medium DC (Fig S3C). 
 
To further characterize the changes occurring during DC activation in the context of cancer, 
we performed RNA sequencing of cDC2 sorted from HNSCC or blood and identified 882 
differentially expressed genes (DEG): 639 increased in tumor cDC2 and 243 in blood cDC2 
(Fig 4A, Table 7 for donors characteristics and Table 8 for DEG). Due to the minimal number 
of cells required for this experiment, inflamed tumors highly infiltrated by DC were 
necessarily selected (Fig S4A). In parallel, we compared transcriptomics data of cDC2 
activated with pRNA, a TLR7/8 ligand expected to induce “secretory” DC or GM-CSF a 
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“helper” DC2 inducer (Fig 4B) from GSE89442 (14). Using both comparisons of the stimuli 
together and towards unstimulated blood cDC2, we defined the “secretory” and “helper” 
signatures including 1473 and 1277 genes respectively (Fig 4C, Table 9). Among the 639 
genes upregulated during tumor-induced maturation, 135 (21%) were shared with the 
“secretory” signature and only 64 (10%) with the “helper” signature, the 440 (69%) remaining 
genes being tumor-specific (Fig 4D). Using supervised lists of genes coding for checkpoints 
and maturation markers (Fig 4E left, Table 10), cytokines and chemokines (Fig 4E center, 
Tables 11 & 12), and of the NFkB pathway (Fig 4E right, Table 13), we confirmed that tumor 
cDC2 shared the majority of the genes with the pRNA “secretory” condition (Fig 4F).  cDC2 
overexpressed CD274/PDL1, and several other “secretory” specific markers identified 
previously at the protein level, such as PDCD1LG2/PDL2, PVR, IL1B, IL12B, IL23A, TNF, 
and CCL19, and also other negative checkpoints such as IDO1, IDO2, and HAVCR2/TIM3, 
and the migration marker CCR7.  
 
Since the concept of immature versus mature DC, and their respective roles in immune 
regulation, attempts have been made to identify classes of mature DC, such as “fully 
mature”, “immunogenic”, “inflammatory”, “semi-mature”, “tolerogenic” (3). These suffer from 
several limitations: 1) they lack a clear and consensual definition, 2) they lack universality 
and specificity, i.e many DC do not fall into any of these categories or may fall into multiple. 
In this study, we report on a novel classification of human activated DC that mature either as 
“secretory” DC or as “helper DC”, recognizable by their opposed PDL1 and ICOSL 
expression. Each phenotype is induced by some specific stimuli, but not restricted to a single 
receptor pathway (Table 3). Tumor infiltrating cDC2 in inflamed HNSCC have the phenotypic 
signature of “secretory” DC. In blood and in non-inflamed HNSCC, DC have an immature 
phenotype (Fig 5). These observations have several applications for immunotherapies 
modulating DC in cancer and inflammatory diseases, such as DC stimuli used directly, or for 
DC-based vaccines, or even for standard cancer treatment that will increase danger signals 
in the tumor microenvironment. For example in cancer, the stimuli inducing “secretory DC” 
should be used in combination with anti-PD(L)1 antibodies, when it is not planned in some 
upcoming trials (NCT02320305, NCT03742804, NCT02180698), and the stimuli inducing 
“helper DC” could be used to increase the T cell response via polyfunctional Th cytokine 
profiles.  
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METHODS 
Human samples and patient characteristics  
Fresh samples of HNSCC tumor tissues and blood of untreated patients with head and neck 
cancers were obtained from the pathology department of the Institut Curie hospital in 
accordance with the ethical guidelines, with the principles of Good Clinical Practice and the 
Declaration of Helsinki, and with patients consent. Patient characteristics for the flow 
cytometry cohort (Fig.1) and RNAseq cohort (Fig.3) are summarized in Supplementary 
Tables 2 and 7, respectively. Fourteen of 22 the patients of the FACS cohort were included 
in the clinical trial SCANDARE NCT03017573.  
 
Single-cell suspensions 
 Tumor tissues were mechanically and enzymatically digested in CO2-independent medium 
(Gibco) containing 5% FBS (HyClone). Enzymatic digestion consisted of three rounds of 15 
min of incubation with agitation at 37 °C, separated by pipetting, with 2 mg/ml collagenase I 
(C0130, Sigma), 2 mg/ml hyaluronidase (H3506, Sigma) and 25 µg/ml DNAse (Roche). The 
samples were filtered on a 40-µm cell strainer (Fischer Scientific) and were diluted in PBS 1X 
(Gibco) supplemented with EDTA 2 mM (Gibco) and 1% de-complemented human serum 
(BioWest). After centrifugation, cells were suspended in the same medium and were counted 
by trypan blue before being assessed by flow cytometry or sorted. PBMC were isolated from 
blood samples using FICOLL (GE Healthcare) gradient centrifugation. 
 
Antibodies, flow cytometry and cell sorting 
 Single-cell suspensions from digested tumor and from blood were stained with antibodies 
(Table 14) for 15 min at 4°C. After washing step, cells were analyzed or sorted directly, 
immediately after having added DAPI (Miltenyi Biotec) for dead cells exclusion. Flow 
cytometry phenotyping was performed on BD LSRFortessa Analyzer. Cell sorting for the 
RNA-seq experiment were performed on BD FACSAria III using the purity and low-pressure 
mode, and a 100-µm nozzle. DC subsets and MMAC were sorted in Eppendorf tubes 
containing TCL buffer (Qiagen) supplemented with 1% β–mercaptoethanol (SIGMA) before 
RNA extraction, as decribed in Michea P, Noël F et al. (15).   
 
In vitro analysis 
Material and methods are described in detail in the resource paper from Grandclaudon et al. 
(13). As compared to the resource paper containing 118 data points for primary blood 
CD11c+HLA-DR+ cells (referred to as bDC), we generated supplementary experiments and 
analysis to specifically address our question. We added 36 data points for the analysis of 
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surface markers (leading to a total of 154 data points) among which 12 for the analysis of DC 
secreted cytokines and chemokines and of the T helper cytokines (leading to a total of 130 
data points). Extra data points included: Curdlan 10ug/ml (n=1), Flu (1X) (n=3), 
Flu(1X)+TSLP(50ng/ml) (n=3), HKSA (MOI10) (n=3), GM-CSF 50ng/ml (n=4), LPS (n=3), 
Medium (n=9), Poly I:C 50ug/ml (n=4), R848 1ug/ml (n=3), TSLP 50ng/ml (n=3), for a total of 
29 blood donors. The antibodies used for the checkpoints and maturation markers analyzed 
by flow cytometry are listed in Table 4. For the DC secreted cytokines and chemokines, we 
measured 24 supplementary cytokines and chemokines. IL1a, IL1b, IL6, IL10, TNF-α and 
IL12p70 were measured by cytometry bead assay flex set (CBA) and we added the measure 
of IFNa. IL23 and IL28a were measured by Luminex and we added the measure of APRIL, 
BCA1, CCL19, CXCL11, CXCL16, CXCL9, Eotaxin2, I309, IFNb, IL12p40, IL16, IL1RA, IL27, 
IL29, IP10, MCP1, MCP2, MCP4, MIP1a, RANTES, TARC, TRAIL, YKL40 (Table S5). The 
17 T helper cytokines were analyzed by CBA or Luminex (Millipore) (Table 6), similarly to the 
resource paper.   
 
RNA extraction, sequencing and data pre-processing 
Material and methods are described in detail in the resource paper (15). Briefly, single Cell 
RNA Purification Kit (Norgen Bioteck) was used for RNA extraction, including on-column 
DNase digestion (Qiagen), as described by the manufacturer's protocol. RNA integrity was 
controlled with a RNA 6000 Pico Kit (Agilent Technologies) in BioAnalyzer. cDNA was 
generated with SMARTer Ultra Low input RNA for Illumina Sequencing-HV (Clontech), 
following manufacturer’s protocol with 14 cycles for amplification. Quality controls were 
performed with Qubit dsDNA high sensitivity (Thermofisher) and an Agilent Bioanalyzer using 
nanochip (Agilent Technologies). Multiplexed pair-end libraries 50nt in length were obtained 
using Nextera XT kit (Clontech). Sequencing was performed in a single batch with Illumina 
HiSeq 2500 using an average depth of 15 million reads. Library, sequencing and quality 
controls were performed by the NGS facility at the Institut Curie. Reads were mapped to the 
human genome reference (hg19/GRCh37) using Tophat2 version 2.0.14. Gene expression 
values were quantified as read counts using HTSeq-count version 0.6.1. Genes with less 
than one read count in at least one sample were filtered out and. The remaining raw data 
were normalized and analyzed using DESeq2 R package. Differentially expressed genes 
were obtained with an adjusted p-value of 0,10. The supervised list of genes used in Fig 4D 
were established by including all markers analyzed at the protein level in the in vitro analysis 
and by adding other known checkpoints and maturation markers, cytokines and chemokines 
from literature search. The NFkB pathway genes list was established by literature search.  
Data availability. RNA-seq data that support the findings of this study will been deposited in 
the NCBI Sequence Read Archive (SRA). 
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Analysis of Flow cytometry data 
We measured a total of 434 parameters including 52 cell/cell ratios. We established a sub-list 
of 81 non-redundant parameters, meaning that each population was expressed in 
percentage of its parental population. The list of 81 parameters was used in Fig 1D, and the 
list of 434 parameters enriched wit 14 clinical parameters was used for the elastic net model 
in Fig S1D. The elastic net model was performed using R software, a Lambda at 1SE, and 
an alpha of 0,5. 
 
Statistical analysis 
Statistical analyses of flow cytometry data (Fig1) and in vitro analysis (Fig2, Fig3) were 
performed using ANOVA or Kruskal-Wallis tests for parametric and non-parametric data 
respectively, with Qlucore and GraphPad Prism 8 (GraphPad Software Inc.) softwares. Data 
were considered significant for adjusted p-values after Tukey or Dunn’s tests superior to 
0.05. t-SNE was performed using Qlucore software and a perplexity of 15. 
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Fig1. T cell infiltration is associated to DC infiltration and PDL1 & ICOSL expression 
on CD11c+HLA-DR+ cell. Phenotypic characterization of 22 human HNSCC primary tumor-
62	
	
infiltrating cells. A. Multicolor flow cytometry analysis scheme. B. Myeloid cell panel gating 
strategy for the CD45+CD3-CD56-CD19- compartment. C. Percentage of CD3 positive cells 
among live cells. D. Anova test between CD3 high, int and low, showing only the 16 
significant variables among the 81 analyzed.  E. Representative staining of PDL1 (right) and 
ICOSL (left) in CD11c+DR+ cells in a representative CD3 high tumor (top), CD3 low (middle) 
and blood from a healthy donor (bottom). F. Quantification of cell populations in percentages 
of their parental population in the 3 groups of CD3 infiltration.  
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Fig 2. PDL1 and ICOSL expression on CD11c+DC were exclusive and PDL1 high DC 
overexpress PVR, Nectin2, CD54, CD40 and PDL2. A. Methods for the in vitro analysis of 
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primary blood DC. B. Expression of PDL1(x) vs ICOSL(y) on DC at H24. Individual tests 
were annotated according to their expression of PDL1 as high/low and ICOSL high/low with 
the thresholds of specific MFI at 3500 and 1000 respectively. C. T-SNE of the 29 surface 
markers colored by stimuli (left), PDL1 specific MFI (center) and ICOSL specific MFI (right) 
using Qlucore software. D. Heatmap representing the expression of the 29 surface markers 
in the 4 groups defined by PDL1 and ICOSL in “B”, and in Medium condition. Multigroup 
comparison by Kruskal-Wallis test and Tukey post-hoc test. Only the variables significant at a 
p-value < 0,05 are represented and ordered by increasing q-value (max q-value = 0,046), 
among 130 individual experiments. E. Correlation of PDL1 (x) with PVR, Nectin2, CD54, 
PDL2 and CD40 (y). « r » values are Spearman correlation coefficients.  
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Fig 3. PDL1 and ICOSL expression pattern characterize “Secretory” and “Helper” DC. 
66	
	
A. Heatmaps representing the cytokines and chemokines secreted by the DC measured in 
H24 supernatants (top), and the CD4 T helper cell cytokines measured after co-culture 
(bottom) in the 4 groups defined by PDL1 and ICOSL expression and Medium condition. 
Only the variables significant at a p-value < 0,05 after Kruskal-Wallis multigroup comparison 
and Tukey post-hoc test are represented and ordered by increasing q-value (max q-value = 
0,035 (top) and 0,055 (bottom)), among 130 individual experiments. Cells in grey are missing 
values. B. Quantification of cytokines and chemokines secreted by the DC (top row) and of 
the CD4 T helper cell cytokines (2 bottom rows) in the Medium, PDL1 high ICOSL low and 
PDL1 low ICOSL high conditions. 
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Fig4. RNAseq of tumor vs blood cDC2 confirms that T cell inflamed HNSCC are 
infiltrated by “secretory” DC. A. Analysis of differentially expressed genes (DEG) by 
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DESeq2 between HNSCC tumor (n=6) and blood cDC2 (n=3). B. Analysis of DEG from 
dataset GS87442 by DESeq2 between unstimulated cell and pRNA, a TLR7/8 ligand (left) or 
GM-CSF (center) and pRNA vs GM-CSF (right). C. Venn diagram of upregulated genes 
identified in “B”. The blue and the yellow-colored area contain the genes of the “secretory” 
and “helper” signatures respectively. D. Venn diagram of the 639 tumor cDC2 upregulated 
genes with the “secretory” and “helper” signatures defined in “C”. E. Supervised analysis of 
the 135 genes shared between tumor & pRNA “secretory” signature (light blue), 440 tumor 
specific genes (black) and the 64 genes shared between tumor & GM-CSF (yellow), using 3 
gene lists: checkpoint and maturation markers (left, 148 genes), cytokines and chemokines 
(center, 169 genes), NFkB pathway (right, 100 genes). F. Expression of selected genes in 
cDC2 from tumors and blood of HNSCC patients. 
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Fig.5 Schematic representation of DC activation into “helper” and “secretory” 
phenotypes 
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FigS1A. T cell panel gating strategy 
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FigS1B. Left: Flow cytometry staining for BDCA3 expression in 4 cell populations in a 
HNSCC primary tumor. This tumor was selected for its high level of cDC1 infiltration.  Right: 
Percentages of cDC1, gated as BDCA3 high, in the cDC1e gate (n = 6 tumors).  
 
 
 
Fig S1C. Flow cytometry staining showing CD15 expression in Lin-HLADR- population. Most 
Lin-HLADR-CD11c+ cells are CD15+, therefore having a neutrophil phenotype.  
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Fig S1D. Heatmap representing the expression of PDL1 and ICOSL in the 4 subsets of 
CD11c+HLA-DR+ cells in the 22 HNSCC samples, ordered by the level of CD3 infiltration 
from the lowest (left) to the highest (right). 
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Fig S1E. Elastic net model of the 434 parameters measured by flow cytometry and 14 
clinical parameters in the 22 HNSCC, showing the parameters the most representative of 
CD3 Low, CD3 Int and CD3 High tumors.  The “Live” gate was established by selecting the 
live cells among a parental gate of all the cells in the FSC-A versus SCC-A graph, excluding 
only the debris and red blood cells. The “Live Lymphocyte” gate was established by selecting 
the live cells among a parental gate of cells having the FSC and SCC levels corresponding to 
lymphocytes only.  
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Fig S3A. Quantification of cytokines and chemokines secreted by the DC, in the Medium, 
PDL1 high ICOSL low and PDL1 low ICOSL high conditions. 
 
 
 
Fig S3B. Quantification of the CD4 T helper cell cytokines, in the Medium, PDL1 high ICOSL 
low and PDL1 low ICOSL high conditions.  
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Fig S3C. T cell expansion at day 6 of DC-T co-culture in the Medium, PDL1 high ICOSL low 
and PDL1 low ICOSL high conditions. 
 
 
 
 
FigS4A. Flow cytometry sorting strategy for RNA sequencing of blood and tumor infiltrating 
cDC2, selected as CD45+, CD3-, CD19-, CD56-, CD11c+, HLA-DR+, CD14-, BDCA1+. Plots 
from a representative donor.  
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ALL TABLES ARE PROVIDED AS SUPPLEMENTARY MATERIAL.  
Large tables that cannot be included fully in this manuscript are partially shown and 
available in a complete format at: https://doi.org/10.1101/721563  
 
TABLE INDEX 
Table 1 Cell populations analyzed by flow cytometry (Fig 1) 
Table 2 Characteristics of the 22 patients whom tumors were analyzed by flow 
cytometry (Fig 1) 
Table 3 In vitro analysis: Percentages of datapoints in each PDL1/ICOSL category per 
perturbator (Fig2) 
Table 4 In vitro analysis: List of measured checkpoints and maturation markers and 
antibodies list (Fig2) 
Table 5 In vitro analysis: List of measured DC Cytokines and Chemokines, and 
corresponding genes (Fig3) 
Table 6 In vitro analysis: List of measured T helper cytokines (Fig3) 
Table 7 Characteristics of the 6 patients, whom tumor was analyzed by RNAseq (Fig 4) 
Table 8 DESeq2 results defining DEG between Blood and Tumor cDC2 at FDR 0.1 (Fig 
4A) 
Table 9 List of genes associated with the Venn diagramm comparing DEG betwenn 
pRNA and GMCSFat FDR 0.1 (Fig 4C) 
Table 10 List of 148 genes used for supervised analysis of checkpoints and maturation 
markers expressed at the RNA level by dendritic cells (Fig 4D) 
Table 11 List of 117 genes used for supervised analysis of cytokines expressed at the 
RNA level by dendritic cells (Fig 4D) 
Table 12 List of 52 genes used for supervised analysis of chemokines expressed at the 
RNA level by dendritic cells (Fig 4D) 
Table 13 List of 100 genes used for supervised analysis of the NFkB pathway (Fig 4D) 
Table 14 Antibody and Panels list for Human HNSCC and Blood FACS phenotyping and 
sorting (Methods) 
 
  
77	
	
Table 1 Cell populations analyzed by flow cytometry (Fig 1) 
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Table 2 - Characteristics of the 22 patients whom tumors were analyzed by flow 
cytometry  
79	
	
Table 3 In vitro analysis: Percentages of datapoints in each PDL1/ICOSL 
category per perturbator (Fig2) 
 
Perturbators Receptor 
Total 
number of 
data points 
PDL1 Hi / 
ICOSL Lo 
PDL1 Lo / 
ICOSL Hi 
PDL1 Lo / 
ICOSL Lo 
PDL1 Hi / 
ICOSL Hi 
PAM3 (1ug/ml) TLR1 :TLR2 2 0% 100% 0% 0% 
GMCSF (50ng/ml) GMCSFR 10 0% 80% 10% 10% 
TSLP (50ng/ml) TSLPR 15 0% 87% 13% 0% 
Flu (1X) 
TLR7, Cytosolic 
sensors 16 0% 75% 6% 19% 
Med  29 0% 24% 76% 0% 
HKCA (MOI1) Dectin-1 4 0% 0% 100% 0% 
HKLM (MOI1) TLR2 8 13% 38% 50% 0% 
Curdlan (10ug/ml) Dectin-1 8 25% 25% 25% 25% 
PAM3 (10ug/ml) TLR1: TLR2 8 38% 13% 50% 0% 
LPS (100ng/ml) TLR4 11 45% 27% 18% 9% 
PolyIC (50ug/ml) TLR3 8 50% 38% 0% 13% 
Flu (1X) + TSLP See Flu and TSLP 3 67% 0% 0% 33% 
Zymosan (10ug/ml) TLR2, Dectin-1 8 75% 0% 25% 0% 
HKSA (MOI10) TLR2 4 75% 0% 0% 25% 
HKSA (MOI1) TLR2 6 83% 0% 17% 0% 
R848 (1ug/ml) TLR7/8 13 92% 0% 8% 0% 
HKLM (MOI100)  TLR2 1 100% 0% 0% 0% 
Total number 154 44 54 46 10 
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Table 4 In vitro analysis: List of measured checkpoints and maturation markers 
and antibodies list (Fig2) 
 
Marker Dye Brand Clone Ref 
4-1BBL APC R&D Systems 282220 FAB2295A 
B7H3 FITC R&D Systems 185504 FAB1027F 
CD100 FITC BioLegend A8 328406 
CD11a PerCP R&D Systems CR38 FAB35951C 
CD18 PE BioLegend TS1/18 302107 
CD229/ 
SLAMF3 APC R&D Systems 249936 FAB1898A 
CD29 AF700 BioLegend TS2/16 303020 
CD30L PE R&D Systems LQI03 FAB1028P 
CD40 PE-Cy7 BioLegend 5C3 334321 
CD54 BV711 BD HA58 564078 
CD70 FITC BD Ki-24 555834 
CD80 BV786 BD L307.4 564159 
CD83 PerCP/Cy5.5 BioLegend HB15e 305320 
CD86 BV650 BioLegend IT2.2 305428 
Galectin 3 AF488 R&D Systems 
Polyclonal Goat 
IgG IC1154G 
HLA-DR BV711 BioLegend L243 307644 
ICAM-2 FITC BioLegend CBR-IC2/2 328507 
ICAM-3 APC BioLegend CBR-IC3/1 330011 
ICOSL APC R&D Systems 136726 FAB165A 
Jagged 2 APC BioLegend MHJ2-523 346906 
LFA3 / CD58 PE-Cy5 BioLegend TS2/9 330909 
LIGHT PE R&D Systems 115520 FAB664P 
Nectin-2 PE BioLegend TX31 337410 
OX40L R-PE Ancell ANC10G1 400-050 
PDL1 
PerCP-eFluor 
e710 eBioscience MIH18 46-5983-42 
PDL2 BV786 BD MIH18 563843 
PVR PE BioLegend SKII.4 337619 
SLAMF5 FITC R&D Systems 
Polyclonal Goat 
IgG FAB1855F 
VISTA AF700 R&D Systems 730804 FAB71261N 
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Table 5 In vitro analysis: List of measured DC Cytokines and Chemokines, and 
corresponding genes  (Fig3) 
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Table 6 In vitro analysis: List of measured T helper cytokines (Fig3) 
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Table 7 Characteristics of the 6 patients, whom tumor was analyzed by RNAseq 
(Fig 4) 
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Table 8 DESeq2 results defining DEG between Blood and Tumor cDC2 at FDR 
0.1 (Fig 4A). Only the top 182 up-regulated genes in tumor cDC2 are shown, ordered by 
Log2 fold change.  
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Table 9 List of genes associated with the Venn diagramm comparing DEG 
betwenn pRNA and GMCSFat FDR 0.1 (Fig 4C). Only 62 up-regulated genes per cluster 
are shown 
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Table 10 List of 148 genes used for supervised analysis of checkpoints and 
maturation markers expressed at the RNA level by dendritic cells (Fig 4D) 
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Table 11 List of 117 genes used for supervised analysis of cytokines expressed at 
the RNA level by dendritic cells (Fig 4D) 
 
 
Table 12 List of 52 genes used for supervised analysis of chemokines expressed 
at the RNA level by dendritic cells (Fig 4D) 
 
 
Table 13 List of 100 genes used for supervised analysis of the NFkB pathway (Fig 
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4D) 
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Table 14 Antibody and Panels list for Human HNSCC and Blood FACS 
phenotyping and sorting (Methods) 
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3.2  MMP2 AS AN INDEPENDENT PROGNOSTIC STRATIFIER IN ORAL 
CAVITY CANCERS 
 
Article available at https://doi.org/10.1101/723650 
 
Abstract 
 
Background: Around 25% of oral cavity squamous cell carcinoma (OCSCC) are not 
controlled by standard of care. Identifying those patients could offer them possibilities for 
intensified and personalized regimen. However, there is currently no validated biomarker for 
OCSCC patient selection in a pre-treatment setting. Our objectives were to determine a 
robust and independent predictive biomarker for disease related death in OCSCC treated 
with standard of care. 
Patients and methods: Tumor and juxtatumor secretome were analyzed in a prospective 
discovery cohort of 37 OCSCC treated by primary surgery. Independent biomarker validation 
was performed by RTqPCR in a retrospective cohort of 145 patients with similar clinical 
features. An 18-gene signature (18G) predictive of the response to PD-1 blockade was 
evaluated in the same cohort. 
Results: Among 29 deregulated molecules in a secretome analysis, we identified soluble 
MMP2 as a prognostic biomarker. In our validation cohort (n=145), high levels of MMP2 and 
CD276, and low levels of CXCL10 and STAT1 mRNA were associated with poor prognosis in 
univariate analysis (Kaplan-Meier). MMP2 (p = 0.001) and extra-nodal extension (ENE) (p = 
0.006) were independent biomarkers of disease-specific survival (DSS) in multivariate 
analysis and defined prognostic groups with 5-year DSS ranging from 36% 
(MMP2highENE+) to 88% (MMP2lowENE-). The expression of 18G was similar in the 
different prognostic groups, suggesting comparable responsiveness to anti-PD-1. 
Conclusion: High levels of MMP2 was an independent and validated prognostic biomarker, 
which may be used to select poor prognosis patients for intensified neoadjuvant or adjuvant 
regimens. 
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STATEMENT OF TRANSLATIONAL RELEVANCE 
There is currently no validated biomarker for risk-based patient stratification in oral cavity 
cancers, preventing the development of personalized approaches. This study started with a 
detailed characterization of the soluble microenvironment in human primary tumors and non-
involved juxta-tumor samples.   Translation to clinical biomarker was obtained by survival 
analyzes on our discovery cohort, and independent validation in a large (n=145) 
retrospective cohort. MMP2 was retained as an independent prognostic biomarker that may 
be measured at the protein or the RNA level to identify high-risk oral cavity cancer patients.  
High levels of MMP2 and the presence of extra-nodal extension defined prognostic groups 
that may serve biomarker-driven clinical trials for intensified neoadjuvant or adjuvant 
regimens. Expression of the 18G signature predictive of response to anti-PD-1 suggests 
possible combination trials with immunotherapy. 
 
 
 
INTRODUCTION 
Oral cavity squamous cell carcinoma (OCSSC) patients treated by primary surgery undergo 
post-operative surveillance, adjuvant radiotherapy, or chemo-radiotherapy, according to 
clinical and histopathological parameters that include disease stage, nodal involvement, 
extranodal extension (ENE), perineural invasion (PNI), vascular embols (VE) and resection 
margin status (1). Despite those numerous clinical decision parameters, around 25% of 
OCSCC will present an unpredictable early and/or severe recurrence (2), (3), (4). Even the 
local failures that are eligible to the best treatment option, that is salvage surgery (5), (6), (7), 
have a poor prognosis with a median overall survival ranging from 20 to 30 months (4), (8). 
Accurately identifying those high-risk patients would allow proposing them an intensified and 
risk-adjusted therapy, such as neoadjuvant chemotherapy or immunotherapy.  
Neoadjuvant chemotherapy has failed to show benefit in head and neck squamous cell 
carcinoma (HNSCC), possibly because trials were made in unselected Stage III/IV HNSCC 
population (9), (10). Immunotherapy is a new treatment modality, and its interest as 
neoadjuvant treatment is currently being evaluated (11), (12), (13). Numerous prognostic 
markers have been proposed for OCSCC, but none of them has shown independent 
validation, and translation to clinical practice (14). In this study, we used a biology-driven 
exploratory strategy, in order to identify a robust predictive biomarker for early severe 
recurrence and disease related death in primary OCSCC after treatment by standard of care.  
We found MMP2 as fulfilling those criteria, and when combined to nodal involvement, 
providing a simple and efficient patient stratification scheme. 
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RESULTS 
Human primary tumor secretome analysis identified 29 deregulated molecules    
To identify candidate biomarkers, we chose an unbiased approach applied to human primary 
tumors, in order to ensure physiopathological relevance. We used a tumor explant-culture 
system to analyze the soluble microenvironment in a prospective discovery cohort of 37 
OCSCC patients treated by primary surgery (Table S1). Fresh standardized tumor and 
juxtatumor (non-involved) specimens were cultured for 24h at 37°C, and we measured a 
panel of 49 soluble molecules relevant to multiple cancer pathways, such as immunity, 
chemotaxis, tumor growth, angiogenesis, and tissue remodeling. We identified 25 molecules 
increased, and 4 decreased, in the tumor tissue (Fig 1, Table S2). CXCL9, the 
metalloproteinases (MMP) MMP1, MMP2 and MMP9, plasminogen activator inhibitor (PAI-1) 
and resistin were among the molecules most increased in tumors, and MCP-1 (CCL2) in 
juxtatumors. SCF, multiple cytokines (IL-1b, TNF-α, IL-15), growth factors (GM-CSF, VEGF) 
and chemokines (MDC, TARC) were also increased in the tumor, as compared to juxta-
tumor samples (Fig 1). The cytokines IL-9, TNFb, TSLP, IL-21 were never detected (Fig 1). 
This provided a global, unbiased protein level profiling of the OCSCC tumor secretome. 
 
High levels of soluble MMP2 were associated with poor prognosis 
Patients were classified as severe if they had a disease-specific survival (DSS) of less than 
36 months and /or a disease-free survival (DFS) of less than 12 months and could not 
achieve a second remission (unsuccessful salvage procedures and/or permanent palliative 
treatment). Among the 29 deregulated secretome molecules, analyzed as candidate 
biomarkers, MMP2 was the only molecule expressed at significant higher levels among 
severe patients as compared to non-severe (p = 0.007) (Table S3). ROC curve defined 29.3 
ng/ml as the optimal cut-off for soluble MMP2, with a sensitivity of 100% and a specificity of 
71.4 % to identify severe cases (Fig2A). MMP2high tumors were associated with reduced 
DSS (p = 0.001), overall survival (OS) (p = 0.012) and DFS (p = 0.003) (Fig 2B). 
 
Soluble MMP2 levels were independent of T cell infiltration 
MMP degrade the extra-cellular matrix and promote tumor cell invasion (15). Tissue damage 
may lead to a local increase in danger signals and initiate an innate and then adaptive 
immune response. Thus, we hypothesized that MMP2 levels might influence T cell infiltration. 
Paired CD3 and CD8 T cell quantification by flow cytometry, and soluble MMP2 
quantification, was available for 18 HNSCC patients. MMP2 was not significantly correlated 
to CD3 (r = 0.01, Spearman correlation coefficient) (Fig 2C) nor to CD8 infiltration (r = -0.13, 
data not shown). Conversely, CD3 and CD8 infiltration were highly correlated to CXCL9 (r = 
0.78 and r = 0.79) and CXCL10 (both r = 0.66) (Fig 2C, data not shown for CD8). In the 
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secretome analysis of the 37 OCSCC samples, MMP2 was not correlated to CXCL9 and 
CXCL10 (r=0.19 and r=0.09), further supporting that MMP2 levels were not associated to T 
cell infiltration (Fig 2D). 
 
RNA levels of MMP2, CD276, CXCL10, and STAT1 predicted prognosis  
To independently validate the prognostic value of MMP2, we measured a 30 genes panel 
(Table S4) by RTqPCR in a large retrospective cohort of 145 OCSCC patients treated by 
primary surgery. Gene panel included MMP-2, -1, -9, other immune-related genes, and a 
published 18-gene signature predictive of the response to anti-PD-1 immunotherapy (16). 
Patients’ characteristics are available in Table 1. Significant variables in univariate analysis 
for DSS, OS and DFS are listed in Table 2. Among the clinical variables, tumor differentiation 
index, stage, ENE, VE and PNI were significant for both DSS and OS, while only the latter 
three were significant for DFS. Among the genes, high levels of MMP2 were associated to 
reduced DSS, OS and DFS. High levels of CD276 (B7-H3) and low levels of CXCL10 and 
STAT1 were also among the 5 and 11 genes associated to reduced DSS and OS, 
respectively (Table 2). This validated the prognostic impact of MMP2, measured by two 
different methods (protein and mRNA), in a large OCSCC cohort. 
 
MMP2 RNA, ENE, PNI and stage were independent prognostic factors 
To identify clinical and biological parameters significant in multivariate analysis, we 
performed two Cox proportional hazards models. Model 1 included all the 145 patients and 
all clinical and biological variables significant in univariate analysis, except PNI and VE, 
because of missing values in 21 patients (14%), whereas Model 2 included all significant 
variables, but was restricted to the 124 patients with complete data (Fig 3A, Table S5). In 
both models MMP2high was an independent prognostic factor for DSS and DFS (Model 1 
DSS: p = 0.001, DFS: p = 0.006, Model 2 DSS: p = 0.034, DFS: p = 0.016). For DSS, ENE 
status (p = 0.006) and PNI (p = 0.020) were also significant in Model 1 and 2, respectively. 
For DFS, ENE status was also significant in Model 1 (p = 0.006), but MMP2 was the only 
significant parameter in Model 2. For OS, MMP2 (p = 0.015) and stage (p = 0.042) were 
significant in Model 1, and PNI (p = 0.01) and stage (p = 0.019) were significant in Model 2 
(Fig 3A, Table S5). We defined prognostic groups using the parameters identified in 
multivariate analysis by the Model 1 to analyze the largest cohort of 145 patients. 
MMP2highENE+ patients had the worse DSS and DFS, as compared to MMP2lowENE- 
patients (p < 0.001), whereas MMP2highENE- and MMP2lowENE+ had an intermediate DSS 
and DFS (Fig 3B) (2 by 2 comparisons available in Table S6). MMP2 status induced clinically 
relevant variations in survival. MMP2high vs MMP2low tumor bearing patients had a 5-year 
DSS of 61% versus 88% when ENE was absent, and of 36% versus 52% when ENE was 
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present (Table 3). MMP2high tumors were associated to the presence of metastatic lymph 
node (p = 0.031), low or intermediate mitotic index (p = 0.001) and the presence of PNI (p = 
0.02) (Table S7).  
 
MMP2 may be used as a biomarker to select patients for treatment intensification 
MMP2 RNA status was an efficient prognostic biomarker as measured by ROC curves 
according to severity criteria, in the whole 145 patient cohort (AUC = 0.66, p = 0.003), and 
among the ENE negative patients (n = 106, AUC = 0.71, p = 0.003) (Fig S1). The optimal 
thresholds were 1.81 and 1.82, which led to high negative predictive values (NPV) of 82% 
and 88% respectively, but lower positive predictive values (PPV) of 41% and 36%. For 29 
patients, both soluble MMP2 and MMP2 RNA data were available, which allowed us to 
observe that both biomarkers were significantly correlated (Spearman r = 0.45, p = 0.016) 
(Fig S2), suggesting that MMP2 protein or RNA levels can be used as biomarker. 
 
The expression of an 18-gene signature predictive of response to PD-1 blockade was 
similar between the different prognostic groups 
The proportions of patients expected to respond to immunotherapy may vary between the 
prognostic groups defined above, and have consequences on the type of treatment that 
could be proposed in a risk-adjusted strategy. Therefore, we measured the expression of an 
18-gene signature (18G) (16) that is a predictive biomarker of response to PD-1 blockade. 
The 18G signature is composed of a core of 17 highly correlated genes (all Spearman 
correlation coefficients of the 17genes > 0.455), and CD276 (Fig S3, Fig S4). 18G score was 
moderately increased in MMP2high tumors (p = 0.019) (Fig S4, Fig S5), but was similar 
whatever the ENE status (p=0,671) and disease stage (p = 0.513) (Fig S5). The 18G score 
was similar between the prognostic groups defined by MMP2 RNA and ENE status 
(p=0.119), MMP2 RNA status and Stage (p = 0.051), MMP2 RNA and PNI statuses (p = 
0.089), and stage and PNI status (p = 0.661) (Fig 3C). This suggests that various prognostic 
groups may show response to anti-PD-1 therapy, with implications for the design of 
biomarker-driven trials in untreated resectable OCSCC patient with the goal of limiting early 
and severe recurrences (Fig S6). 
 
 
DISCUSSION 
In this study, we identified MMP2 as an independent prognostic biomarker for severe 
outcomes in OCSCC patients treated by primary surgery.  
First, we prospectively produced and analyzed tumor and juxtatumor secretomes, which 
revealed 29 deregulated soluble molecules, the majority of them being upregulated in the 
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tumor tissue. Those molecules belonged to various biological classes such as MMPs, 
chemokines, interleukins, adipokines and growth factors. One may consider that all these 
deregulated proteins reflect mechanisms of tumor progression and could be candidate 
biomarkers. However, only soluble MMP2 was associated to poor prognosis in our study. 
Primary tumor-derived supernatant is not a widely applied method for biomarker identification 
and data on OCSCC secretome are scarce (17) if we exclude cancer cell-line derived 
supernatants. A database for healthy body fluids proteome was created in 2008, highlighting 
the general interest for such approach (18). Here, we cannot exclude that tissue handling, 
although limited to the minimum in our protocol, may have induced or enhanced the 
production of some proteins, but this limitation was partially overcome by the comparison 
with paired juxtatumor supernatant. By the mean of an ultrafiltration catheter, interstitial fluid 
from a single HNSCC patient was analyzed and revealed 525 proteins by mass 
spectrometry, but the method was not applicable to juxtatumor tissue, which limited the 
potential to identify candidate biomarkers (19).  Another difficulty is that tumor secretome 
needs to be produced prospectively using fresh tumor samples, which limits the access to 
large cohorts with sufficient follow-up in order to identify prognostic biomarkers. However, we 
could overcome these difficulties, and our study illustrates the added value of this approach 
in providing data with strong biological relevance. 
For further validation, we designed a homogenous retrospective cohort of patients with the 
same clinical setting of resectable OCSCC treated by primary surgery and extracted tumor 
RNA from biobanked frozen samples to ensure the best quality of RNA (20). Univariate 
analysis confirmed the prognostic value of MMP2 to predict DSS, OS and DFS. High levels 
of CD276 and low levels of CXCL10 and STAT1 were also associated to reduced DSS and 
OS, but only MMP2 remained significant in multivariate analysis. Several studies have 
proposed MMP2 as a prognostic biomarker for OCSCC, but all had important limitations, 
such as the absence of multivariate analysis (21), (22), (23),  the inclusion of heterogeneous 
head and neck cancer patients with different tumor locations and treatments (24), (25),  or 
retrospective cohorts with less than 60 patients (22), (23), (26), (27). Most of these studies 
quantified MMP2 by immunohistochemistry (IHC) through semi-quantitative methods.  Our 
study provided unbiased and definite evidence for the independent prognostic role of MMP2, 
in a large homogeneous OCSCC cohort, within a multivariate prognostic model. 
The biological basis explaining why MMP2 is associated with poor prognosis is well known. 
MMP2 degrades type IV collagen and promotes epithelial-mesenchymal transition and 
metastasis (15),  (28). MMP may also skew the anti-tumor immune response by their effect 
on immune cells (29). MMP2 is secreted in an inactive form (pro-MMP2) and is activated by 
MMP1 (30) and MMP14 (31). Many cell types may produce MMP2, but fibroblasts seem to 
be the main source of this molecule in the tumor microenvironment (32), (33). From MMP 
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biology, we understand that a high level of MMP is a risk factor for cancer-related events, 
such as recurrence and disease-related death. This explains why in our study the accuracy 
of MMP2 as prognostic biomarker was better for DSS than for OS, both in univariate and 
multivariate analysis. It is well known that HNSCC patients have a reduced cancer-
independent life expectancy, which explains the differences observed between OS and DSS 
(34). In this line, in the TCGA data, MMP2 was co-expressed with MMP1, MMP9 and 
MMP14 in HNSCC, but the authors did not report the impact of any MMP on OS in HNSCC 
(35). The absence of DSS evaluation may explain this discrepancy. Beyond prognosis, MMP 
were also candidate therapeutic targets in cancer, but, so far, most molecules failed in their 
development because of their toxicities (36). Selective inhibitors are still in development (37), 
(NCT03486730), as well as other drugs that have an indirect effect on MMP (38).   
Clinical and histopathological parameters fail to identify around 25% of high-risk patients. 
Here, we propose that combining MMP2 status to those parameters would improve patients’ 
risk stratification. MMP2-high tumor bearing patients could be proposed for an intensified 
therapeutic plan, as compared to standard of care. MMP2 status may be defined pre-
operatively on the initial biopsy, or post-operatively if analyzed on the resection specimen 
(Fig S6). Pre-operative stratification would guide neoadjuvant treatment such as 
immunotherapy or chemotherapy, when post-operative stratification would guide adjuvant 
treatment. The latter setting is particularly important for ENE negative patients who may, in 
some cases, not be offered any adjuvant treatment. To address the question of the best 
(neo)adjuvant treatment option in high risk patients, we measured the expression of an 18-
gene signature predictive of response to PD-1 blockade. This signature was established on a 
large cohort of patients treated by pembrolizumab for head and neck cancers (n=107), 
melanoma (n=89) and other cancers (n=119) (16). The fact that this signature was 
established by merging the data from 22 different types of cancers and limited to advanced 
and recurrent cancers might not reflect the clinical setting of the present study. However, 
PDL1 and interferon gamma response genes (STAT1, CXCL9, IDO1, HLADR, HLADQ) were 
part of this 18-gene signature and were identified as predictive of response to neoadjuvant 
pembrolizumab in a window-of-opportunity trial including untreated head and neck cancer 
patients (13). Therefore, this 18G signature may be used to estimate expected response 
rates to PD-1 blockade of untreated OCSCC. There was no difference in expression of the 
18G score among the different prognostic groups defined by our multivariate analysis for 
DSS, DFS and OS. In this line, using soluble CXCL9 and CXCL10 as surrogates for tumor T 
cell infiltration, or direct measures of frequencies of tumor-infiltrating T cells by flow 
cytometry, we observed that soluble MMP2 levels were not associated to T cell infiltration. 
Similar results were previously described for MMP2 measured by IHC in endometrial cancer 
(39). From these results, we may estimate that the proportion of patients expected to 
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respond to PD-1 blockade should be similar in the different prognostic groups, leaving 
immunotherapy as a valid treatment option. Patient stratification in future OCSCC trials and 
clinical practice would definitely benefit from robust biomarkers used in combination with 
clinical variables, such as our MMP2 / ENE scoring, and with predictive biomarkers for final 
treatment decision-making. 
 
 
 
MATERIALS AND METHODS 
Patients and cohorts 
Tumor and juxtatumor samples were obtained from operative specimens from previously 
untreated head and neck cancer patients. Patients with previous head and neck radiotherapy 
or chemotherapy were excluded. Juxta-tumor samples were taken on the specimens’ 
margins, at least 1cm away from the tumor. Three cohorts of patients treated in our anti-
cancer center were included in this study. All analysis on secretome presented in Fig.1 were 
done on a 37 patient cohort including OCSCC patients only, with the exception of the 3 
graphs of Fig1D that show the correlation of CD3 infiltration with soluble MMP2, CXCL9 and 
CXL10, that was done in a 18 patients HNSCC cohort. This 18 patient cohort had paired 
secretome and flow cytometry data available and included the following tumor locations: 8 
oral cavity, 6 oropharynx, 3 larynx, 1 hypopharynx. The third cohort included 145 OCSCC 
patients and was used to analyze gene expression by RTqPCR and prognosis. Twenty-nine 
patients were in common between the n=37 and n=145 cohorts and served for the RNA 
versus soluble protein correlation. Patients were treated between March 2010 and October 
2016, for the 37 patients cohort, between January and July 2017 for the 18 patients cohort, 
and between February 1991 and November 2016 for the 145 patients cohort.  The clinical 
parameters analyzed were all binarized as follows: gender (male/female), HPV status 
(positive by PCR/negative), Differentiation (well differentiated or verrucous or basaloid / 
moderate or poor), Mitotic index (high if ≥10mitoses/field at X400, otherwise low), Perineural 
invasion (absent/present), Vascular embols (absent/present), Alcohol (positive if ≥30g/day), 
Tobacco (smoker active or former ≥2PY/non-smoker or former smoker < 2PY), Stage (I or II / 
III or more) using the pTNM 8th edition AJCC (40), Extranodal extension (absent/present), 
Margins (negative or close / positive), Age (more or less than 70). For outcomes analysis, we 
used 3 survivals: disease free survival, in which the censoring event was the first occurrence 
of recurrence, disease specific survival, in which the censoring event was the occurrence of 
death caused by the evolution of the cancer (to the exclusion of treatment related toxicities 
and post-operative complications), and overall survival. We also used a binary criteria of 
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severity defined as present in cases of DSS < 36 months and /or a DFS < 12 months without 
subsequent remission (unsuccessful salvage procedures and/or permanent palliative 
treatment); we considered that these criteria define the population with the most urgent need 
for prognosis biomarkers (41). This study was done in compliance with the principles of Good 
Clinical Practice and the Declaration of Helsinki. All patients signed a consent form 
mentioning that their operative specimens might be used for scientific purposes, and 12 of 
the 18 patients cohort were also included in the clinical trial NCT03017573.  
 
 
Tumor and juxta-tumor secretome analysis 
Fresh tumor and juxta-tumor were cut into fragments of 17.5 +/-2.5mg. Each fragment was 
placed in a 48-well flat bottom plate in 250µl of RPMI 1640 Medium Glutamax (Life 
Technologies) enriched with 10% Fetal Calf Serum (Hyclone), 100 U/ml 
Penicillin/Streptomycin (Gibco), 1% MEM Non-Essential Amino Acids (Gibco), and 1% 
pyruvate (Gibco), and incubated at 37°C with 5%CO2. After 24 hours, supernatants were 
filtered through a 0,22µm Millex-GP filter (SLGP033RS, Merck), diluted ½ in the same 
enriched RPMI Medium and stored at -80°C until the secretome analysis. The 49 analytes 
measured are listed in Table S2. Analytes concentrations were obtained using Milliplex Map 
kits used as recommended: Human MMP magnetic Bead panel 2, Human 
cytokine/chemokine Magnetic Bead panels I, II, III, and Human Adipocyte Magnetic Bead 
Panel (Millipore), a Bio-Plex 200 plate reader and the Bio-Plex Manager 6.1 software (Bio-
Rad Laboratories). All analytes were measured as stored, but MMP1 and MMP9 were also 
measured after 1/25th dilution for the 18 HNSCC patients with paired flow cytometry data. 
 
Analysis of CD3 and CD8 infiltration by Flow Cytometry  
Details are available at (42). Briefly, single-cell suspensions were obtained from 
enzymatically digested tumor samples, then filtered, washed, counted and stained for 15 
minutes with DAPI (Miltenyi Biotec) to exclude dead cells, CD3 (Alexa700, clone UCHT1, 
from BD, #557943) and CD8b (PC5, clone 2ST8.5H7, from Beckman Coulter, #6607109) 
antibodies, among other antibodies (data not used in the present paper), before phenotyping 
by flow cytometry (BD LSRFortessa Analyzer). 
 
Gene expression analysis by Real-Time RT-PCR 
Samples and RNA Extraction 
Tumor and juxtatumor samples were snap-frozen in liquid nitrogen upon surgical removal 
after pathologist's review and were stored in the corresponding our biological resources 
center. Samples were sectioned using Tissue-Tek optimal cutting temperature (O.C.T) 
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compound to estimate the percentage of tumor cells and to remove non-malignant tissue by 
macrodissection if necessary. Median percentage of tumor cells was 80% (range 40-95). 
RNA extraction was performed on the same sample, using the miRNeasy miniKit (Qiagen) 
according to the manufacturer's protocol. RNA was quantified using Nanodrop 
spectrophotometer ND-1000 and the integrity and purity were assessed by the Agilent 2100 
Bioanalyzer and RNA 6000 Nano Labchip Kit (Agilent Biotechnologies, Palo Alto, CA, USA). 
Total RNA was extracted from 145 OCSSC and 31 juxtatumor frozen samples from HNSCC 
bearing patients by using the acid-phenol guanidium method. RNA samples quality was 
assessed by electrophoresis through agarose gels and staining with ethidium bromide, and 
the 18S and 28S RNA bands were visualized under UV light. 
cDNA Synthesis 
RNA was reverse transcribed in a final volume of 20 µl containing 1X RT buffer, 0.01M DTT, 
0.5mM each dNTP, 0.15µg/µL random primers, 100U SuperScript™ II Reverse 
Transcriptase (Life Technologies, Carlsbad, Californie), 20U RNasin® Ribonuclease Inhibitor 
(Promega, Madison, Wisconsin) and 1 µg of total RNA. The samples were incubated during 
10min at 25°C 30min at 42°C, and reverse transcriptase was inactivated by heating 5min at 
99°C and cooling 5min at 5°C. 
 
PCR Amplification and quantification 
All of the PCR reactions were performed using an ABI Prism 7900HT Sequence Detection 
system (Thermo Fisher Scientific, Waltham, Massachusetts). PCR was performed using the 
Power SYBR™ Green PCR Master Mix (Life Technologies, Carlsbad, Californie). The 
thermal cycling conditions comprised an initial denaturation step of 10min at 95°C followed 
by 50 cycles at 95°C for 15 s and 65°C for 1 min. Cycle Threshold (Ct value) was defined by 
the cycle number at which the increase in the fluorescence signal associated with 
exponential growth of PCR products started to be detected, using Applied Biosystems 
analysis software according to the manufacturer’s manuals. For quality controls, we 
quantified the housekeeping gene TBP (Genbank accession NM_003194). Primers for TBP 
and the 30 target genes were designed with the assistance of Oligo 6.0 computer program 
(National Biosciences, Plymouth, MN). dbEST and nr databases were used to confirm the 
total gene specificity of the nucleotide sequences chosen as primers and the absence of 
single nucleotide polymorphisms. The primer pairs selected were unique relative to the 
sequences of closely related family member genes and the corresponding 
retropseudogenes. One of the two primers was placed at the junction between two exons or 
on two different exons to avoid genomic DNA contaminating. Specificity of PCR amplicons 
was verified by agarose gel electrophoresis. The oligonucleotide primers sequences used 
are shown in Table S8. 
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Data processing 
TBP was used for each sample normalization. ΔCt value was equal to mean Ct value of the 
target gene minus mean Ct value of TBP. The N-fold differences per sample in target gene 
expression relative to TBP was equal to 2ΔCt. For each gene, 2ΔCt values of the 31 juxtatumor 
samples were multiplied by a factor named “k” so that their median was equal to 1. The final 
values for tumor samples were equal to k2ΔCt. The 30 genes of this study are listed in Table 
S5. To obtain a score for the 18 genes signature, we standardized each gene separately, 
and used those values in the formula: 18G score = (CCR7+ HLADRB + CCL5 + CD27 - 
CD276 + CMKLR1 + CXCL9 + CXCR6 + HLA-DQA1 + HLA-E + IDO1 + LAG3 + NKG7 + 
PDCD1LG2 + PSMB10 + STAT1 + TIGIT)/18.   
 
Statistical Analysis 
Descriptive and statistical analyses were performed using GraphPad Prism V8, Xlstat 
(Addinsoft), and Qlucore softwares. Paired tumor and juxtatumor secretome comparison was 
done by Wilcoxon test. Univariate unpaired non-parametric comparisons used Mann-Whitney 
tests and Kruskal-Wallis test for multigroup comparisons. All correlations used Spearman 
method. Optimal threshold for ROC curves was defined as the value maximizing the sum of 
sensitivity and specificity. Univariate survival analysis was performed on clinical parameters 
and biological parameters (soluble molecules or 30 genes measured by RT-PCR) 
categorized as high or low by cut-off at median, or at optimal threshold when specified. Log-
rank tests were used for univariate analysis. For the 145 patient validation cohort, significant 
variables at the threshold of p < 0.05 were selected for the Cox proportional hazard models 
for multivariate analysis. Model 1 included 145 patients and all clinical and biological 
parameters significant in univariate analysis, but PNI and VE, because of missing values, 
whereas Model 2 included all significant parameters, but was restricted to the 124 patients 
with complete data. The heatmap representing the 18-gene signature in Fig3A was 
performed with Qlucore software. 
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Fig 1. Tumor secretome analysis identified 29 deregulated molecules    
Quantification of 49 molecules from the soluble microenvironment of 37 OCSCC and paired 
juxtatumor tissue. P-values obtained by Wilcoxon tests are represented by range: * < 0.05, ** 
< 0.01, *** < 0.001, **** < 0.0001.  
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Fig 2. Soluble MMP2 is a prognostic biomarker of OCSCC, independent of T cell 
infiltration 
A. ROC curve of soluble MMP2 for severity criteria (DSS < 36 months and /or a DFS < 12 
months followed by permanent palliative treatment). The optimal threshold was 29.3 ng/ml. 
B. DDS, DFS and OS survival curves according to soluble MMP2 level, define as high or low 
relatively to the threshold defined in “B”. 
C. Correlation between CD3 in live cells and soluble MMP2 (left), CXCL9 (center) and 
CXCL10 (right), in tumors of 18 HNSCC patients. r values are Spearman correlation 
coefficients. 
D. Correlation between soluble MMP2 and CXCL9 (left) and CXCL10 (right), in 37 OCSCC 
samples. r values are Spearman correlation coefficients. 
Abbreviations. OCSCC: oral cavity squamous cell carcinoma, ROC: receiver operating 
characteristic, DSS: disease specific survival, DFS: disease free survival, OS: overall 
survival, HNSCC: head and neck squamous cell carcinoma 
 
  
112	
	
Fig 3. MMP2, ENE and stage define prognostic groups with equivalent expression of 
an 18-gene signature predictive of response to PD-1 blockade 
113	
	
A. Cox proportional hazards Model 1, including n = 145 patients, and all clinical and 
biological data significant at p < 0.05 in univariate analysis, excepted perineural invasion and 
vascular embols. 
B. Survivals according to the prognostic groups defined by the Cox Model 1: DSS (top left) 
and DFS (top right) in the 4 groups defined by MMP2 RNA and ENE status. OS (bottom) in 
the 4 groups defined by MMP2 status and Stage. P-value obtained by Log-rank tests are 
represented by range: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001, and relatively to the best 
prognosis groups that are MMP2 low/ENE- for DSS and DFS, and MMP2 low/Stage I or II for 
OS. 
C. Distribution of the 18-gene signature score among the prognostic groups defined by the 
Cox Model 1 and 2 for DFS, DSS and OS. 
Abbreviations. DSS: disease specific survival, DFS: disease free survival, ENE: extranodal 
extension, OS: overall survival. 
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SUPPLEMENTARY FIGURES 
 
Fig S1. ROC curve of MMP2 RNA for severity criteria in the cohort of 145 patients (left) and 
among the 106 patients without ENE (right). 
 
 
Fig S2. Correlation between soluble MMP2 and MMP2 RNA (Spearman correlation 
coefficient). 
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Fig S3. Heatmap representing the expression of the 18 genes of the signature ordered by the 
18-gene signature score from low values (left) to high values (right). Each column represents 
one patient sample (n=145). 
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Fig S4. Correlation matrix of MMP2 RNA and the genes of the 18-gene signature (Spearman 
correlation coefficient). 
 
 
Fig S5. Distribution of the 18-gene signature score among MMP2 RNA high and low tumors 
(left), absence or presence of ENE (center) and disease stage (right). 
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Fig S6. Flow-chart representing proposals of MMP2-driven clinical trials  
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TABLES   
Table 1 - Patients characteristics of the RT-qPCR retrospective validation cohort (n=145) 
Parameter Percentage (n) 
Gender female  39% (57) 
 male  61% (88) 
Age  63.8 +/- 13.99 (mean +/- SD) 
Alcohol abuse (n=121) absent 60% (73) 
 present 40% (48) 
Tobacco (n=137) non smoker 43% (59) 
 smoker 57% (78) 
T stage T1 12% (18) 
 T2 23% (34) 
 T3 40% (58) 
 T4 24% (35) 
N stage N0 51% (74) 
 N1 11% (16) 
 N2 16% (23) 
 N3 22% (32) 
Stage  I 11% (16) 
 II 17% (24) 
 III 20% (29) 
 IVA 30% (43) 
 IVB 23% (33) 
Differentiation verrucous 3% (5) 
 well 70% (102) 
 moderate 20% (29) 
 poorly 6% (8) 
 basaloid 1% (1) 
Mitotic Index (n=119) high 40% (48) 
 low 33% (39) 
 mid 27% (32) 
Perineural invasion (n=125) absent 48% (60) 
 present 52% (65) 
Vascular embols (n=126) absent 61% (77) 
 present 39% (49) 
ENE absent 73% (106) 
 present 27% (39) 
Margins negative or close 83% (120) 
 positive 17% (25) 
HPV negative 94% (136) 
 positive  6% (9) 
Adjuvant treatment none 41% (59) 
 RT 40% (58) 
 RT + CT or Cetuximab 19% (27) 
 curietherapy 1% (1) 
Recurrence absent 61% (88) 
 local 23% (33) 
 regional 19% (27) 
 metastatic 13% (19) 
Severity non-severe 74% (107) 
 severe 26% (38) 
Numbers in brackets beside clinical parameters indicate the number of patients for which the 
information was available   
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Table 2 – Prognosis value of the clinical parameters and genes measured by RTqPCR in the 
validation cohort (univariate analysis, Log-Rank test) 
 
Parameter Mean +/- SD Poor prognosis if p-values per survival (Log-rank) 
 
  DSS OS DFS 
Gender  ns 0.8420 0.4387 0.801 
Age (</> 70)  ns 0.9460 0.9785 0.434 
Alcohol  ns 0.8710 0.1860 0.848 
Tobacco  ns 0.7839 0.1191 0.670 
Stage  III or more 0.0120 0.0036 0.053 
Differentiation  moderate or poor 0.0350 0.0434 0.117 
Mitotic index  ns 0.1957 0.7066 0.928 
Perineural invasion  present < 0.0001 < 0.0001 0.0046 
Vascular embols  present 0.0004 0.0002 0.0130 
ENE  present < 0.0001 0.0004 0.003 
Margins  ns 0.1020 0.1484 0.193 
HPV  ns 0.4950 0.4536 0.823 
MMP2 1.84+/-1.75 high 0.0009 0.0140 0.0440 
CD276 2.4+/-1.18 high 0.0056 0.0340 0.0870 
CXCL10 18.67+/-27.62 low 0.0083 0.0008 0.0820 
STAT1 3.72+/-2.35 low 0.0160 0.0007 0.1300 
MMP9 8.55+/-12.93 high 0.0190 0.0880 0.0610 
LAMP3 7.43+/-5.59 low 0.1500 0.0008 0.4300 
CXCR6 1.22+/-0.92 low 0.6200 0.0037 0.6600 
HLA-E 1.12+/-0.51 low 0.1100 0.0056 0.0810 
CD274 3.3+/-3.25 low 0.2100 0.0070 0.4100 
IDO1 13.98+/-20.3 low 0.0650 0.0095 0.1800 
PSMB10 1.68+/-0.99 low 0.2000 0.0270 0.2800 
CCR7 8.41+/-10.73 low 0.4700 0.0300 0.5900 
TIGIT 3.28+/-2.8 ns 0.8800 0.0560 0.7700 
CCL5 2.3+/-2.41 ns 0.7700 0.0600 0.8800 
LAG3 3.04+/-3.28 ns 0.4700 0.0640 0.7900 
PDCD1 2.19+/-2.17 ns 0.8500 0.0670 0.5400 
CXCL9 19.04+/-30.47 ns 0.7000 0.0680 0.9800 
HLA-DQA1 1.5+/-1.2 ns 0.5600 0.0850 0.7200 
IL3RA 0.9+/-0.69 ns 0.6300 0.0990 0.3700 
CD27 1.88+/-2.06 ns 0.7700 0.0990 0.7000 
NKG7 1.83+/-2.12 ns 0.7900 0.1300 0.4700 
CD3E 2+/-1.9 ns 0.8100 0.1400 0.7700 
pan_HLA-DRB 1.35+/-1.04 ns 0.7000 0.1500 0.6300 
PDCD1LG2 2.64+/-2.24 ns 0.3100 0.2000 0.2200 
CD8A 1.74+/-2.1 ns 0.6200 0.2800 0.4000 
ICOSLG 0.68+/-0.35 ns 0.9400 0.4200 0.4600 
CMKLR1 1.13+/-0.8 ns 0.4200 0.4300 0.4800 
MMP1 774.76+/-1051.42 ns 0.3000 0.6300 0.3500 
FUT4 1.06+/-0.53 ns 0.1600 0.8600 0.4000 
CD1C 0.36+/-0.42 ns 0.2300 0.9400 0.4500 
Cells highlighted in grey contain significant values at p < 0.05 
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Table 3 - Survival durations by prognostic groups defined by the Cox Model 1 
 
Survival Prognostic groups n (%) MST 
(months) 
2-y S 
 
3-y S 5-y S 
         
DSS MMP2 high / ENE- 50 (34%) 116.07 69.19% 66.72% 60.63% 
  MMP2 high / ENE+ 22 (15%) 20.04 49.23% 43.76% 36.47% 
  MMP2 low / ENE- 56 (39%) not reached 88.44% 88.44% 88.44% 
  MMP2 low / ENE+ 17 (12%) not reached 67.31% 60.58% 51.92% 
         
DFS MMP2 high / ENE- 50 (34%) 103.89 64.45% 61.87% 54.86% 
  MMP2 high / ENE+ 22 (15%) 22.57 45.85% 45.85% 38.21% 
  MMP2 low / ENE- 56 (39%) 172.39 79.25% 77.27% 73.20% 
  MMP2 low / ENE+ 17 (12%) not reached 56.31% 56.31% 56.31% 
         
OS MMP2 high / I or II 17 (12%) 116.07 75.00% 68.75% 56.25% 
  MMP2 high / III or more 55 (38%) 23.98 49.06% 47.09% 32.96% 
  MMP2 low / I or II 23 (16%) 135.43 86.96% 82.61% 82.61% 
  MMP2 low / III or more 50 (34%) 91.83 71.49% 65.16% 54.47% 
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SUPPLEMENTARY TABLES 
Table S1 - Patients characteristics of the secretome prospective discovery cohort (n = 37) 
Parameter  Percentage (n) 
Gender female  32% (12) 
 male  68% (25) 
Age  68.31 +/- 12.81 (mean +/- SD) 
Alcohol abuse (n=27) absent 67% (18) 
 present 33% (9) 
Tobacco (n=34) non smoker 50% (17) 
 smoker 50% (17) 
T stage T1 14% (5) 
 T2 22% (8) 
 T3 32% (12) 
 T4 32% (12) 
N stage N0 59% (22) 
 N1 8% (3) 
 N2 14% (5) 
 N3 19% (7) 
Stage  I 14% (5) 
 II 11% (4) 
 III 19% (7) 
 IVA 38% (14) 
 IVB 19% (7) 
Differentiation well 78% (29) 
 moderate 22% (8) 
 poorly 0% (0) 
Mitotic Index (n=36) high 53% (19) 
 low 25% (9) 
 mid 31% (11) 
Perineural invasion (n=36) absent 47% (17) 
 present 53% (19) 
Vascular embols  absent 59% (22) 
 present 41% (15) 
ENE absent 76% (28) 
 present 24% (9) 
Margins negative or close 86% (32) 
 positive 14% (5) 
HPV (n=21) negative 90% (19) 
 positive  10% (2) 
Adjuvant treatment none 30% (11) 
 RT 54% (20) 
 RT + CT or Cetuximab 16% (6) 
Recurrence absent 73% (27) 
 present 27% (10) 
Severity non-severe 76% (28) 
 severe 24% (9) 
Numbers in brackets beside clinical parameters indicate the number of patients for which the 
information was available  
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Table S2 - Comparison of the analytes of the soluble microenvironment of 37 paired OCSCC 
and juxtatumor samples (Wilcoxon) 
Analyte Tumor Median (min-max) 
Juxtatumor 
Median (min-max) Higher in p-value 
CXCL9 35380 (61-52000) 2934 (31-52000) Tumor <0.0001 
GM-CSF 1093 (0-10800) 105 (0-3386) Tumor <0.0001 
IL-15 5 (0-17) 1 (0-8) Tumor <0.0001 
MMP-2 28457 (4155-51500) 5414 (0-51500) Tumor <0.0001 
MMP-9 10500 (783-10500) 2522 (159-10500) Tumor <0.0001 
PAI-1 19392 (1513-34000) 4579 (61-34000) Tumor <0.0001 
Resistin 10460 (109-24500) 1263 (27-24500) Tumor <0.0001 
SCF 22 (0-242) 9 (0-42) Tumor <0.0001 
TNF-α 83 (1-2402) 37 (0-330) Tumor <0.0001 
MCP-1 1103 (163-19500) 10669 (0-19500) Juxtatumor <0.0001 
IL-1b 843 (1-5996) 163 (0-3221) Tumor 0.0001 
IL-12(p40) 0 (0-24) 0 (0-8) Tumor 0.0002 
IL-16 143 (18-2085) 35 (0-632) Tumor 0.0003 
TARC 4 (0-87) 0 (0-15) Tumor 0.0003 
TRAIL 17 (0-238) 6 (0-136) Tumor 0.0003 
VEGF 72 (0-2399) 39 (0-228) Tumor 0.0006 
MMP-1 21000 (7281-21000) 21000 (28-21000) Tumor 0.0024 
IL-12(p70) 1 (0-14) 0 (0-2) Tumor 0.0029 
MCP-3 0 (0-52) 0 (0-519) Juxtatumor 0.0078 
MDC 198 (0-2264) 45 (0-1226) Tumor 0.0083 
TGFa 14 (0-209) 9 (0-76) Tumor 0.0104 
IL-1RA 1529 (17-10200) 311 (0-10200) Tumor 0.0110 
Leptin 12 (0-328) 22 (0-426) Juxtatumor 0.0162 
MCSF 2897 (634-27235) 2124 (24-13266) Tumor 0.0173 
MIP-1b 85 (4-517) 45 (0-262) Tumor 0.0181 
CXCL10 527 (0-11000) 106 (0-11000) Tumor 0.0200 
FGF-2 192 (29-1553) 120 (0-501) Tumor 0.0233 
MCP-2 7 (0-151) 13 (0-1037) Juxtatumor 0.0376 
CCL20 113 (0-8227) 73 (0-547) Tumor 0.0496 
HGF 2218 (115-8862) 1195 (24-7529) ns 0.0621 
RANTES 197 (4-5222) 112 (0-3188) ns 0.0884 
TSLP 0 (0-0) 0 (0-13) ns 0.1250 
IL-8 11000 (3545-11000) 11000 (2-11000) ns 0.1324 
LIF 38 (0-731) 75 (0-479) ns 0.1579 
IL-33 5 (0-135) 15 (0-136) ns 0.2367 
I-309 0 (0-7) 0 (0-3) ns 0.2789 
IL-23 0 (0-24) 0 (0-24) ns 0.3750 
GRO 12000 (236-12000) 12000 (6-12000) ns 0.4634 
TPO 0 (0-14) 0 (0-22) ns 0.5000 
TNFb 0 (0-2) 0 (0-1) ns 0.6250 
G-CSF 10500 (353-10500) 10500 (0-10500) ns 0.6578 
MIP-1a 207 (7-2100) 193 (0-2100) ns 0.7152 
ENA-78 2212 (26-23000) 2137 (0-23000) ns 0.8231 
CXCL6 65 (0-523) 69 (0-2600) ns 0.8463 
CXCL7 1813 (144-7802) 1447 (93-8201) ns 0.8815 
EGF 4 (0-13) 4 (0-27) ns 0.9809 
SDF-1 0 (0-77) 0 (0-40) ns 1.0000 
IL-21 0 (0-0) 0 (0-0) ns all values at 0 
IL-9 0 (0-0) 0 (0-0) ns all values at 0 
Cells highlighted in grey contain significant values at p < 0.05 
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Table S3 - Prognosis value of the 49 analytes measured in the tumor soluble microenvironment 
(Mann-Whitney) 
Analyte Non-severe  Median (min-max) 
Severe  
Median (min-max) p-value 
MMP2 17432 (4155-51500) 34839 (29414-51500) 0.0074 
IL12(p70) 1 (0-14) 0 (0-2) 0.0738 
EGF 0 (0-13) 7 (0-12) 0.1422 
CCL20 82 (0-1160) 303 (26-8227) 0.1729 
MCP2 8 (0-151) 0 (0-21) 0.1934 
ENA78 2712 (26-23000) 1468 (65-11471) 0.2264 
CXCL9 52000 (61-52000) 7350 (2415-52000) 0.2286 
IL23 0 (0-24) 0 (0-11) 0.2501 
MCP3 0 (0-52) 0 (0-0) 0.2505 
IL1RA 1137 (17-10200) 2126 (421-10200) 0.2958 
PAI1 19392 (1513-34000) 22582 (12431-34000) 0.3297 
CXCL6 85 (0-523) 40 (5-394) 0.3365 
IL1b 748 (1-3519) 1072 (88-5996) 0.4122 
CXCL7 1348 (144-6613) 2251 (535-7802) 0.4325 
I309 0 (0-7) 1 (0-2) 0.4392 
TRAIL 17 (0-238) 20 (7-167) 0.4679 
IL12(p40) 0 (0-14) 4 (0-24) 0.5056 
TARC 3 (0-87) 7 (0-32) 0.5351 
CXCL10 584 (0-11000) 314 (168-1863) 0.5588 
GRO 10378 (236-12000) 12000 (2966-12000) 0.5810 
Resistin 11045 (109-24500) 8741 (413-24500) 0.5851 
MMP9 10500 (783-10500) 10500 (2806-10500) 0.6027 
MMP1 21000 (7281-21000) 21000 (21000-21000) 0.6143 
TPO 0 (0-14) 0 (0-0) 0.6143 
RANTES 200 (4-5222) 189 (98-1565) 0.6385 
Leptin 13 (0-226) 6 (0-328) 0.6957 
FGF2 159 (29-1553) 250 (43-993) 0.7149 
IL16 158 (18-2085) 131 (35-1464) 0.7411 
IL8 11000 (3545-11000) 11000 (7858-11000) 0.7421 
GCSF 10500 (353-10500) 10500 (1095-10500) 0.7496 
TNFb 0 (0-2) 0 (0-1) 0.7648 
IL15 5 (0-15) 6 (2-17) 0.7904 
IL33 3 (0-60) 5 (0-135) 0.8068 
LIF 38 (0-731) 67 (0-231) 0.8593 
MIP1b 87 (4-517) 82 (31-177) 0.8595 
MCP1 1103 (163-19500) 1162 (269-12495) 0.8734 
VEGF 101 (0-2399) 49 (26-1072) 0.9154 
SDF1 0 (0-40) 0 (0-77) 0.9215 
MIP1a 214 (7-2100) 169 (60-889) 0.9295 
MCSF 2918 (634-12946) 2639 (814-27235) 0.9308 
SCF 25 (0-93) 21 (5-242) 0.9435 
TNF-α 94 (1-2402) 75 (29-1035) 0.9584 
MDC 184 (0-2264) 219 (33-1050) 0.9859 
TGFa 16 (0-147) 12 (5-209) 0.9861 
HGF 2218 (115-7258) 2223 (363-8862) 0.9861 
GMCSF 1236 (0-10800) 946 (753-10800) 1.0000 
IL21 0 (0-0) 0 (0-0) 1.0000 
IL9 0 (0-0) 0 (0-0) 1.0000 
TSLP 0 (0-0) 0 (0-0) 1.0000 
Cells highlighted in grey contain significant values at p < 0.05 
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Table S4 - List of the 30 genes measured by RTqPCR 
Gene Alias(es) Included in the 18 
gene signature 
MMP1  no 
MMP2  no 
MMP9  no 
CXCL10  no 
CD3E CD3 no 
FUT4 CD15 no 
ICOSLG ICOS-L no 
CD1C  no 
LAMP3  no 
IL3RA  no 
CD8A CD8 no 
PDCD1 CD279, PD1 no 
CD274 B7H1, PDL1, PDCD1L1 yes 
CCR7  yes 
HLADRB  yes 
CCL5 RANTES yes 
CD27 TNFRSF7 yes 
CD276 B7H3 yes 
CMKLR1  yes 
CXCL9  yes 
CXCR6  yes 
HLA-DQA1  yes 
HLA-E  yes 
IDO1 IDO yes 
LAG3 CD223 yes 
NKG7  yes 
PDCD1LG2 B7DC, PDL2 yes 
PSMB10 LMP10 yes 
STAT1  yes 
TIGIT  yes 
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Table S5 - Multivariate Cox proportional hazards Model 2, including n = 124 patients, and all 
clinical and biological data significant at p < 0.05 in univariate analysis 
 
Survival Parameters P value HR (95% CI) 
DSS MMP2 0.034 1.168 (1.012-1.349) 
  PNI 0.020 2.599 (1.161-5.818) 
  
  
  
OS PNI 0.010 2.198 (1.204-4.01) 
  Stage 0.019 2.646 (1.175-5.957) 
  
  
  
DFS MMP2 0.016 1.162 (1.028-1.312) 
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Table S6 - Comparison of survivals in the prognostic groups defined by the Cox Model1 
   Prognostic groups Log-rank  HR (Mantel-Haenszel) 
   P value HR Inf CI 95% Sup CI 95% 
DSS MMP2 high / ENE- vs. MMP2 high / ENE+  0.0093 0.3417 0.1522 0.7671 
  MMP2 high / ENE- vs. MMP2 low / ENE-  0.0022 3.228 1.524 6.834 
  MMP2 high / ENE- vs. MMP2 low / ENE+  0.6203 0.7928 0.3165 1.986 
  MMP2 high / ENE+ vs. MMP2 low / ENE- <0.0001 21.49 7.226 63.94 
  MMP2 high / ENE+ vs. MMP2 low / ENE+ 0.1851 1.795 0.7556 4.264 
  MMP2 low / ENE- vs. MMP2 low / ENE+ 0.0016 0.1079 0.02715 0.4286 
        
DFS MMP2 high / ENE- vs. MMP2 high / ENE+ 0.0317 0.4281 0.1973 0.9285 
  MMP2 high / ENE- vs. MMP2 low / ENE- 0.0893 1.771 0.916 3.426 
  MMP2 high / ENE- vs. MMP2 low / ENE+ 0.6349 0.8029 0.3243 1.987 
  MMP2 high / ENE+ vs. MMP2 low / ENE- 0.0002 5.539 2.236 13.72 
  MMP2 high / ENE+ vs. MMP2 low / ENE+ 0.3634 1.497 0.6273 3.57 
  MMP2 low / ENE- vs. MMP2 low / ENE+ 0.0705 0.3582 0.1177 1.09 
        
OS MMP2 high/I or II vs. MMP2 high/III or more  0.0402 0.5285 0.2873 0.972 
  MMP2 high/I or II  vs. MMP2 low/I or II  0.2129 1.886 0.6948 5.122 
  MMP2 high/I or II vs. MMP2 low/III or more 0.653 6e-310 2e-322 infinite 
  MMP2 high/III or more vs. MMP2 low/I or II 0.0004 2.8878 1.597 5.186 
  MMP2 high/III or more vs. MMP2 low/III or more 0.0398 6e-310 2e-322 infinite 
  MMP2 low/I or II vs. MMP2 low/III or more 0.0646 6e-310 2e-322 infinite 
Inf: inferior. CI: confidence interval. Sup: infinite. Cells highlighted in grey contain significant 
values at p < 0.05  
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Table S7 - Clinical parameters according to MMP2 RNA status  
 
Parameter Percentage (n) MMP2 Low 
(n=73) 
MMP2 high 
(n=72) 
p value 
(Fisher) 
Odd Ratio 
[95%CI] 
Gender female  40% (29) 39% (28) 1.0000   
  male  60% (44) 61% (44) 0.9506   
Age mean +/- SD 63,21 +/- 
13,68 
63,35+/-14,39    
Alcohol abuse 
(n=63, n=58) 
absent 59% (37) 62% (36) 0.7148   
  present 41% (26) 38% (22)    
Tobacco (n=70, 
n=67) 
non smoker 43% (30) 43% (29) 1.0000   
  smoker 57% (40) 57% (38)    
T stage T1 or T2 40% (29) 32% (23) 0.3876   
  T3 or T4 60% (44) 68% (49)    
N stage N0 60% (44) 42% (30) 0.0310 2.11 [1.04; 4.35] 
  N+ 40% (29) 58% (42)    
Stage  I or II 32% (23) 24% (17) 0.3536   
  III or more 68% (50) 76% (55)    
Differentiation verrucous, well, 
basaloid 
75% (55) 74% (53) 0.8506   
  moderate, poorly 25% (18) 26% (19)    
Mitotic Index (n=63, 
n=56) 
high 54% (34) 25% (14) 0.0015 3.48 [1.51; 8.35] 
  low / mid 46% (29) 75% (42)    
Perineural invasion 
(n=63, n=62) 
absent 59% (37) 37% (23) 0.0200 2.40[1.12; 5.28] 
  present 41% (26) 63% (39)    
Vascular embols 
(n=65, n=61) 
absent 63% (41) 59% (36) 0.7157   
  present 37% (24) 41% (25)    
ENE absent 77% (56) 69% (50) 0.3536   
  present 23% (17) 31% (22)    
Margins negative or close 82% (60) 83% (60) 1.0000   
  positive 18% (13) 17% (12)    
HPV negative 93% (68) 94% (68) 1.0000   
  positive  7% (5) 6% (4)    
Adjuvant treatment none 41% (30) 40% (29) 0.9636   
  RT 41% (30) 39% (28)    
  RT + CT or Cetuximab 18% (13) 19% (14)    
  curietherapy 0% (0) 1% (1)    
Severity low 82% (60) 65% (47) 0.0241 2.44[1.07; 5.80] 
  high 18% (13) 35% (25)    
Recurrence absent 70% (51) 51% (37) 0.0398   
  local 30% (22) 29% (21)    
  regional 14% (10) 24% (17)    
  metastatic 7% (5) 19% (14)     
Numbers in brackets beside clinical parameters indicate the number of patients for which the 
information was available. Cells highlighted in grey contain significant values at p < 0.05. 
 
Table S8 - Primer sequences 
Primer Name Primer Sequence 5' to 3' 
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D-ALB-U GCTGTCATCTCTTGTGGGCTGT 
D-ALB-L ACTCATGGGAGCTGCTGGTTC 
TBP-U TGCACAGGAGCCAAGAGTGAA 
TBP-L CACATCACAGCTCCCCACCA 
MMP1-U2 GGCTTGAAGCTGCTTACGAATTT 
MMP1-L2 ACAGCCCAGTACTTATTCCCTTTGA 
MMP2-U1 ACTGCGGTTTTCTCGAATCCA 
MMP2-L1 GGTATCCATCGCCATGCTCC 
MMP9-U1 CGGCTTGCCCTGGTGCAGT 
MMP9-L1 CGTCCCGGGTGTAGAGTCTCTCG 
CXCL10-U1 CTGACTCTAAGTGGCATTCAAGGAG 
CXCL10-L1 GGTTGATTACTAATGCTGATGCAGG 
CD3E-U2-Hs AAGATGGTAATGAAGAAATGGGTGGT 
CD3E-L2-Hs TGAGGGCATGTCAATATTACTGTGGT 
FUT4-U3-Hs CTGCCATGGACCGTCTGTGT 
FUT4-L3-Hs CCCCAGCAAGCGTAGGTGA 
CD274-U1-Hs GCTGAATTGGTCATCCCAGAACTAC 
CD274-L1-Hs AAACGGAAGATGAATGTCAGTGCTAC 
ICOSLG_U1_Hs CTTCTGCAGCAGAACCTGACTGT 
ICOSLG_L1_Hs CGGTACTGACTGGATTCTCTGTGAT 
CD1C-U1 GACAATGCAGACGCATCCCA 
CD1C-L1 CAACTCGTCCAGCCATCCTGA 
CCR7-U2 GGGGAAACCAATGAAAAGCGT 
CCR7-L2 ATCTTGACACAGGCATACCTGGAA 
LAMP3-U2 ACCCGAAAATCCAACCTTCTGT 
LAMP3-L2 GTCAAATAGGCTCCCACTTCACTG 
IL3RA-U1 ATCGCAAATTTCGCTATGAGCTT 
IL3RA-L1 GGAGGTTCTGTCTCTGACCTGTTCT 
HLA-class2-DRB-U2-Hs TGCCAAGTGGAGCACCCAA 
HLA-class2-DRB-L2-Hs CAGATTCAGACCGTGCTCTCCAT 
CCL5-U2 GCCCACATCAAGGAGTATTTCTACA 
CCL5-L2 TTCGGGTGACAAAGACGACTG 
CD27-U1-Hs GTGCACCGAGTGTGATCCTCTT 
CD27-L1-Hs GGCCTCCAGCATCTCACTGAC 
CD276-U1-Hs AGGAGAATGCAGGAGCTGAGGA 
CD276-L1-Hs TCAGAGGCTGCAGGGCTGTC 
CMKLR1-U2 TCAACCTGGCAGTGGCAGAT 
CMKLR1-L2 CCCGAAAACCCAGTGGTAGTC 
CXCL9-U2 ATCCACCTACAATCCTTGAAAGAC 
CXCL9-L2 TCCATTCTTCAGTGTAGCAATGATTT 
CXCR6-U1 GGTTCAGCAGTTTCAATGACAGCA 
CXCR6-L1 CAGACCACAGACAAACACCACCAG 
HLA-DQA1-U3 CTACCGCTGCTACCAATGAGGTTC 
HLA-DQA1-L3 TGGGCTGACCCAGTGTCACG 
HLA-E-U3 GCTACTCTAAGGCTGAGTGGAGCGA 
HLA-E-L3 TTTACAAGCTGTGAGACTCAGACCCCT 
IDO1-U1 TGTTTCACCAAATCCACGATCAT 
IDO1-L1 CCTTCATACACCAGACCGTCTGAT 
LAG3-U2-Hs CCTTTCTCTGCTCCTTTTGGTGACT 
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LAG3-L2-Hs AATCGTCTTGGTCGCCACTGTCT 
NKG7-U1 CCCCAGATCCAGACCTTCTTCTC 
NKG7-L1 CCAGGCTCAGGGCACCTGTA 
PDCD1LG2-U1-Hs TCCTGCTAATGTTGAGCCTGGAA 
PDCD1LG2-L1-Hs GTCACATTGCTGCCATGCTCTATTAT 
PSMB10-U1 CGCCCCCAAAATCTACTGCTG 
PSMB10-L1 TGGACGCCACCATCCGTGT 
STAT1-U1 AGCATGAAATCAAGAGCCTGGA 
STAT1-L1 ACCATTGGTCTCGTGTTCTCTGTT 
TIGIT_Hs_U3 CTCCCCTCGCCTCAGGAATGAT 
TIGIT_Hs_L3 CCGTGGTGGAGGAGAGGTGACA 
CD8A-U3-Hs CCGGTCTTCCTGCCAGCGAAG 
CD8A-L3-Hs GGCGCCGGTGTTGGTGGTC 
PDCD1-U1-Hs TCGTCTGGGCGGTGCTACAAC 
PDCD1-L1-Hs AGGGCCTGTCTGGGGAGTCTAAG 
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4. DISCUSSION AND PROSPECTS 
 
4.1 Discussion 
 
4.1.1 DC maturation states: towards a novel classification? 
 
In our study, we are proposing a novel classification of cDC maturation states, based on 
systematic in vitro analysis of DC-T cell features. We used 16 stimuli activating 6 different 
TLR, 1 CLR, cytosolic sensors and 2 cytokine receptors, covering a broad spectrum of 
signaling pathways, reviewed in the introduction. PRR signaling pathways have some 
specificities but are also very redundant as shown by the transcription factors shared by the 
different pathways. The exact mechanisms by which a cell will present with different outputs 
after stimulation by 2 different ligands binding the same receptor or a unique ligand present 
at different concentration or for different duration remains to be fully elucidated. Here, we 
could further classify our observations in 3 categories: (i) different ligands for different 
receptors that all induce the same phenotype (e.g. “secretory” for Zymosan/TLR2-Dectin1 
and R848/TLR7/8, and “helper” for GM-CSF/GM-CSFR and Flu/TLR7-Cytosolic sensors); (ii) 
2 different ligands for the same receptor that induce “secretory DC” or “helper DC” (e.g. 
TLR2 and the ligands HKSA and Pam3); (iii) ligand-receptor pairs that have their own 
specificity, such as Poly I:C/TLR3 that was one of the few stimuli with an intermediate 
phenotype between “secretory” and “helper”, and was also unique at inducing high levels of 
IFN-a and IL-28. Most observations were in the first category, so that we may now ask the 
question of the universality of this classification.  
 
Would any other DC stimuli induce necessarily “secretory” or “helper DC”? Are there stimuli, 
combinations or doses able to induce simultaneous high expression of PDL1 and ICOSL, or 
are these molecules exclusive at high expression levels on cDC?  and what would be the 
associated DC and T cell outputs? Other types of stimuli and combination would need to be 
tested to address this question, for instance using pure cytosolic sensor activators such as 
cGAMP (117). 
Another aspect of universality would be the impact of the DC subset, as we have seen in the 
introduction that the same stimuli on different DC subsets, even when both express the 
corresponding receptor, could have a different impact. Two years ago, in our team, we had 
identified functional pDC subsets after CpG or Flu stimulation, labelled “P1”, “P2” and “P3”, 
according to their final state of maturation with the same stimuli. The markers best 
discriminating these subsets were PDL1 and CD80. “P1” were PDL1high and CD80low and 
associated to an increased secretion of IFN-α, whereas “P3” PDL1lowCD80high were the 
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most potent activators of T cell (294), and “P2” had an intermediate phenotype. This suggest 
that our classification may apply to pDC, but that PDL1 and ICOSL were not the best 
functional subset markers in this case. However, ICOSL was also overexpressed in “P3” as 
compared to “P1”.  
As the extensive literature on DC maturation states was obtained with Mo-DC, it would also 
be interesting to determine if our cDC classification applies to this in vitro-generated subset.  
Finally, our dataset contained data from primary blood CD11c+ DC, composed of a majority 
of cDC2 and a minority of cDC1. We therefore cannot be sure if this classification would 
apply to cDC1 stimulated alone, especially since cDC1 do not express the same PRR than 
cDC2. A potential influence of cDC1 on cDC2 was also possible in our model. For instance, 
cDC1 express high levels of TLR3, the receptor for Poly I:C, which might explain the 
specificity of this stimuli described above.  
 
Another question is the mechanisms responsible for the DC phenotypes and the T cell 
outputs. PDL1 and ICOSL are efficient markers to identify each functional DC state, but this 
does not necessarily mean that they are responsible for the effect observed on T cells. PDL1 
was co-expressed with other negative checkpoints and with the integrin CD54 and the 
costimulatory CD40 on “secretory” DC. We did not identify any other surface marker 
systematically associated to ICOSL on “helper” DC. The predominance of negative signals 
for “secretory” DC is in line with a limited stimulation of T cells, although it remains to be 
demonstrated by blocking experiments. “Secretory” DC secreted high levels of IL-10 that 
may be responsible for the absence of stimulation of T cell cytokine production, and may also 
be the signal responsible for PDL1 upregulation in an autocrine manner (169). In our system, 
IL-10 signaling towards T cell seems to have a dominant immunosuppressive effect on IL-12 
that was also produced by “secretory” DC. Additionally, although “secretory-DC”- activated 
naïve CD4 T cells were not able to produce more cytokines than T cell co-cultured with 
medium DC, they acquired higher proliferation capacity.  
CD4 T helper cells promote CD8 cytotoxic activation by the secretion of cytokines but also by 
membrane-bound molecules that were not measured in our model, such as CD40L (245), 
and cDC2 may cross-present. We have not performed subsequent DC/CD8+Tcells or 
CD4+Tcell/CD8+Tcell functional assays and cannot further conclude on the level of CD8+T 
cell immunosuppression or anergy associated with “secretory DC”. Finally, it is possible that 
some molecules not measured in our model may also play a role on the observed 
phenotypes, such as TGF-β (254). 
Transcriptomic analysis of tumor infiltrating DC and of a public dataset of DC activated with 
one “secretory” and one “helper” stimuli allowed us to observe that the NFkB pathway was 
strongly upregulated in “secretory” DC. The transcription factors IRF-1, -7, -8, -9 and the 
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STAT-1, -4, -5a were also associated to the “secretory” signature, whereas IRF4, CREB3 
and CREB3L2 were associated to the “helper signature”, and IRF2, JUN(gene for AP1) and 
CREB3L1 were part of the common maturation trunk (Section 3.1, Fig4E and Table 9). 
Additional transcriptomic analysis of DC stimulated with some of the other stimuli of our 
model would help us to confirm the differential expression of the transcription factors 
associated with each phenotype.  
 
Ex vivo phenotypic and transcriptomic analyses of human tumor infiltrating cDC2 showed 
that the cells from inflamed tumors had important similarities with our in vitro “secretory” DC. 
These results are very encouraging for the relevance of our in vitro model to human 
physiopathology. Our classification also conciliates the observations of simultaneous 
immunosuppressive and immunogenic features observed in various context in human and 
presented in the introduction (71), (236). 
Former observations that lead to the existing classification of immunogenic and tolerogenic 
matured DC are not necessarily conflicting with the classification presented here. Two main 
aspects related to the experimental settings of former studies may explain how: (i) the lack of 
molecules analyzed, (ii) the relativity of the comparator. The added value of our model is the 
unbiased and systematic measurement of multiple DC and T cell outputs. Most studies 
presented in the introduction studied the expression of few DC membrane markers and 
cytokines to define immunogenic and tolerogenic DC and might have lacked a more global 
view. As per the relativity of the comparator, in our model, each stimuli could be compared to 
the classical negative control that is medium, but more importantly to multiple different 
positives controls that were the other stimuli, and we tended to observe the “true” highest 
level of expression the molecules studied. For example, a dual comparison of TSLP-DC with 
Medium-DC will conclude that TSLP induces an upregulation of PDL1 on DC and define the 
PDL1high DC. The same experiment with a supplementary condition such as R848 will 
conclude that PDL1 is only mildly upregulated by TSLP as compared to R848, and the TSLP-
DC will become PDL1low/intermediate, whereas R848 will appear as PDL1high. This 
relativity shows how much the choice of one or the other positive control is impactful for the 
interpretation of experimental results. 
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4.1.2 Translation of DC “Secretory” and “Helper” patterns into a theoretical 
basis for the use of DC modulators in cancer and other diseases 
 
In the introduction section 1.2.3.5, we have seen that some of the stimuli used in our in vitro 
model are also pharmaceutical compounds approved or under evaluation. They may be used 
to modulate DC maturation state before DC therapy, or as peptide-based vaccine adjuvants 
(273).  
Stimuli inducing “secretory” DC, such as R848 (TLR7/8 ligand), may be proposed as 
candidate drugs to induce immune cell recruitment in cold tumors and DC maturation in the 
TME. However, our results suggest that they should not be used in cancer patients without 
combining them with PD(L)1 blockade, otherwise, T cell activation in the peripheral lymph 
node or within the tumor might be further limited. R848 is frequently used as a vaccine 
adjuvant, but we have not been able to identify a trial in combination with PD(L)1 blockade 
(NCT02126579). TLR4 activator GSK1795091 injected in tumors is under evaluation and is, 
to date to or knowledge, the sole Phase I/II in this category to have planned one cohort with 
concomitant PD1 blockade (NCT03447314). Combination with IL-10 blocking would in theory 
also be needed (56). Zymosan has shown some pre-clinical efficacy in a mice model of 
melanoma, but no clinical trial is ongoing with this compound (295). The analysis of the effect 
of those compounds in the human TME is required to translate our in vitro observations and 
anticipate the factors of resistance and needs for treatment combinations.  
 
We have not observed “Helper” cDC in the HNSCC TME, but we have defined the stimuli 
that may induce them in vitro, which include GM-CSF, TSLP, Flu and low dose of Pam3. 
ICOSL high myeloid cells have been described to infiltrate tissues in inflammatory diseases, 
auto-immune disorders and in allergy (296). As stated above, we have not yet shown that 
ICOSL was the key molecule for T cell activation in our model, and it may well be the 
absence/low levels of IL-10 and inhibitory checkpoints that simply allow a final 
immunostimulatory signal to transit from the DC to the T cell. That said, ICOSL has 
previously been shown to promote T cell activation, and is unambiguously classified as a 
positive checkpoint (297).  
Whether DC targeting in a sense that would favor “Helper” DC polarization would be 
beneficial or deleterious in the context of cancer remains to be shown. This question faces 
the dual role of ICOS/ICOSL targeting with potential anti-tumor and pro-tumor effect in the 
TME, which explains why both agonists and antagonists are being tested in clinical trials in 
the context of cancer (298). A better understanding of the factors regulating ICOSL 
expression in our in vitro model and in the HNSCC TME would help for clinical translation. 
ICOS is highly expressed on Treg (296), (299), (300), but ICOS+CD8 T cells are also 
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present in cancer tissues, although with lower percentages of expression (28), (study 3.1, 
data not shown). Several studies report that these ICOS+CD8 T cells are the cytotoxic T cell 
responsible for the spontaneous anti-tumor immune response (30), (31), and that they are 
the cells that increase under PD1 blockade in cases with treatment efficacy (32). In this line, 
ICOS was used to enhance the efficacy of CAR-T cell-based therapies (33). 
 
In parallel, other types of stimuli, such as cytosolic sensors activating cGAMP/STING 
pathway are entering the clinics [NCT03010176, NCT03172936]. cGAMP is able to activate 
myeloid cells and upregulate MHC molecules (301), but whether it drives a “secretory”, a 
“helper” or even an undescribed third type of activation needs to be determined in order to 
have a rational for the need of optimized combinations. The combination of cGAMP-
nanoparticles and anti-PDL1 did not significantly enhance the anti-tumor response over 
cGAMP-nanoparticles alone (301), which supports the importance of increasing our 
knowledge in the field. 
 
 
 
4.1.3 What favors a hot versus cold immune microenvironment?  
The major T cell attracting chemokines are CXCL9 and CXCL10 (302), (303), which is 
consistent with our results (Results 3.2 Fig 3.C). In the introduction, we reported that cDC1 
were the main source of those 2 chemokines in a mice model of melanoma, but that there 
was a possible discrepancy between the low number of cDC1 and the high levels of 
chemokines (241). CXCL9 and CXCL10 were also produced by human tumor infiltrating 
cDC2 in our study (Results 3.1 Fig 4E).  This difference may be due to differences in mice 
and human DC biology, and/or between tumor models and spontaneous human tumors.  
Interestingly, there was no correlation between tumor mutational burden (TMB) and tumor 
inflammation, so that is not likely that the level of neoantigens is responsible for DC/T cell 
recruitment into tumors (304). From the biology presented in the introduction and in the 2 
studies of this thesis, DC attracting chemokines seem to vary with the PRR and cytokine 
signaling occurring in the TME. Fig 1 from Results 3.2 shows that many DC attracting 
chemokines are increased in the tumor tissue, except the MCP-1, -2, -3 that are significantly 
decreased. A better understanding of the relationship between those the MCP, the other 
upregulated CCL and the main T cells attracting chemokines CXCL9 and CXCL10 would be 
one way to decipher the hot and cold tumors. 
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4.1.4  MMP2: towards a clinical-use biomarker for OCSCC?   
In the second study (3.2) we propose to use pre-operative MMP2 status or post-operative 
MMP2 and extranodal extension status for biomarker-driven clinical trial. The gold standard 
way to implement biomarkers into clinical practice is to run a prospective randomized trial 
comparing the biomarker-driven approach (the experimental arms were described in 3.2 Fig. 
S6) with the control arms treated by standard of care. The objective would be to show a 
benefit in survival. The preparation of randomized clinical trials includes an important 
statistical work aimed at defining the number of patients to include in each experimental arm. 
To do so, existing data is used to estimate the expected outcomes in the control arms and 
the expected benefit of the approach tested (305). The present study delivers valuable data 
to prepare such trial, and we even indirectly estimated the expected rates of responders to 
PD1-blockade, since it would be one of the proposed options for treatment intensification. 
Randomized clinical trials deliver the highest level of evidence and are the best way to obtain 
authorities approval and the adherence of the clinicians (306). 
Another way for a biomarker to enter the clinical practice is to gather an important number of 
evidences from studies with lower levels of evidence. For example, clinical parameters 
usually enter the TNM classification by such cumulated evidences, as it was the case 
recently for depth of invasion in OCSCC (307). Another example is the urokinase-type 
plasminogen activator (uPA) and its inhibitor (PAI-1) signature for prognostic stratification of 
breast cancer, associated with the indication of adjuvant chemotherapy (308). This biomarker 
was validated after a meta-analysis merging 8377 patients from 18 datasets (309). Many 
studies supported the prognostic role of MMP2 in OCSSC but only 1 was performed with 
OCSCC patients treated by primary surgery and showed a significant result in an appropriate 
multivariate analysis, and included only 60 patients (310). This low number of patients is of 
course insufficient to reach a robust level of evidence, but on the other hand shows that 
MMP2 is a sufficiently powerful biomarker that it may be significant even with so few patients 
and events, as in our 37 patient prospective discovery cohort. Another larger study in Taiwan 
included 256 patients in the same clinical setting, but did not present any multivariate 
analysis, (311). Therefore, I am not convinced that the studies available to date would be 
enough for a well conducted meta-analysis. 
An important prerequisite is the standardization of the biomarker testing across the different 
centers participating to the trial in the first case, or in the medical health system in the second 
case. Optimal biomarkers are defined as independent in multivariate analysis, robust with a 
narrow confidence interval of their hazard ratio, simple to implement in routine, reproducible 
within the different assessors from different laboratories and cost-efficient (312). In the 
present case MMP2 fulfils the first two criteria, but the technology to be used in clinical 
practice remains to be determined. Soluble MMP2 is an elegant way to measure directly the 
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protein and obtain a continuous measure, as most biological analysis in medicine, but the 
need for standardized fresh samples to produce tumor-derived secretome is not compatible 
with the simplicity criteria. RTqPCR or semi-quantitative IHC would be standard alternatives, 
and have shown their applicability in former studies in OCSCC (310), (311).  
 
 
 
 
4.2 PROSPECTS 
 
4.2.1 Redefining tumor infiltrating DC functional subsets: the contribution of 
unsupervised single cell sequencing 
 
Single cell RNA sequencing, possibly combined to antibody-barcoding, has been a 
technological revolution that took place during my PhD. In section 1.2.1.4, we described 2 
single-cell studies on blood DC, which highlight the added value of unsupervised analysis of 
data obtained from single cell transcriptomic sequencing, as compared to the historical 
supervised analysis of multicolor flow cytometry data. Single cell RNA sequencing allows to 
redefine the different subsets and/or states of the different cell types by grouping them 
according to their level of transcriptomic similarities. The signature of each subset may then 
be analyzed to (i) identify predicted surface markers that may serve to further study each 
subset, and need to be confirmed by flow cytometry, (ii) decipher overexpressed genes and 
infer cell state and function, (iii) identify potential therapeutic targets (64). Only one study 
analyzing in detail the innate compartment by single-cell transcriptomics of a human tumor is 
available to date (237). The only single-cell study available in head and neck cancer from 
Puram et al. included so few DC that this dataset cannot be further exploited for this cell 
subset (25).  
In the team, and in collaboration with the Team of Pierre Saintigny in the Centre Léon 
Bérard, Lyon and the INRA, Lyon, we have implemented a protocol for single cell sequencing 
of tumor-infiltrating immune cells. The specificity of our protocol is to make an asymmetric 
enrichment of the various immune subsets, in order to obtain data on all cell types, but with 
an equivalent resolution for frequent (T cells) and rare (DC) cells types. To date, we have 
analyzed one OCSCC patient. Our preliminary result show that the genes that are specific to 
the cDC2 in the bulk transcriptomic data presented in Fig 4 of Results section 3.1 are in fact 
secreted by a subset of matured cDC2. Next, we will complete the analysis of our first patient 
sample, confirm our results in 2 other tumors and identify and confirm the surface markers of 
newly identified subsets, before implementing functional studies. Our objective is to obtain a 
comprehensive resource on the innate immune infiltrate of OCSCC patients, to be used for 
clinical translation. 
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4.2.2 The challenges of translational medicine and the contribution of window-
of-opportunity trials  
 
All experiments presented in this thesis were performed with human samples, either from 
cancer patients of from healthy blood donors. We believe that it is the shortest path to clinical 
translation. However, human sample biology has several limitations: (i) ethical issues and 
requirements of informed consents, (ii), synchronization of the players of the sample circuit, 
(iii), experimental limitations, such as the use of gene-KO models, (iv) limited access to 
samples and need for invasive procedures. Therefore, if working on human samples is very 
efficient for the identification of prognosis biomarkers, it is way more complicated for the 
study of the associated biological mechanisms or the identification of predictive biomarkers.  
Pre- and post- treatment comparison is a basic of research on mechanism and predictive 
biomarkers. While mouse biologists are developing humanized mouse models (313), (314), 
clinicians and biologists working on human samples have developed a new way to perform 
such pre and post-treatment comparisons in patients: pre-operative window-of-opportunity 
trials. It is an optimal setting for predictive biomarker identification in human (315), (316). 
Such trials, as the one presented in Annex 3.2, require an excellent synchronization of the 
multiple teams involved, to be able to perform in a limited timeframe the neoadjuvant 
treatments, the surgical planning, the surveillance of adverse events, repeated imaging and 
other efficacy endpoints evaluation, and importantly the translational research on blood and 
tumor samples. Window-of-opportunity trials is a nice example of how we may overcome the 
limitations of human sample-based research.  
 
 
 
4.2.3 The role of the tumor draining lymph node in the anti-tumor immune 
response 
 
I introduced this thesis with the question of how a head and neck surgeon comes to 
immunology. I will end up this manuscript explaining what happens when a junior 
immunologist goes back to the operating theater. As a head and neck surgeon, I often 
perform therapeutic or even elective (prophylactic) neck dissection. With my new 
immunology perspective, I am quite puzzled to remove the lymph nodes that are supposed to 
contain patients’ immune memory against cancer. Several studies support the role of the 
tumor draining lymph node for the anti-tumor immune response (235), (317), and other have 
shown that response to PD-1 blockade occurs in the lymph node and not in the tumor (318). 
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In the ongoing Keynote-689, pembrolizumab is given at D0 and D15 and surgical removal of 
the tumor and the draining lymph nodes is performed around day 30. Even in the cases 
classified as N0 by pre-operative MRI and TEP-CT, the lymph nodes are removed, as it is 
the standard of care. The objective is to remove the occult micro-metastasis that are 
eventually found in 30% of the N0 patients (319), (320).  
The study of human tumor draining lymph node could give us some answers. Flow cytometry 
and even single cell technologies are hard to apply to lymph nodes in humans, because the 
markers allowing to distinguish lymph node resident DC, inflammatory migratory DC coming 
from the tumor tissue, inflammatory migratory DC coming from another benign inflammatory 
local area such as dental infection, or homeostatic migratory DC is not trivial. Deciphering 
tumor related and unrelated events is more robust when studying T cells, because tumor 
antigens can be matched with the clonal T cell with the corresponding TCR.  
For the future, we may imaging that advances in micro-imaging and tagging technologies 
could allow us to determine precisely which lymph node needs to be removed and which one 
doesn’t and/or which lymph node contains the pool of anti-tumor T cells clones, and could be 
preserved or collected and stored for T cell adoptive therapy.   
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5. ANNEX 
5.1 Table of correspondences between mice and human DC subsets 
 
 
 
Adapted from Dalod et al. (106) 
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5.2 Synopsis of ICING, a Phase II trial of M7824 (MSB0011359C), a bifunctional 
fusion protein targeting TGF-β and PDL1, in a pre-operative setting for 
resectable and untreated head and neck squamous cell carcinoma. 
 
I will be with Christophe Le Tourneau the principal investigator of this trial that has just been 
funded by Merck and GSK and will lead the translational research.  
Realized with the help of the Methods in Clinical Cancer Research Workshop and all the 
faculties. 
 
 
  Version  1.1 Date 13.06.201
8 
Title Phase II trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting 
TGF-β and PDL1, in a pre-operative setting for resectable and untreated head 
and neck squamous cell carcinoma 
Abbreviated title ICING 
Sponsor Unicancer 
Coordinating 
investigators 
Prof Christophe Le Tourneau, MD, PhD 
Head, Department of Drug Development and Innovation 
Institut Curie, 26 rue d’Ulm, 75005 Paris, France 
Christophe.letourneau@curie.fr 
Dr Caroline Hoffmann, MD, PhD student 
Department of Head and Neck Surgery 
Institut Curie, 26 rue d’Ulm, 75005 Paris, France 
Caroline.hoffmann@curie.fr 
 
Biostatistics Jocelyn Gal, MSc, PhD student 
Epidemiology and Biostatistics unit – research center 
Centre Antoine-Lacassagne, 33 av de Valombrose, 06189 Nice cedex 2 
Jocelyn.gal@nice.unicancer.fr 
 
Pharmacy Dr Laurence Escalup 
Department of Pharmacy 
Institut Curie, 26 rue d’Ulm, 75005 Paris, France 
Laurence.escalup@curie.fr 
 
Number of 
centers 
7 
 
France Yes International No 
Indication Histologically or cytologically confirmed squamous cell carcinoma of the oral 
cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication 
of primary surgery. Patients with a diagnosis of SCCHN from unknown primary 
will not be enrolled. 
 
Primary 
objective 
To evaluate the efficacy of M7824 (MSB0011359C), a bifunctional fusion 
protein targeting transforming growth factor (TGF-β) and PDL1, as measured 
by pathological response (PathR), given in a pre-operative setting, in 
resectable and previously untreated head and neck squamous cell carcinoma 
(HNSCC). 
Secondary 
objectives 
1/ To evaluate the efficacy of M7824 using alternative readouts, namely:  
a) . The pathological response using alternative threshold of tumor cell 
death as compared to the one used for primary objective  
a) . The clinical response, as measured by to RECIST v1.1. 
b) . The response rate, using primary endpoint criteria, by PDL1 status 
assessed by combined positive score (CPS) as <1 (absent), ≥ 1CPS < 
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20 (low), and ≥ 20 (high). 
c) Note: cTNM and pTNM will be recorded to evaluate the post-treatment 
down-staging, but it will not be a secondary endpoint in the absence of 
control cohort, knowing that, from literature and study coordinators 
expertise, cTNM might be different from pTNM in the absence of any 
treatment in a significant number of patient. 
2/    2/ To evaluate the safety and tolerability profile of M7824  
3/  3/ To evaluate the usefulness of having inked the tumor margins during 
baseline endoscopy in avoiding surgical plan changes putatively induced by 
tumor shrinking under therapy. 
Exploratory 
objectives 
To evaluate the pharmacodynamics value of potential biomarkers comparing 
pre and post-treatment blood and tumor samples 
Methodology This study is a prospective open label, multicenter, phase II, window-of-
opportunity preoperative, single-agent trial. 
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Registration 
criteria  
1) Age ≥ 18 years 
2) Histologically or cytologically confirmed, or highly suspected* 
squamous cell carcinoma of the oral cavity, oropharynx, larynx or 
hypopharynx, previously untreated, with indication of primary 
surgery. Patients with a diagnosis of SCCHN of unknown primary are 
excluded. 
(*: In order to avoid repeated biopsies procedures under general 
anesthesia, patients with clinically highly suspected squamous cell 
carcinoma could be registered before the histological or cytological 
proof. In these cases, the diagnosis will be confirmed intra-
operatively, during the initial panendoscopy, by frozen sections.) 
3) ECOG performance status ≤ 1 
4) Patients must be willing and able to comply with scheduled visits, 
treatment plan, laboratory tests and other study procedures 
5) Patients must be affiliated to a Social Security System  
6) Patient information and written informed consent form signed 
 
Inclusion 
criteria 
1) Histologically or cytologically confirmed squamous cell carcinoma of 
the oral cavity, oropharynx, larynx or hypopharynx, previously 
untreated, with indication of primary surgery. Patients with a 
diagnosis of SCCHN of unknown primary are excluded. 
2) Absence of distant metastases determined by CT scan or Pet CT  
3) TNM and primary tumor location-related inclusion criteria are similar 
in the 2 cohorts of patients, and are, according to the 7th edition 
AJCC: T2 with N1 or more; T3 or T4 and N. These inclusion criteria 
are summarized in the following table.  The 7th edition of AJCC is 
used here in order to have a unique table for both HPV-negative and 
oropharyngeal HPV-positive cancer patients. 
 
 
Table1: Eligibility criteria according to TNM status, AJCC 7th edition. 
 
4) Baseline radiology studies evaluating tumor primary (MRI or CT 
scan) must be performed within 28 days prior to registration.  
5) ECOG performance status ≤ 1 
6) Adequate organ and marrow function as defined below: 
. Hemoglobin ≥ 9,0 g/dL 
. Absolute neutrophil count (ANC) ≥ 1,500/mm3 
. Platelet count ≥ 100,000/mm3 
. AST and ALT ≤ 2.5 × institutional upper limit of normal (ULN); 
. Total bilirubin ≤ 1.5 × ULN; 
. Creatinine clearance > 30 mL/min as determined by the Cockcroft-
Gault equation (Cockcroft and Gault, 1976)  
7) Negative serology for hepatitis B and C 
8) Women of childbearing potential must have a negative serum β-HCG 
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pregnancy test within 7 days prior to the administration of the first 
study treatment and/or urine pregnancy 48 hours prior to the 
administration of the first study treatment. Both sexually active 
women of childbearing potential and males (and their female 
partners) patients must agree to use two methods of effective 
contraception, one of them being a barrier method, or to abstain from 
sexual activity during the study and for at least 6 months after last 
dose of study drugs. 
9)  Absence of any psychological, familial, sociological or geographical 
condition potentially hampering compliance with the study protocol 
and follow-up schedule; those conditions should be discussed with 
the patient before registration in the trial 
Exclusion 
criteria 
1) Primary site of head and neck carcinoma in nasopharynx, sinuses, or 
skin  
2) Patients receiving other anti-cancer medication such as, 
chemotherapy, immunotherapy, biologic therapy, targeted therapy, 
monoclonal antibodies, hormonal therapy (other than leuprolide or 
other GnRH agonists) or other investigational agent within 6 months 
prior to the first dose of study drug and while on study treatment. 
3) Patients receiving other anti-cancer non-drug therapies: radiation, or 
tumor embolization within 6 months prior to the first dose of study 
drug and while on study treatment. 
4) Participation in another clinical study with an investigational product 
during the last 30 days 
5) Uncontrolled intercurrent illness including, but not limited to, ongoing 
or active infection, active peptic ulcer disease or gastritis, active 
bleeding diatheses.  
6) Patient under guardianship or deprived of his liberty by a judicial or 
administrative decision or any condition (e.g psychiatric 
illness/social/familial/geographical condition) that would limit 
compliance with study requirement or compromise the ability of the 
subject to give written informed consent 
7) Current or prior use of immunosuppressive medication within 28 
days before the first dose of M7824, with the exceptions of 
intranasal, intraocular and inhaled corticosteroids or systemic 
corticosteroids at physiological doses, which are not to exceed 10 
mg/day of prednisone or an equivalent corticosteroid. 
8) Receipt of live attenuated vaccination within 30 days prior of 
inclusion 
9) Active or prior documented autoimmune disease within the past 2 
years. NOTE: Subjects with vitiligo, Grave’s disease, or psoriasis not 
requiring systemic treatment (within the past 2 years) can be enrolled  
10)  Active or prior documented inflammatory bowel disease (eg, Crohn’s 
disease, ulcerative colitis) 
11)  History of primary immunodeficiency 
12)  History of allogenic organ transplant that requires the use of 
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immunosuppressive drugs 
13)  Pregnant or breast-feeding women 
14)  Any previous treatment with an anti-PD-1/PDL1 agent  
15)  Any condition that, in the opinion of the investigator, would interfere 
with evaluation of study treatment or interpretation of patient safety 
or study results 
16)  Known positive HIV status 
  
Treatment M7824 
2 infusions of M7824 will be administered on D1 and D15 
Dose: 1200mg intravenously over 60 minutes  
 
Primary prophylactic administration of anti-histaminic must be 
administered systematically after before each infusion. 
 
Criteria of 
evaluation  
Primary endpoint: Rate of pathological response defined as tumor 
necrosis and/or giant cell/histolytic reaction to keratinous debris in ≥ 
10% of tumor area  
 
Secondary endpoints: 
1) Evaluation of the efficacy of M7824 using alternative 
readouts: 
a) The pathological response, using a threshold of 50% (PathR50), 
70% (PathR70) and 90% (PathR90): will be considered as 
responders, the patients presenting 50% or more, 70% or more, 
and 90% or more, respectively, of tumor necrosis and/or giant 
cell/histolytic reaction to keratinous debris. 
b) The pathological response according to PDL1 status using CPS. 
c) The clinical response, as measured by to RECIST v1.1 clinical 
response using RECIST on CT or MRI (same imaging than as 
baseline). 
 
2) The safety profile of M7824 described using the common toxicity 
criteria from the NCI CTCAE v5.0  
3) The evaluation of the usefulness of having inked the tumor 
margins during baseline endoscopy in avoiding surgical plan 
changes putatively induced by tumor shrinking under therapy will be 
assessed by: 
a. A question for the surgeon to be answered on the day of curative 
surgery “Would your surgical plan have been different in the absence 
of ink labelling?”  
b. Optional, if feasible: measure of the distance between current 
tumor front and the ink in 2 to 4 different points and take a picture. 
 
 
Exploratory objectives / Translational research 
Immuno-monitoring and genomic analysis will be performed on pre- 
and post-treatment blood and tumor samples. This multi-parametric 
evaluation, including dynamical changes along treatment, will allow 
to identify differential parameters between responders and non-
responders (supervised analysis), that will be coupled to 
unsupervised analysis.  
The main axis of research will be:  
       .  Targets: TGFb & PDL1 expression 
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. Immune microenvironment: immune subsets proportions, 
characteristics (other checkpoints expression, spatial distribution, 
antigen specific response…) and dynamical changes  
. Cancer cell related parameters: TMB, molecular class, checkpoint 
expression, RNA     expression 
       .  Fibrosis: ECM remodeling, CAF 
       .  ADCC, ADCP: Fc receptors balance and polymorphism 
 
 
Sample size 
determination 
 
The primary endpoint is to evaluate the efficacy of M7824 
(MSB0011359C) evaluated by the rate of pathological response 
defined as tumor necrosis and/or giant cell/histolytic reaction to 
keratinous debris in > 10% of tumor area. Given the differences in 
prognosis between oropharyngeal HPV-positive non-smokers or 
smoker < 10PY (1), on the potential differential drug efficacy in these 
2 groups (2) (3) (4), the patients enrolled will be distributed in two 
distinct cohorts for statistical considerations and analysis. HPV 
status will be determined by p16 staining performed on the biopsies 
obtained during baseline endoscopy for all patients, even for non-
oropharyngeal tumors. Since all trial-related interventions will be 
strictly similar for the 2 cohorts, the result of p16 status will not be 
required for the inclusion, until one of the 2 cohorts will be complete. 
Once 1 of the 2 cohorts will be complete, p16 status will be required 
for the inclusion, in no more than 7 days after the biopsy, to avoid 
any surgical delays. 
Cohort A: Non-oropharyngeal HNSCC, or Oropharyngeal SCC that 
are HPV negative, or Oropharyngeal SCC that are HPV positive and 
smoker ≥ 10PY 
Cohort B: Oropharyngeal SCC that are HPV positive and non-
smoker or smoker < 10PY (former or active). 
 
M7824 
In the NCT02517398 trial evaluating M7824 in the recurrent and/or 
metastatic setting, in the cohort enrolling SCCHN tumors unselected 
for PDL1 and HPV status that were either metastatic or not 
amenable to local therapy with curative intent, and that progressed 
or recurred <6 months since the last platinum dose, an ORR of 
27.9%, 13.6% and 50.0% in all, HPV-negative and HPV-positive 
patients respectively were reported (5). No data on the efficacy of 
M7824 in untreated HNSCC is available to date. 
In the same trial, an ORR of 36.5% was obtained when merging data 
of all HPV-associated solid cancers (6).  
In the cohort enrolling second-line metastatic non-small cell lung 
cancer (NSCLC) patients, an ORR of 27.5%, 40.7% and 71.4% in all, 
PDL1 positive (>1%), and PDL1 high (> 80%) patients respectively 
were reported (7).  
In 2 pre-clinical models of melanoma and triple-negative breast 
cancer (TNBC) bearing humanized mice, such a-PDL1-TGFBRII 
antibody had a significantly increased anti-tumor activity as 
compared to anti-PDL1 alone or even anti-PDL1 and anti-TGFBRII 
given as a combination (8).  
 
Efficacy of neoadjuvant PD-1/PDL1 targeting 
M7824 is structurally close to Avelumab for anti-PDL1 targeting (9). 
However, no data is available to date on the efficacy of Avelumab in 
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the neoadjuvant setting. In a previous window-of–opportunity trial 
with Pembrolizumab, an immunotherapy targeting PD-1, a 43% (95% 
CI: 21%-64%) pathological response rate was reported (10).  In the 
CheckMate 358 trial, 2 doses of neoadjuvant Nivolumab (targeting 
PD-1) induced an investigator-assessed tumor size reduction 
superior to 25% in 13% of the patients (11).  However, the 
extrapolation of these results is limited by the facts that 
Pembrolizumab and Nivolumab target PD-1 whereas M7824 targets 
PDL1. In addition, M7824 has antibody dependent cell cytotoxicity 
(ADCC) and also targets TGFb. 
 
Estimation of M7824 minimal and target response rates 
The primary endpoint is the rate of pathological response, observed 
in the post-treatment operative specimen, defined as tumor necrosis 
and/or giant cell/histolytic reaction to keratinous debris in more than 
10% of the tumor area. 
The minimal pathological response rate with M7824 should not be 
inferior to PD1/PDL1 targeting alone, measured at 43% (10). To take 
into account the fact that this 43% rate has been determined in a 
small number of patients, and is necessarily associated with a large 
confidence interval (95% CI (21%-64%)) and given the results 
obtained with M7824 above-mentioned trials, we consider that a 
pathological response rate of 30% or less as unacceptable. 
In untreated resectable HNSCC, we estimate that 1/3 of patients with 
HPV negative tumors present a tumor microenvironment poor in both 
T cells and dendritic cells, and are very unlikely to respond to 
immunotherapy. Thus, we estimate that the maximal pathological 
response rate to an optimal immunotherapy would be 67% in this 
setting. Our objective would be to induce a pathological response in 
half of the candidate responders to M7824 that are not responding to 
anti-PD1/PDL1 alone (calculation:  (67%-33%)/2= +17%). Therefore, 
the fixed target improvement will be of 17% corresponding to a target 
ORR for M7824 of 33+17 = 50,0%. 
 
Sample size determination  
For Cohort A, the objective is efficacy determination with sufficient 
power, to compare to the historical control of neoadjuvant 
pembrolizumab mentioned above. 
We will use the two-stage Minimax design described by Simon et al. 
(12) with an unacceptable rate of pathological response of 30% or 
less and a hypothesized actual pathological response rate of 50% or 
more.  
The sample size was determined by testing the null hypothesis H0: p 
≤ 30% versus the alternative H1: p ≥ 50% at a one-sided significance 
level of 0.1 and a power of 0.9. In the first stage, 28 patients will be 
accrued and the study will conclude to inefficacy and should be 
stopped if the observed number of patients with a pathological 
response is 7 or less. If 8 or more patients present pathological 
response, then an additional 11 subjects will be accrued (second 
stage), bringing the total number of patients to n=39. The null 
hypothesis of p ≤ 30% will be rejected and M7824 will be considered 
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effective if the total number of patients with a pathological response 
is 16 or more. 
 To account for non-assessable patients (10%), we will include 4 
additional patients. 
 Required sample size is 43 for cohort A. 
 
 For Cohort B, the objective is to estimate the rate of response with a 
limited width of confidence interval (CI).  
 The sample size estimation for cohort B was completed by using the 
95% CI method. We propose a sample size of 14. The half width of 
the 95% CI will be less than 25% if the response rate is at least 65%. 
       To account for non-assessable patients (10%), we will include 2 
additional patients. 
 Required sample size is 16 for cohort B. 
 
Number of 
patients 
43 patients in cohort A and 16 in cohort B: 59 patients 
 
Duration of the 
trial 
1/ Enrollment period: 24 months 
2/ Treatment: 2 weeks 
3/ Follow-up: 6 months 
4/ Duration of the study: 31 months 
 
The HPV status, which might need different duration to be obtained 
in the various centers, will not have to be determined at the time of 
the inclusion, since it does not influence the treatment protocol, in 
order to avoid surgical delays. Patient will be enrolled in the study as 
they come, independently of the HPV status. The accrual will be 
monitored continuously in order to respect the number of patients 
planned per cohort. More precisely, 2 situations might be 
encountered:  
Case 1: accrual of cohort B (n = 16) is completed before cohort A. 
From then, only patients with non-oropharyngeal SCC or with 
oropharyngeal SCC and smokers > 10PY will be enrolled. 
Knowledge of p16 status will still not be necessary for any new 
inclusion. 
Case 2: accrual of cohort A (n = 43) is completed before cohort B. 
From then, only patients with oropharyngeal SCC and non-smoker or 
smoker < 10PY will be registered. The HPV status, determined as 
per p16 staining by immunohistochemistry, will have to be obtained 
within 6 days after the baseline endoscopy, in order to be able to 
include the patient and start the treatment no longer than 7 days 
after the baseline endoscopy. This is due to guaranty the absence of 
surgical delay related to the need of the HPV status determination 
and to respect the recommended maximum duration between 
baseline endoscopy and the day of surgery (<45days). Centers that 
cannot not offer to obtain p16 results within this timeframe should 
stop enrolling patients. 
 
Rationale for 
this study per 
objective 
Anti-tumor activity 
M7824 is an innovative first-in-class bifunctional fusion protein 
composed of a human IgG1 mAb against PDL1 fused with 2 
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extracellular domains of TGF-β receptor II (a TGF-β“trap”) and has 
shown promising antitumor activity and manageable safety in phase 
1 trials, including as 2L treatment for NSCLC and HPV+ HNSCC (1), 
(7), (13).  
Anti-PD1/PDL1 agents have shown antitumor activity in recurrent 
and/or metastatic HNSCC (14), (15), and in primary tumors in the 
preoperative setting (10), (11). However, the majority of patients do 
not respond to PD-1 /PDL1 antagonists used as single agents. 
Research aimed at identifying biomarker of response have 
highlighted the role of tumor mutational load, the intensity of intra-
tumoral CD8+ T cell infiltrates, interferon gamma (IFNg) signature, 
and tumor and immune cell PDL1 expression (4) (16) (17) (18). 
Additionally, another signature of resistance, corresponding to the 
transforming growth factor β (TGF-β) pathway, associated with 
cancer associated fibroblasts (CAF), has been identified in 2 different 
pre-clinical models (urothelial and microsatellite-stable colorectal 
cancer) and in patients with metastatic urothelial cancer who were 
resistant to an anti-PDL1 agent (atezolizumab) (19). The role of 
TGF-β in treatment resistance has also been observed in HNSCC in 
vitro (20). Therefore, there is a strong rationale to inhibit both the PD-
1/PDL1 axis and the TGF-β signaling in cancer patients, namely in 
tumor types showing both evidence of anti-tumor activity of PD-
1/PDL1 inhibitors and high levels of primary resistance, such as 
HNSCC.  
M7824 is aimed at neutralizing the TGFb, a pleiotropic cytokine that 
is overexpressed in HNSCC (21). TGFb is implicated in the 
epithelial-to-mesenchymal transition, invasion, and metastases of 
tumor cells, in fibroblast activation and deposition of collagenous 
extra-cellular matrix, and favors immunosuppression (22), (23), (24). 
Indeed, TGFb suppresses IFNg expression by T cells, inhibits CD8 
effectors cells cytotoxicity, inhibits the differentiation of central 
memory cells (25), (26), and skews the differentiation of CD4 T cells 
away from Th1 polarization towards regulatory T cells (Treg) (27).  
Additionally, M7824 is an IgG1 antibody has structural similarities to 
Avelumab and as shown to be able to induce ADCC (9), an 
additional mechanism of anti-tumor activity (28).  
 
Therefore, the rationale for this fusion protein is the couple: (i) 
negative checkpoint blockade by targeting PDL1 on tumor cells and 
immune cells, (ii) TGFb targeting, in order to inhibit its 
immunosuppressive effects and and pro-tumoral effect on stroma 
and extra-cellular matrix (29), (iii) NK-mediated anti-tumor effect via 
ADCC. In a pre-clinical model, this fusion protein has shown to be 
more efficient than anti-PDL1 antibodies alone (Figure1) (8).  
 
 
Figure 1: adapted from Ravi et al., Nature Comm, 2018 (8). 
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Evaluation of alternative outputs of anti-tumor activity  
Given the limited number of windows-of-opportunity trials in the pre-
operative setting, the appropriate criteria of evaluation of anti-tumor 
activity remains unknown, in particular for immunotherapy: although 
tumor shrinkage occurred in almost half of patients, few patients 
experienced an objective response in the Pembrolizumab and 
Nivolumab pre-operative trials. In the present study, the threshold of 
10% tumor necrosis has been defined as primary endpoint, similarly 
to the study with neoadjuvant Pembrolizumab. This low threshold is 
adapted to these very short durations of treatment. However, some 
patient showed 50% of even 90% pathological response rates even 
after a single injection (30). Therefore, analysis of the pathological 
response with the 50% and 90% tumor necrosis thresholds, and of 
the tumor size reduction per RECIST v1.1 will complete our 
evaluation of anti-tumor response. 
 
Safety 
Limited data on the safety of M7824 are available to date. In the 
NCT02517398 and NCT02517398 trials, 3/16 (19%) and 20/80 
(25%) of the patients experienced grade 3 or 4 adverse events 
respectively (6), (7). No treatment-related death as been reported to 
date.  
 
Usefulness of having inked the tumor margins during baseline 
endoscopy in avoiding surgical plan changes  
Any neoadjuvant treatment, even given for a short period such as in 
window-of-opportunity pre-operative trials, lead to the risk of 
downgrading surgical plans in case of significant tumor size 
decrease. However, to date, primary surgery for head and neck 
cancers needs to be performed according to baseline tumor size, 
disregarding the effect of any neoadjuvant therapy, because the 
safety of considering the new margins as not been assessed. 
Therefore, we believe that inking the tumor margins during baseline 
endoscopy will help to prevent this risk of surgical under-treatment. 
This procedure will be evaluated in the present trial. 
 
Identification of biomarkers 
Identification of predictive and PD biomarker of response to M7824 is 
key to appropriately select the patients that will benefit from the 
treatment in future phase III trials and beyond.  
For anti-PD1/PDL1 targeting, baseline levels of PDL1, intra-tumor 
CD8 T cells infiltrate, IFNg signature and tumor mutation burden are 
proposed predictive biomarkers, but their sensitivity and specificity 
remain limited (31). 
For M7824, no predictive biomarker has been identified to date, and 
the addition of this TGFb “trap” significantly influences the 
mechanisms of action as compared to anti-PD1/PDL1 targeting 
alone, therefore requiring further efforts to identify the appropriate 
biomarkers. 
Several studies have shown that whereas pre-treatment biopsies 
were unable to identify responders, the biopsies done after 1 or 2 
treatment doses were much more informative (32), (33), (34), (35), 
(36). These early post-treatment biopsies match exactly with the 
design of the present pre-operative trial. 
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Translational 
research 
 
 
  Translational research 
Immuno-monitoring and genomic analysis will be performed on pre- 
and post-treatment blood and tumor samples. Pre-treatment tumor 
samples will come from additional biopsies done during baseline 
endoscopy, and post-treatment tumor samples will come from 
additional biopsies done immediately before the removal of the 
surgical specimen.  
 
 
  Rationale and axes of research 
The aim of the proposed biological analysis is to address specific 
scientific questions related to potential predictive biomarkers of 
efficacy and the mechanism of action of the anti-tumor immune 
response in the context of the treatment by M7824: 
. Which biomarkers are specifically associated with a/o predictive of 
tumor response to treatment versus resistance to treatment? 
. Are these biomarkers present at baseline?, or only measurable 
after one cycle of treatment?, or only relevant when measured as an 
intra-patient variation between baseline and after one cycle of 
treatment? 
This multiparametric evaluation, including dynamical changes along 
treatment, will allow identifying differential parameters between 
responders and non-responders (supervised analysis), which will be 
coupled to unsupervised analysis.  
The main axis of research will be:  
       . Targets: TGF-β & PDL1 expression 
. Immune microenvironment: immune subsets proportions, 
characteristics (other checkpoint expression, spatial distribution…) 
and dynamical changes 
. Cancer cell related parameters: TMB, molecular class, checkpoint 
expression, RNA expression 
. Fibrosis: ECM remodeling, CAF 
. ADCC, ADCP: Fc receptors balance and polymorphism 
. Specific immune response towards tumor antigens 
 
Biological sample collection  
Tumor tissue and blood sample collection will be performed at 
baseline and on the day of surgery.  
Blood 
30ml of blood will be collected from each patient in EDTA tubes and 
processed to obtain samples of peripheral blood monolayer cells 
(PBMC), plasma, and for genomic analysis. Additionally, each time a 
sufficient amount of tissue will be available to perform FACS on fresh 
tumor (see below), a fraction of fresh PBMC will be also analyzed by 
FACS. 
The procedures for blood sampling and processing will be described 
in greater detail in a separate Laboratory Manual. Processed 
samples will be stored on site at -80°C until such a time as the 
Sponsor request transfer to the central storage center.  
 
Tumor 
At least two core biopsies are to be collected at each time point. 
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One sample will be fixed in formalin and embedded in paraffin 
(FFPE). This sample will be transferred to the central laboratory for 
IHC analysis of biomarker expression levels. 
One sample will be frozen in nitrogen or fixed using the optimum 
cutter temperature (OCT) compound method, and stored at -80°C. 
This sample will be used for whole genome and/or RNA sequencing 
analyses. 
If the tumor lesion volume is not sufficient to obtain two biopsy cores, 
priority will be given to the FFPE biopsy. 
If the tumor lesion volume is sufficient for one or two additional 
biopsies, they will be transferred in CO2 independent medium, at 
4°C, within 24h, to the laboratory of the center of immunotherapy in 
Institut Curie, Paris, in order to perform immune-monitoring by flow-
cytometry.  
The procedures for tumor tissue processing will be described in 
greater detail in a separate Laboratory Manual. FFPE and frozen 
samples will be stored on site at -80°C until such a time as the 
Sponsor request transfer to the central storage center. Only fresh 
tumor tissue, when available, will be shipped immediately as 
mentioned above.  
 
 Analysis planned  
Blood (all delayed analysis) 
1) biobanking of plasma, in order to perform soluble biomarkers 
analysis at a later date, such as measurement of serum levels of 
TGF-β, soluble PDL1, cytokines, etc...  
2) biobanking of frozen PBMC, in order to study the TCR clonality, the 
sub-populations of the innate immune system of the lymphocyte sub-
populations with analysis of their activation and expression of 
positive and negative immune checkpoints 
3) whole blood will be processed to obtain DNA and RNA for delayed 
genomic analysis 
 
Tumor 
Real-time analysis 
Fresh tumor samples, when available, will be analyzed by flow-
cytometry and/or single cell sequencing according to the budget and 
the availability of pre- and post-treatment samples. 
4) Immuno-monitoring with flow cytometry on digested fresh tumor 
samples at baseline (pre-treatment) and at surgery (post-treatment) 
(for information purposes, (a) 15 to 20 color panel(s) may include the 
following markers: CD45; CD3; CD8; CD4; CD56; CD25; CD127; 
CD27; CD39; CD69; CD103; CD29; FAP; CD15; EPCAM; PD1; 
PDL1; ICOSL; CD14; CD16; BDCA1; CD11c; HLADR; Live dead)   
5) Gene expression analysis by single cell sequencing on fresh 
samples on sorted CD45+ cells. Ideally, we would perform a 5’ 
sequencing together with TCR sequencing in order to obtain both 
information on targets and pathways of immune cells at the single 
cell level and information on the specific immune response towards 
tumor antigens (identification of the recurrent TCR that amplify under 
treatment, differentially between responders and non-responders). 
Taking into account the cost of such analysis and the supplemental 
amount of samples required, it should be limited to a small number of 
patients with pre and post-treatment comparisons. 
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Delayed analysis    
6) Immunohistochemistry (1 FFPE sample): single or multicolor panels, 
that may include, but are not limited to:  
HPV status for non-oropharyngeal tumors (p16) 
Panel 1 (Pre-ttt and post-ttt*): TGFb, PDL1, CK, CD4, CD8 (Targets 
+ hot/excluded/cold tumor identification);  (*Post-ttt panel may be 
adapted with regard to the potential negativity of TGFb and PDL1 
staining after treatment). 
Panel 2 (Pre and post-ttt): TGFb pathway baseline activation status 
and effect of the M7824: (i) receptor: TBRII, (ii) canonical pathway: 
p-SMAD2, p-SMAD5, (iii) non canonical pathway: TAK1, p-p65, (iv) 
negative feedback: SMAD7 
Panel 3 (Pre and post-ttt): Collagen remodeling;  
Panel 4 (Pre and post-ttt): Fc Receptors CD32a, CD32b 
 
7) Gene expression analysis, that will be performed, according to the 
budget and technology development, by: 
. Targeted sequencing, OR 
. RNAseq (1 frozen sample): we will perform unsupervised analyzes 
to determine predictive signatures of treatment response, and test 
published signatures, a/o 
. RNAseq of microdissected stroma and epithelium (1FFPE sample; 
eg. DSP Nanostring® or Spatial transcriptomics®).  
 
Supervised analysis will be performed and explore tumor cell, 
checkpoints, EMT signature, immune subsets signatures & cell 
proportions and signaling pathways. 
Unsupervised analysis will be performed in order to identify a novel 
and M7824 specific response signature. 
 
8) Tumor mutation burden evaluation (same frozen sample than 
RNAseq) 
We will prioritize these analyzes to adapt to the quantity of material 
available and to the budget.  
 
 
Timeline 
 
 
 
Milestones First Proposed Plan 
CSA - Concept Sheet (Proposal) Approval Jan-2019 
FPA - Final Protocol Approved May-2019 
     Research Ethics Committee Review Jun/Jul-2019 
FSFV - First Subject Signed ICF   Sep-2019 
30 pc - 30 percent of subjects consented Jun-2020 
60 pc – 60 percent of subjects consented / Interim 
Analysis Jan-2021 
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LSFV - Last Subject Signed ICF Sep-2021 
LSLV - Last Subject Last Visit Oct/Nov-2021 
Key Stats - Key Stats Available Dec-2021 
CTR - Clinical Trial Report Approved Apr-2022 
  
Long term follow-up 
LTFU - Last Subject Last Visit  Apr-2022 
DB Lock - Database Lock   Apr-2022 
LTFU - Full Stats Available  Jun-2022 
LTFU - Clinical Trial Report-Addendum Approved  Apr-2023 
 
 
List of centers 
 
Comprehensive cancer centers 
1/ Institut Curie, 26 rue Ulm, 75005 PARIS 
PI: Christophe LE TOURNEAU (Med.O) & Caroline HOFFMANN (Surg.O) 
 
2/ Centre Antoine Lacassagne, 227 av de la Lanterne, 06000 NICE 
PI: Joel Guigay (Med.O) & Alexandre BOZEC (Surg.O) 
 
3/ Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 VILLEJUIF 
PI: Caroline Even (Med.O)  & Philippe GORPHE (Surg.O) 
 
4/ Institut de cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519 
VANDŒUVRE-LÈS-NANCY 
PI: Gilles DOLIVET (Surg.O) 
 
5/ Institut de Cancérologie de l'Ouest, 15 Rue André Boquel, 49100 
ANGERS 
PI: frederic.rolland@ico.unicancer.fr  
 
6/ Institut Claudius Regaud, 1 Av. Irène Joliot-Curie, 31100 TOULOUSE 
PI: Jean-Pierre Delord (Med.O) & Dupret-Bories.Agnes@iuct-oncopole.fr; 
 
7/ Centre Léon Bérard:  
PI : Jerôme FAYETTE (Med.O) & Pierre-Eric ROUX (Surg.O) 
 
8/ ICM Montpellier:  
PI: Didier CUPISSOL (Med.O) & Renaud GARREL (Surg.O) 
 
9/ Centre Becquerel, rue d’Amiens, 76038 Rouen cedex 
PI : Florian Clatot (Med. O) florian.clatot@chb.unicancer.fr & Rais Obongo 
(Surg. O) 
 
Academic Hospital 
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10/ BORDEAUX 
PI: Amaury DASTE (Med.O) & Erwan DE-MONES-DEL-PUJOL (Surg.O) 
 
11/ CHU Marseille:  
PI : Sebastien SALAS (Med.O) (sebastien.salas@ap-hm.fr) & Nicolas 
FAKHRY (Surg.O) (nicolas.fakhry@ap-hm.fr) 
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5.3  Plasmacytoid pre-dendritic cells (pDC) from molecular pathways to 
function and disease association.  
 
Personal implementation: I have authored the chapter on pDC function in cancer.  
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5.4  Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor 
immunity by unleashing both T and NK cells 
 
Personal implementation 
During my PhD, I participated to an industrial collaboration with the company Innate Pharma 
located in Marseille. Together with Olivier Lantz and Ana Lalanne, we performed deep 
immune-monitoring of HNSCC and skin SCC samples and their paired juxtatumor, blood and 
draining lymph node from 26 patients, with the goal of identifying and quantifying immune 
targets and NK cell receptors in particular. Some results on 19 patients are presented in 
figure 4 of this paper. 
 
 
Abstract 
Immuno-oncology, including checkpoint inhibitors targeting the PD-1/PDL1 (PD-x) axis in 
particular, has revolutionized cancer treatment. However, only a minority of patients respond 
to these immunotherapies, and the development of drug resistance is frequent. Here, we 
report that the blocking of the inhibitory NKG2A receptor enhances tumor immunity by 
promoting both Natural Killer (NK) and CD8+ T-cell effector functions in mice and humans. 
Monalizumab, a humanized anti-NKG2A antibody, enhanced NK cell activity against various 
tumor cells and rescued CD8+ T-cell function in combination with PD-x axis blockade. 
Monalizumab also stimulated NK-cell activity against antibody-coated target cells. We also 
established proof-of-principle for the use of combined immunotherapy with monalizumab and 
cetuximab, in a phase II clinical trial for squamous cell carcinoma of the head and neck 
(SCCHN), in which the combination gave a better response rate than cetuximab alone. 
NKG2A targeting with monalizumab is thus a novel checkpoint inhibitory mechanism 
promoting anti-tumor immunity by enhancing the activity of both T and NK cells, which may 
complement the first-generation immunotherapies against cancer.  
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ANTI-NKG2A MAB IS A CHECKPOINT INHIBITOR THAT PROMOTES ANTI-TUMOR 
IMMUNITY BY UNLEASHING BOTH T AND NK CELLS 
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Introduction 
 
Immuno-oncology has revolutionized cancer treatment (Baumeister et al., 2016; Fridman et 
al., 2017; Schreiber et al., 2011; Schumacher and Schreiber, 2015; Sharma and Allison, 
2015a, b). Unprecedented improvements in tumor control have been achieved by the use of 
therapeutic monoclonal antibodies (mAbs) that block immune inhibitory (‘checkpoint’) 
receptors. In particular, mAbs directed against the PD-1 (programmed-cell death protein 
1)/PDL1 (programmed -cell death ligand 1) axis (PDx) in monotherapy or combination 
therapy have been approved for the treatment of several indications including metastatic 
melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, oral cancer, Hodgkin 
lymphoma, and solid tumors that are microsatellite instability-high or mismatched repair-
deficient. Such treatment often yields durable benefits and, in most patients, toxicity can be 
controlled. However, only a minority of the patients treated with antibodies specific for PD-1 
or PDL1 display a strong response, and the cancers of a substantial fraction of patients are 
resistant to these immune checkpoint inhibitors (ICI). One of the major challenge in immuno-
oncology is, therefore, understanding the mechanisms of resistance to ICI, to increase the 
proportion of patients benefiting from such treatment and to control treatment toxicity. One 
approach that could be used is to identify novel molecular targets, the modulation of which 
boosts anti-tumor immunity. Blocking inhibitory pathways of effector lymphocytes, such as T 
cells and NK cells, are attracting considerable research interest in this context.  
 Cell-surface receptors harboring intracytoplasmic tyrosine-based inhibitory motifs 
(ITIMs) are particularly relevant in this respect. These motifs are phosphorylated and recruit 
the phosphatases (SHP-1/2 or SHIP) responsible for transmitting the inhibition signal to 
immune effector cells (Daeron et al., 2008). Bioinformatics analyses of the human genome 
have predicted the presence of more than 300 type I and type II integral membrane proteins 
containing at least one ITIM domain (Daeron et al., 2008), but only a few of these receptors 
are currently targeted in therapeutic approaches. 
NKG2A is an ITIM-bearing receptor expressed on both T and NK cells. NKG2A is expressed 
as a heterodimer with CD94 in humans and mice and recognizes the non-classical Class I 
major histocompatibility complex (MHC-I) molecules HLA-E in humans and Qa-1b in mice. 
The binding of NKG2A/CD94 to its cognate ligand inhibits T and NK cell effector functions 
(Le Drean et al., 1998; Rapaport et al., 2015). This inhibition is dependent on the recruitment 
of the SHP-1 tyrosine phosphatase to the tyrosine-phosphorylated form of NKG2A (Viant et 
al., 2014).  
 We show here, that NKG2A blockade enhances the anti-tumor immunity mediated by 
NK and CD8+ T cells. We developed a humanized anti-NKG2A IgG4 blocking mAb 
(monalizumab) and we describe its anti-tumor efficacy, in vitro and in vivo when used as a 
single agent or in combination with other therapeutic antibodies, such as durvalumab, 
blocking PDL1, or cetuximab, directed against EGFR expressed by tumor cells.  
 
 
 
190	
	
 
 
Results 
NKG2A blockade promotes anti-tumor immunity 
We assessed the impact of NKG2A on cytotoxic lymphocyte activity, by using BALB/c B cell 
lymphoma A20 cells, which express the non-classical MHC-I Qa-1b molecule, the mouse 
homologue of HLA-E, and generating the corresponding Qa-1b-knock-out cells (Figure S1A). 
The growth rates of parental and Qa-1b-deficient A20 cells were similar in vitro (data not 
shown). As expected, the frequency of cytotoxic NKG2A+ NK cells — assessed on the basis 
of the expression of CD107a, a degranulation marker — was higher in cocultures with Qa-1b-
deficient A20 cells than in cocultures with parental cells (data not shown). Following their 
subcutaneous injection into syngeneic BALB/c mice, wild-type A20 B-cell lymphoma cells 
grew progressively in all mice (Figure 1A, left panel). By contrast, 70% of the mice into 
which genetically engineered Qa-1b-deficient A20 cells were injected did not display tumor 
growth (Figure 1A, right panel). Both NK cells and CD8+ T cells were required to control 
tumor growth, because the administration of anti-asialo-GM1 and anti-CD8a antibodies, 
respectively, into tumor-bearing mice abolished the control of parental and Qa-1b-deficient 
tumor growth and led to premature death (Figures 1B and 1C).  
 These results validate Qa-1b as a potentially useful target. We then dissected the 
immune response to A20 in the tumor bed, by analyzing tumor-infiltrating lymphocytes (TILs). 
A20 tumors were found to be infiltrated with NK and CD8+ T cells. As in the spleen, ~60% of 
NK TILs expressed the NKG2A receptor (Figure 2A). We also monitored PD-1 expression, 
because the immune control of A20 tumors has been reported to be partially dependent on 
PD-1 (Sagiv-Barfi et al., 2015). The expression of PD-1, either alone or together with 
NKG2A, was barely detectable on the surface of NK TILs. We did not observe NKG2A 
expression on the surface of CD8+ T cells from the spleen, and few cells expressed PD-1 
(~4%) (Figure 2A). However, PD-1+ CD8+ T cells accounted for ~44% of TILs. Importantly, 
NKG2A was also expressed on the surface of half the PD-1+ CD8+ TILs. In this model, we 
also observed that double-positive PD-1+ NKG2A+ CD8+ TILs displayed higher levels of PD-1 
and NKG2A expression at their surface than cells positive only for PD-1 or for NKG2A 
(Figure 2A). Very few CD8+ TILs (~2%) expressed NKG2A without PD-1.  
 We then investigated whether NKG2A blockade could promote anti-tumor immunity. 
We generated a recombinant mouse version of the rat anti-NKG2A antibody, 20d5 (Vance et 
al., 1999). We confirmed that the blockade of NKG2A in vitro promoted the expression of 
CD107a by NK cells cocultured with Qa-1b+ A20 tumors but not with Qa-1b- YAC-1 target 
cells (Figure S1B). When used as single agents in vitro, anti-NKG2A or anti-PDL1 mAbs 
only modestly improved ex vivo tumor-infiltrating CD8+ T-cell effector activities after 
restimulation with A20 cells (Figure S1C). By contrast, the use of anti-NKG2A and anti-PDL1 
mAbs in combination, increased the frequency of CD107a-expressing NKG2A+ PD-1+ CD8+ 
TILs.  
 We further investigated the effects of immunotherapy with anti-NKG2A and anti-PDL1 
antibodies by treating A20 tumor-bearing mice with anti-NKG2A mAb, anti-PDL1 mAb or a 
combination of these two blocking reagents (Figure 2B). In this experimental setting, anti-
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NKG2A mAb did not rescue mice from death when used as a single agent when compared to 
control group. By contrast, anti-PDL1 mAb rescued ~40% of tumor-bearing mice from death, 
as shown by comparison with untreated mice. Interestingly, a combination of anti-NKG2A 
and anti-PDL1 mAbs had a synergistic effect, improving the control of tumor growth and 
rescuing ~60% of the mice from death (Figure 2B). The results obtained for mice treated 
with anti-asialo-GM1 or anti-CD8a antibodies also demonstrated that the anti-tumor effect of 
the anti-NKG2A/PDL1 mAb combination therapy was dependent on both NK and CD8+ T 
cells (Figure 2C). Thus, the combination of an anti-NKG2A mAb with an anti-PDL1 mAb had 
a therapeutic anti-tumor effect, because it unleashed NK cells and CD8+ T cells in the A20 
model Similar results were obtained with a combination of anti-NKG2A/PD-1 mAbs (Figure 
S2). 
 
Combined blockade of NKG2A and PDL1 promotes the generation of protective anti-
tumor memory 
We investigated the anti-tumor therapeutic properties of the anti-NKG2A mAb further, by 
using this antibody to treat C57BL/6 mice bearing another tumor, subcutaneously injected 
RMA-Rae-1β T lymphoma. Like A20 cells, RMA-Rae-1β tumor cells express Qa-1b and 
PDL1 (Figure S3). The frequency of NKG2A+ NK cells in the tumor was higher than that in 
the spleen, but NK TILs did not express PD-1, as observed in the A20 model (Figure 3A). 
We found that ~21% of total CD8+ TILs expressed NKG2A but not PD-1, ~14% expressed 
both these molecules and ~21% expressed PD-1 but not NKG2A (Figure 3A). Anti-NKG2A 
mAb or anti-PDL1 monotherapy was not effective in RMA-Rae-1b tumor-bearing mice 
(Figure 3B). However, treatment with a combination of mAbs against NKG2A and PDL1 
resulted in tumor growth control in 45% of the tumor-bearing mice, which were rescued from 
death. The combination therapy acted through the release of CD8+ T-cell but not NK cell 
inhibition, as the injection of a depleting anti-CD8a mAb but not anti-NK1.1 antibodies 
abolished tumor growth control and impaired mouse survival (Figure 3C). 
 We observed the generation of CD62L- CD44+ effector memory CD8+ T cells in the 
spleens of mice in which RMA-Rae-1b tumors were implanted and then cured by 
immunotherapy, but not in the spleens of untreated mice (Figure 3D). Accordingly, RMA-
Rae-1β tumor cells were completely rejected when injected into mice that had already been 
injected with the tumor and cured by treatment with anti-NKG2A and anti-PDL1 mAbs, 
whereas the injection of these cells led to unchecked tumor growth in untreated mice (Figure 
3D). Therefore, in addition to curing mice of their implanted tumors, blocking NKG2A in 
combination with another ICI can promote durable protective anti-tumor CD8+ T-cell memory 
response in a preclinical mouse model.  
  
HLA-E and NKG2A expression in human tumors 
We then monitored the expression of NKG2A and HLA-E at the surface of several tumors, to 
identify the indications for which anti-NKG2A therapeutic blocking mAbs might promote anti-
tumor immunity in cancer patients. HLA-E was found to be widely expressed on the surfaces 
of several human tumors. We observed HLA-E expression in lung, pancreas, stomach, 
colon, head and neck and liver tumor tissues (Figure 4). By contrast, PDL1 expression was 
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restricted to some lung, stomach and colon tissue tumors (Figure S4). HLA-E was strongly 
expressed by SCCHN and colorectal carcinoma (Figure 4A and B), in which we also 
detected NKG2A-positive cells. NKG2A-positive cells and HLA-E expression were also found 
in ovarian, endometrial and cervical cancers (Figure 4B). NKp46+ NK (Figure 4B) and CD8+ 
TILs were also present in all these tumors. We investigated SCCHN more closely by flow 
cytometry and detected high frequencies of CD8+ TILs expressing PD-1 and co-expressing 
both PD-1 and NKG2A in the tumor (Figure 4C). NKG2A-expressing NK cells were also 
present at high frequency, and some of these cells had a PD-1+ NKG2A+ phenotype. Similar 
results were obtained for CRC and lung tumors (data not shown). Thus, several tumors 
expressed HLA-E and were infiltrated with NK and CD8+ TILs expressing NKG2A. We 
therefore reasoned that NKG2A blockade, either alone or together with the use of other 
checkpoint inhibitors, such as anti-PD-1/PDL1 antibodies, might improve the anti-tumor 
efficacy of NK and CD8+ TILs in cancer patients. 
 
Generation and characterization of a chimeric blocking mAb directed against human 
NKG2A 
A murine anti-human NKG2A IgG1 monoclonal antibody clone, Z270, was generated in a 
previous study (Sivori et al., 1996). We humanized this antibody by fusion with an IgG4 with a 
single point mutation in the Fc heavy chain to prevent the formation of half-antibodies and 
screened the selected humanized clones for binding to CD94-NKG2A with an affinity similar 
to that of the original murine monoclonal antibody. The selected humanized clone was 
named monalizumab (IPH2201/NNC141-0100). Importantly unlike other anti-NKG2A mAbs 
described to date, monalizumab is specific for human NKG2A, as it bound human NKG2A+ 
cells, but not Ba/F3 transfected cells expressing human NKG2C, the activating isoform of 
NKG2A (Figure S5A). The EC50 calculated by whole blood titration was 4.5 ng/ml for 
NKG2A+ NK cells and 11.4 ng/ml for NKG2A+ CD8+ T cells (Figure S5B). Finally, another 
critical feature of monalizumab resided in its capacity to inhibit the binding of HLA-E 
tetramers to human NK cells expressing NKG2A (Figure S5C). 
 
Monalizumab promotes the anti-tumor cell activities of human NK cells and CD8+ T 
cells 
We then sought to assess the blocking activity of monalizumab on effector cells, by 
monitoring the production of CD107 by NKG2A+ NK cells cocultured with K562 tumor target 
cells expressing HLA-E (Figure 5A). The prototypic K562 cells, which lack HLA-E, activated 
NK cells, but forced HLA-E expression decreased the frequency of CD107+ NKG2A+ NK 
cells. The addition of monalizumab to the assay restored the production of CD107 by 
NKG2A+ NK cells to the levels observed with parental K562 targets. We then assessed the 
anti-tumor efficacy of monalizumab in co-cultures of NK cells with tumor cell lines with 
different levels of HLA-E expression (Figure S6). Monalizumab increased the frequency of 
activated NKG2A+ NK cells, as assessed by measuring the cell-surface induction of CD107 
and CD137 (4-1BB), an activation-induced costimulatory molecule, in co-cultures with three 
different SCCHN cell lines and three different ovarian tumor cell lines, although this 
stimulation was weaker for the CAL-27 and Caov-2 cell lines (Figure S6).  
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The anti-NKG2A mAb and the anti-PDL1 mAb had synergistic effects in our preclinical 
mouse tumor models. We therefore assessed the effects of a combination of the anti-human 
NKG2A mAb monalizumab and the anti-human PDL1 mAb durvalumab on NK cell activity 
against K562 cells co-expressing HLA-E and PDL1 in vitro. NKG2A+ PD-1+ NK cells were 
generated by chronically stimulating various donor PBMCs with IL-15 (Figure 5B). The anti-
NKG2A monalizumab, used as a single agent, increased the frequencies of CD107+ NKG2A+ 
PD-1- NK cells in cocultures with K562-HLA-E or K562-HLA-E PDL1 cells (Figure 5C). 
Addition of the anti-PDL1 antibody durvalumab did not improve NK-cell reactivity in this 
assay. When used as a single agent, monalizumab also improved CD107 expression by 
NKG2A+ PD-1+ NK cells cocultured with K562-HLA-E targets. The use of monalizumab or 
durvalumab as single agents only modestly increased the reactivity of NKG2A+ PD-1+ NK 
cells cocultured with K562-HLA-E PDL1 cells, whereas these two antibodies had additive 
effects when used in combination. Thus, monalizumab efficiently released the inhibition 
conferred by the engagement of the inhibitory receptor NKG2A. In combination with other 
ICI, monalizumab has additive effects, promoting NK-cell effector functions. 
We assessed the boosting effect of monalizumab on CD8+ T-cell functions in more detail 
because, in our preclinical model, many CD8+ TILs expressed NKG2A (Figures 2A and 3A). 
We aimed to generate antigen-specific NKG2A+ CD8+ T cells in vitro through chronic 
stimulation with IL-15, monocytes and antigenic peptides derived from human influenza virus 
(Flu) (Figure 5D). The Flu-specific CD8+ T cells obtained after nine days of culture harbored 
different phenotypes. In addition to PD-1+ NKG2A- Flu-specific CD8+ T cells, a substantial 
fraction of the Flu-specific CD8+ T cells co-expressed PD-1 and NKG2A (Figure 5D). Cells 
were then cocultured with Flu peptide-pulsed K562-HLA-A2 cells expressing or not 
expressing the inhibitory ligands HLA-E and PDL1. The addition of monalizumab or 
durvalumab modestly increased the frequency of CD107+NKG2A+ Flu-specific-CD8+ T cells 
(Figure 5E). However, the combination of monalizumab with durvalumab improved CD8+ T-
cell activity. Thus, monalizumab can promote activation and effector functions of both NK 
cells and CD8+ T cells, and this effect is more marked when it is used in combination with 
durvalumab. 
 
Monalizumab promotes human NK-cell antibody-dependent cell-mediated cytotoxicity 
(ADCC) 
Blockade of the NKG2A/Qa-1 axis added with PD-1/PDL1 blockade to boost NK-cell 
cytotoxicity. We then evaluated the potential of monalizumab to promote NK-cell effector 
functions when combined with other commonly used anti-tumor reagents, such as those 
promoting ADCC (Figure 6). The anti-epidermal growth factor (EGF-R) mAb cetuximab is 
used to treat advanced and recurrent and/or metastatic SCCHN and metastatic CRC (Ferris 
et al., 2018). Cetuximab mobilizes adaptive and innate immunity against tumor cells, partly 
by promoting ADCC (Ferris et al., 2018). HLA-E membrane expression in CRC could inhibit 
cetuximab-mediated cellular cytotoxicity (Levy et al., 2009). We used a combination of 
monalizumab and cetuximab to stimulate NK cells against an SCCHN cell line in vitro 
(Figure 6A, left panel), and the induction of CD137 as a marker of NK cell activation 
including ADCC. This combination of antibodies amplified the anti-tumor efficacy of NK cells, 
as shown by the higher frequencies of CD137+ NK cells. Monalizumab also enhanced the NK 
cell-mediated ADCC by the anti-CD20 mAb obinutuzumab in cocultures with B cell lines 
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expressing MHC class I (Figure 6A, right panel). Thus, the anti-NKG2A mAb monalizumab 
can amplify the beneficial effects of other IO treatments, such as those promoting ADCC.  
 
In vivo tumor control by a combination of monalizumab and cetuximab in patients with 
SCCHN 
We found that combinations of NKG2A-blocking mAbs with other IO treatments, such as anti-
PD-1 mAbs, anti-PDL1 mAbs or cetuximab, had additive effects on anti-tumor immunity in 
preclinical experimental settings in vitro and in vivo. These results provide a scientific 
rationale for evaluations of the efficacy and safety of monalizumab in cancer patients. 
SCCHN tumors were strongly positive for HLA-E and were infiltrated with CD8+ T cells and 
NK cells, which may express NKG2A (Figures 4A-C). Cetuximab is used in the standard 
care regimen for SCCHN. We therefore assessed the safety and efficacy of the combination 
of monalizumab and cetuximab in patients with previously treated recurrent or metastatic 
(R/M) SCCHN in a phase II clinical trial (NCT02643550). We evaluated five doses of 
monalizumab (0.4, 1, 2, 4, 10 mg/kg every 2 weeks) in combination with the approved dose 
of cetuximab (400 mg/m² loading dose and then 250 mg/m² weekly). The maximum tolerated 
dose was not reached and the highest dose of monalizumab tested (10 mg/kg) was used for 
expansion of the phase II cohort. We used a one-stage Fleming design with futility analysis 
after the first 11 patients; the overall phase II study will include 40 patients. The 
characteristics of the patients are shown in Table 1. As of March 9, 2018, thirty-one patients 
with R/M SCCHN were treated and evaluable for safety, of which 26 patients to date are 
evaluable for efficacy and remaining patients were studied too early for baseline assessment. 
All 31 patients had been previously treated with platinum-based chemotherapy, and 24 
patients received one or two systemic treatment regimens. Fourteen patients had already 
received IO, and three had been already treated with cetuximab for locally advanced disease 
and had been free from progressive disease for at least four months. Safety was the primary 
endpoint of the part I and objective response rate (ORR) of this part II. The combination was 
well tolerated. Most of the adverse events (AE) observed (93%) were of grade 1-2 severity, 
rapidly reversible and easily manageable. The most common monalizumab-related AEs were 
fatigue (17%), pyrexia (13%) and headache (10%). The most frequent AEs reported for 
cetuximab in previous studies (7) were skin disorders (rash 49%, acne 26%, nail disorders 
16%, dry skin 14%), and these effects were not exacerbated by monalizumab. No infusion-
related reactions were observed (patients received premedication for cetuximab as specified 
on the label). No treatment-related deaths were reported. No new or unusual signs 
suggestive of poor safety were observed with the combination of monalizumab and 
cetuximab. We thus concluded that the safety profile of the combination was similar to that 
for the two single agents.  
Interim treatment efficacy results for the phase II trial showed that treatment with the 
monalizumab and cetuximab combination resulted in a confirmed RECIST partial response in 
8 of 26 patients (31%), stable disease (SD) in 14 of 26 (54%) and progressive disease (PD) 
in 3 of 26 (11%) patients and one patient died from progressive disease at week 8 without 
post-baseline imaging (Figure 6B-D). The lesion disappeared in one patient, as shown in 
Figure 6D. Assuming an ORR of 25%, using 10% as the cutoff for inactivity, α =0.05, and a 
power of 0.76, the predefined number of eight responses required to declare a positive result 
for the trial has already been reached. Two of the eight patients with confirmed responses 
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had previously received immunotherapy. The median response duration was not reached; six 
responding patients were still on treatment. Median follow-up time was 129 days: 17 patients 
(55%) were still on treatment, 14 patients (45%) had stopped treatment, due to progressive 
disease in 12 (38%), and adverse event in one and on the decision of the investigator in the 
final case Overall, these data showed that the combination therapy of monalizumab with 
cetuximab has promise for the treatment of patients with SCCHN with exptected toxicity 
profile of either agent alone. 
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Discussion 
 
Immuno-oncology is an emerging field that has revolutionized cancer treatment. Immune 
checkpoint inhibitors have greatly improved the control of several types of cancer, but there 
is a need to improve the efficacy of these treatments further, and to control their toxicity. One 
way of achieving this goal would be to identify critical immune checkpoints other than PD-1 
and CTLA-4 for targeting by therapeutic antibodies to promote effective immune responses 
to cancers. Most immunomodulatory strategies to date have focused on enhancing T-cell 
responses, but there has been a recent surge of interest in harnessing the relatively 
underexplored natural killer (NK) cell compartment for therapeutic interventions (Cerwenka 
and Lanier, 2018; Guillerey and Smyth, 2016; Rautela et al., 2018; Vivier et al., 2012). The 
manipulation of NK cells in cancer is designed to initiate a multilayered immune response 
culminating in protective and long-lasting immunity to tumors based on a number of different 
cell types, including T cells.  
We focus here on the NKG2A receptor, a well-known ITIM-bearing inhibitory receptor 
expressed on both T and NK cells (Moretta et al., 2001), emitting inhibitory signals 
transduced via the protein tyrosine phosphatase SHP-1 (Viant et al., 2014). The abundance 
of NKG2A+CD8+ T cells is low in human blood, but NKG2A expression can be induced at the 
surface of CD8+ T cells upon activation (Braud et al., 2003). The targeting of NKG2A with a 
monoclonal blocking antibody would therefore have the unique advantage of enhancing T- 
and NK cell responses. Another advantage of targeting NKG2A is the safety of this 
approach, as no abnormalities have been reported in mouse strains lacking CD94 (Vance et 
al., 1999), which forms a heterodimer with NKG2A. These mice therefore lack cell-surface 
NKG2A expression.  
One critical point for such an approach is the expression of NKG2A and HLA-E during 
cancer. We have shown that the NKG2A receptor is expressed on NK and T cells in the 
tumor bed in many human cancers and we have also shown that its ligand, HLA-E, is 
frequently overexpressed in tumors. By contrast, classical MHC-I expression is often weak 
on tumor cells, and this downregulation has been recognized as a major mechanism by 
which tumor cells escape T-cell control (Garrido et al., 2017; Sharma et al., 2017). Unlike 
classical HLA class I molecules, HLA-E continues to be expressed on the surface of tumor 
cells, sometimes even more strongly than on healthy cells, in 50–80% of patients with solid 
tumors or leukemia/lymphoma (Benson et al., 2012; Mamessier et al., 2011; Platonova et al., 
2011; Talebian Yazdi et al., 2016). This conservation of expression likely results from the 
dependence of cell-surface HLA-E expression on the leader peptides of HLA-A, B or C. 
Downregulation therefore would require the elimination of three types of HLA molecule. Our 
data for NKG2A expression are consistent with earlier reports on tumor-infiltrating NK and T 
cells in melanoma, breast and cervical cancers (Mamessier et al., 2011; Sheu et al., 2005).  
One of the key findings of our studies is the demonstration that NKG2A is often co-expressed 
with PD-1 on CD8+ T cells. PD-1 expression is a hallmark of exhausted CD8+ T cells 
(Hashimoto et al., 2018). This result therefore suggested that NKG2A expression might 
constitute an additional brake on release, for reversing CD8+ T-cell exhaustion. The 
regulation of NKG2A expression on both NK and CD8+ T cells remains to be dissected in 
detail. Nevertheless, unlike PD-1 expression, which can be observed on the surface of CD8+ 
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T cells from whole blood or lymph nodes from cancer patients, NKG2A-expressing CD8+ T 
cells are found selectively localized in the tumor bed or adjacent tissue. These results 
suggest that signals derived specifically from the tumor would be required to induce, or, more 
probably, to sustain NKG2A expression.  
We also found that HLA-E was more frequently expressed than PDL1 in several types of 
cancer. This finding is consistent with previous suggestions that HLA-E expression may 
account for some of the lack of responsiveness to anti-PDx observed in Merkel cell 
carcinoma (Paulson et al., 2018) and in an in vivo CRISPR screening program that identified 
Qa-1b (the mouse HLA-E ortholog) as a cancer immunotherapy target, because Qa-1b loss-
of-function increased the efficacy of immunotherapy by PD-1 blockade (Manguso et al., 
2017). These data support the use of a combination of monoclonal antibodies blocking the 
PDx and NKG2A:HLA-E inhibitory pathways. Our results for mice indicate that NKG2A 
pathway blockade does indeed improve tumor control when combined with a blockade of the 
PD-1/PDL1 inhibitory pathway. We also demonstrated the generation of protective memory 
CD8+ T cells in mice into which RMA-Rae-1β tumors were implanted and then cured by 
combined PDL1 and NKG2A blockade. Thus, our preclinical results provide a rationale for 
combining monalizumab and durvalumab into a novel immunotherapy for cancer patients. 
Importantly, such a clinical trial is ongoing (NCT02671435) and very recently preliminary 
safety and efficacy data were reported (Segal et al., 2018). Briefly, the dose escalation part 
of the study demonstrated the feasibility of combining the two agents with no new safety 
signals noted beyond the known safety profile for each individual agent. The initial clinical 
activity data from a cohort expansion in pretreated (median of three previous lines of 
systemic therapy) microsatellite stable colorectal cancer (MSS CRC; n=39) demonstrated an 
ORR of 8% (median duration of response of 16.1 weeks) and a disease control rate (DCR) at 
16 weeks of 31% (Segal et al., 2018). Although these results are very preliminary, they are 
an example of potential therapeutic opportunities for immunotherapy in MSS CRC, a setting 
where immune checkpoint-based therapy has so far failed to demonstrate any consistent and 
meaningful clinical benefit. 
Combining a blockade of inhibitory signals with the delivery of activating signals should 
improve the efficacy of immunotherapies. Many possible approaches of this type are being 
tested, including the triggering of innate immunity via the delivery of TLR ligands (Du et al., 
2016), activation of the STING pathway at the tumor bed (Corrales et al., 2016), treatment 
with antibodies targeting activating cell surface receptors (Callahan et al., 2016; Muntasell et 
al., 2017) and the use of engineered forms of cytokines, such pegylated IL-2 (Charych et al., 
2017; Charych et al., 2016), and IL-2 variants (Sockolosky et al., 2018). Antibodies directed 
against tumor cells could also be used to stimulate the immune response to tumor cells, 
thereby helping to eliminate cancer. The mode of action of these treatments differs between 
antibodies, but efficacy is partly dependent on ADCC, as for rituximab, an anti–CD20 mAb 
used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (Cartron and Watier, 
2017). Other antibodies are also used to stimulate the immune system via ADCC. One such 
antibody is cetuximab, which is used in metastatic CRC and SCCHN. We showed in vitro 
that NKG2A blockade with monalizumab boosts NK cell-mediated ADCC against cetuximab-
coated SCCHN tumor cells. Consistent with these data, treatment with a combination of 
monalizumab and cetuximab was found to be potentially effective and expected toxicity 
profile in a phase II clinical trial for SCCHN. These encouraging results require consolidation 
in further clinical trials, but they constitute a key step towards the use of monalizumab in 
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combination treatments against cancer, and are consistent with the improvement in tumor 
control achieved by NKG2A blockade, through the activation of NK cells via ADCC. 
In conclusion, we report here the full characterization of a first-in-class immune checkpoint 
inhibitor, monalizumab. This therapeutic antibody has several key features. First, it enhances 
the antitumor activities of both T and NK cells, by blocking the inhibitory function of NKG2A, 
which forms heterodimers on both NK cells and CD8+ T cells. Second, the ligand of NKG2A 
is the non-classical MHC class I molecule HLA-E, which is frequently overexpressed on 
human tumors, providing a mechanism of resistance to lymphocyte activation in the tumor 
bed. Third, monalizumab is well-tolerated in humans and has yielded encouraging efficacy 
results in clinical trials assessing its use in combination with cetuximab in SCCHN, and in 
combination with durvalumab in MSS CRC, two clinical conditions with low ORRs, for which 
no major response is observed in many patients. Anti-NKG2A mAb is, therefore, a promising 
checkpoint inhibitor that promotes antitumor immunity by enhancing the activities of both T 
and NK cells. Interestingly, NKG2A has been shown to contribute to the inhibition HIV-
infected target cell clearance by NK cells (Ramsuran et al., 2018). The therapeutic blockade 
of HLA-E:NKG2A interaction by monalizumab may, therefore, be beneficial in patients with 
HIV disease, in addition to those with cancer.  
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Figures 
 
Figure 1. NKG2A is an inhibitory receptor that blocks the anti-tumor efficacy of NK and 
CD8+ T cells 
(A) Qa-1b-sufficient or -deficient A20 tumor cells were engrafted subcutaneously in BALB/c 
mice. Effective engraftment was quantified by measuring tumor volumes. 
200	
	
(B) BALB/c mice were left untreated or treated with an anti-asialo-GM1 pAbs to deplete NK 
cells or an anti-CD8a mAb to deplete CD8+ T cells and then subcutaneously engrafted with 
A20 tumor cells. Graphs show tumor growth in each individual and combined survival curves. 
Complete regressions are indicated. Log-rank test, **p=0.0020, ns: no significant.  
(C) Experiment similar to that in (B), but with Qa-1b KO A20 tumor cells. Log-rank test, 
***p=0.0002 (NK cell depletion) and ***p=0.0006 (CD8+ T cell depletion). 
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Figure 2. The combined blockade of NKG2A and PD-1/PDL1 promotes anti-tumor 
immunity in A20 tumor-bearing BALB/c mice 
(A) Flow cytometry characterization of NK and CD8+ TILs 19 days after the injection of A20 
tumor cells. The spleen was used as the standard. Upper panels: representative FACS 
profiles of PD-1 and NKG2A expression at the surface of NK and CD8+ T cells in the spleen 
and the tumor bed. Lower panels: Pie chart analysis (mean ±SD). The data presented are 
the pooled results of three independent experiments (n=12). 
(B) A20 tumor cells were engrafted in BALB/c mice. Tumor-bearing mice were then treated 
at three- to four-day intervals with isotype control (IC) antibody, anti-NKG2A antibody, anti-
PDL1 antibody or a combination of these last two antibodies. Graphs show tumor growth in 
each individual and combined survival curves. The data presented are the pooled results of 
three independent experiments. Log-rank test, **p=0.0087, ***p=0.0001, ****p<0.0001. 
 (C) Experiment similar to that described in (B) but with treatment of the mice with an anti-
asialo-GM1 pAbs or an anti-CD8a mAb one day before the initiation of immunotherapy.  
Graphs show tumor growth in each individual and combined survival curves. Log Rank test, 
*p<0.0016, **p<0.01, ***p=0.0001. 
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Figure 3. The combined blockade of NKG2A and PD-1/PDL1 promotes anti-tumor 
immunity in RMA Rae-1β tumor-bearing C57BL/6J mice. 
(A) RMA Rae-1β tumor cells were injected subcutaneously into C57BL/6J mice. Flow 
cytometry characterization of NK and CD8+ TILs 12 days post-injection, with the spleen used 
as the standard. Upper panels: representative FACS profiles of PD-1 and NKG2A expression 
at the surface of NK and CD8+ T cells in the spleen and the tumor bed. Lower panels: Pie 
chart analysis (mean ±SD). The data presented are the pooled results of two independent 
experiments (n=8 mice). 
(B) RMA Rae-1β tumor-bearing C57BL/6J mice were treated with IC antibodies, anti-
NKG2A, anti-PDL1 mAbs or a combination of these last two antibodies, as indicated. Graphs 
show tumor growth in each individual and combined survival curves. The data presented are 
the pooled results of four independent experiments. Log-rank test, ****p<0.0001. 
(C) Experiment similar to that in (D), except that the mice were treated with anti-NK1.1 mAb 
or anti-aCD8a mAb one day before the initiation of immunotherapy. Graphs show tumor 
growth in each individual and combined survival curves. Log-rank test, **p=0.0024. 
(D) Upper left panels: FACS profiles of CD44 and CD62L expression on the surface of CD8+ 
T cells in the spleen of naive (no tumor) mice, mice receiving their first injection of RMA Rae-
1β tumor cells (RMA Rae-1β) and mice previously injected with RMA Rae-1β tumors, cured 
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by immunotherapy and re-challenged (RMA Rae-1β + mAbs re-challenged). Percentages of 
naive (CD44-CD62L+), central memory (TCM, CD44+CD62L+), effector memory (TEM, 
CD44+CD62L-) and effector CD8+ T cells (eff, CD44-CD62L-) are indicated. Upper right panel: 
Absolute numbers of effector memory CD8+ T cells in the spleen are shown. Lines represent 
medians. Lower panels: RMA Rae-1β tumor-bearing C57BL/6J mice were treated with IC 
antibody or with a combination of anti-NKG2A and anti-PDL1 mAbs. Mice cured by 
immunotherapy (n=13) were re-challenged subcutaneously with RMA-Rae-1β tumor cells 
after 70 days. Untreated C57BL/6J mice (n=15) also received injections of RMA-Rae-1β cells 
as a control. The graphs show tumor growth in each individual. The data presented are the 
pooled results of two independent experiments. 
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Figure 4. CD8+, NKp46+ or NKG2A+ immune cells are present in several types of HLA-
E-expressing solid cancers 
(A) Representative example of HLA-E and NKG2A expression on frozen sections from head 
and neck (SCCHN) and colorectal (CRC) cancer samples. Scale bars correspond to 250 µm.  
(B) Semi-quantitative analysis of NKG2A-, NKp46-, and CD8-positive cells and of HLA-E 
expression on frozen human cancer samples. SCCHN (n=23), colorectal cancer (n=48), 
ovarian cancer (n=40), endometrial cancer (n=40) and cervical cancer (n=17). CD8, NKp46 
and NKG2A cells were quantified in the tumor bed. HLA-E expression was assessed on the 
surface of cancer cells.  
(C) Percentages of NK cells (upper panels) and CD8+ T cells (lower panels) expressing 
NKG2A and PD-1 in SCCHN cancer samples. Cells from WB (whole blood, n=16), LN 
(normal lymph node, n=5), meta LN (metastatic lymph node, n=7), Adj (healthy tissue 
adjacent to the tumor, n=5) and tumor (n=9) were analyzed by flow cytometry. Box and 
whiskers plot, in which the means are indicated by crosses. Kruskal-Wallis analysis followed 
by Dunn’s multiple comparisons test. * p<0.05, ** p≤0.001, ****p<0.0001. 
 
Patients characteristics for FACS analysis Fig 4.C 
 
Patient Characteristics N=19 N (%) 
Age, median [range]   65 [51-94] 
Sex 
  
Female 
Male 
5 (26%) 
14 (74%) 
HPV status 
  
  
Positive 
Negative 
To be determined 
4 (21%) 
11 (58%) 
5 (26%) 
Tobacco Never 
Former 
Current 
4 (21%) 
3 (16%) 
10 (53%) 
Tumor site 
  
  
  
  
Oral cavity 
Oropharynx 
Larynx 
Hypopharynx 
Cutaneous 
6 (31%) 
2 (11%) 
3 (16%) 
2 (11%) 
6 (31%) 
History of radiotherapy (overall) Yes 
No 
10 (53%) 
9 (47%) 
Systemic therapy (last 6 months)  
 
 Platinum 
 IO 
Cetuximab 
 Nivo+liri  
2 (11%) 
3 (16%) 
1 (5%) 
1 (5%) 
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Figure 5. Monalizumab and durvalumab unleash NK and CD8+ T-cell function in vitro 
(A) NK cells were co-cultured with K562 or K562 cells expressing HLA-E in the presence or 
absence of monalizumab. The frequencies of CD107-producing NK cells are shown. Box and 
whiskers plot, with the means indicated by crosses. N=8. The whiskers are drawn down to 
the 25th percentile minus 1.5 times IQR (interquartile range) and up to the 75th percentile 
plus 1.5 times IQR. Friedman analysis followed by Dunn’s multiple comparisons test. ** 
p=0.006, ***p=0.0001. 
(B) NK cells were stimulated in vitro with IL-15 for 9 days. The data shown are the 
frequencies of NK cells expressing NKG2A or PD-1 before (day 0) and after (day 9) culture.  
(C) The NK cells generated in (B) were co-cultured with K562 cells expressing HLA-E or co-
expressing HLA-E and PDL1 without (control) or with monalizumab (mona), durvalumab 
(durva) or both these antibodies (combo). The data shown are the frequencies of CD107-
expressing NKG2A+ PD-1+or PD-1- NK cells. Box and whiskers plot, with the means indicated 
by crosses. N=13 donors. The whiskers are drawn down to the 25th percentile minus 1.5 
times IQR and up to the 75th percentile plus 1.5 times IQR. Friedman analysis followed by 
Dunn’s multiple comparisons test. * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001. 
 (D) CD8+ T cells were co-cultured in vitro with monocytes in the presence of IL-15 and Flu-
peptide for 9 days. Top panel: one representative dot plot showing the frequency of tetramer 
(TMr+)CD8+ T cells after culture (n=14). Bottom panel: frequencies of NKG2A+ and/or PD-1+  
cells after gating on TMr+ CD8+ T cells (n=14).  
(E)  The CD8+ T cells generated in (D) were co-cultured with flu peptide-pulsed K562 cells 
expressing PDL1, HLA-E and HLA-A2 without (control) or with monalizumab (mona), 
durvalumab (durva) or both antibodies (combo). The data shown are the frequencies of 
CD107-expressing (upper panels) and IFN-γ-secreting (lower panels) NKG2A+ or NKG2A- 
CD8+ T cells. The whiskers are drawn down to the 25th percentile minus 1.5 times IQR and 
up to the 75th percentile plus 1.5 times IQR. Friedman followed by Dunn’s test for multiple 
comparisons. * p≤0.05, ** p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 6. Monalizumab enhances human NK cell-mediated ADCC and anti-tumor 
activity of monalizumab and cetuximab 
(A) Left panel: NK cells from healthy donors were co-cultured with the CAL-27 SCCHN cell 
line in the presence or absence of monalizumab (Mona) or cetuximab (Ctx). The data shown 
are the frequencies of CD137-expressing NKG2A+ NK cells after 24 hours of co-culture. 
N=13. Student t-test comparing Mona+Ctx combination with Ctx as single agent 
****p<0.0001. Right panel: NK cells from healthy donors were co-cultured with 721.221 cells 
expressing HLA-Cw3 and HLA-Cw4 in the presence or absence of monalizumab (Mona) or 
obinutuzumab (Obz). The data shown are the frequencies of CD137-expressing NKG2A+ NK 
cells after 24 hours of culture. N=12. Student t-test comparing Mona+Obz combination with 
Obz as single agent ****p<0.0001.  
(B) Waterfall plot of target lesion reduction relative to baseline. 
(C) Spider plot of target lesion reduction relative to baseline. 
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The patient who died early, due to disease progression, before the first assessment is not 
represented in these graphs. In accordance with RECIST 1.1, a confirmation of response 
was required. 
(D) Example of a partial response after treatment with a combination of monalizumab and 
cetuximab in a patient with recurrent oral cavity cancer (left masticator space) previously 
treated by surgery, chemotherapy (cisplatin) and radiation therapy. 
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Table 1. Characteristics of the patients with recurrent or metastatic (R/M) SCCHN 
enrolled in the phase II clinical trial  
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6. SYNTHESE EN FRANÇAIS  
Les cellules dendritiques dans le micro-environnement tumoral des 
cancers ORL : des mécanismes aux biomarqueurs 
 
INTRODUCTION 
 
Les carcinomes épidermoïdes des voies aéro-digestives supérieures 
Les carcinomes épidermoïdes des voies aéro-digestives supérieures (CEVADS) sont les 
cancers O.R.L. les plus fréquents. Il existe quatre localisations principales de CEVADS : 
cavité buccale, oropharynx, larynx et hypopharynx. Les facteurs de risques de cancer O.R.L. 
sont le tabac et l’alcool, dans des proportions variées en fonction de ces localisations. Le 
papilloma virus humain (HPV) est également responsable de plus de la moitié des cancers 
de l’oropharynx, et ceux-ci sont plus sensibles à la radiothérapie et ont globalement un 
meilleur pronostic (6). Il existe plusieurs classifications moléculaires des CEVADS, mais 
celles-ci n’ont pas de valeur pronostique et restent peu utilisées. 
En dehors du virus HPV, dont la valeur pronostique est restreinte aux cancers de 
l’oropharynx, il n’existe pas de biomarqueur pronostic validé pour les autres types de 
CEVADS, et notamment ceux de la cavité buccale qui font l’objet du deuxième article de 
cette thèse. Le traitement habituel fait appel à la chirurgie, la radiothérapie et la 
chimiothérapie. L’ensemble de ses traitements entraîne une toxicité importante et des 
séquelles locales lourdes. Environ 25 % des cancers de la cavité buccale présentent des 
récidives précoces et sévères et aboutissants au décès lié à la maladie dans les premières 
années qui suivent le diagnostic (11) (15). L’immunothérapie par anticorps monoclonal anti-
PD1 est un nouveau traitement validé en seconde ligne pour les CEVADS avancés et/ou 
métastatiques après échec du cisplatine. Les taux de réponses étaient de 13,3% et 14,6% 
dans les 2 études princeps CheckMate-141 (16) et Keynote-040 (17). 
.  
Nous faisons ainsi face à un double besoin médical : (i) améliorer les taux de réponse à 
l’immunothérapie : c’est le fondement du premier article de cette thèse via un travail sur les 
cellules dendritiques dont nous verrons l’importance dans ce cadre (ii) savoir dépister à 
l’avance les patients à haut risque de récidive sévère pour pouvoir leur proposer une 
intensification thérapeutique : c’est l’objectif du second article de cette thèse.  
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Bases d’immunologie 
Il existe deux types de système immunitaires : le système inné et le système adaptatif. Le 
système inné reconnaît le non-soi de façon non spécifique par des motifs de microbiens 
redondants via des récepteurs « PRR ». Inversement, le système adaptatif reconnaît 
spécifiquement chaque antigène. Les cellules présentatrices d’antigènes font le lien entre 
ces deux systèmes. Elles capturent par endocytose, phagocytose ou macropinocytose les 
antigènes anormaux, les couplent aux molécules du complexe majeur d’histocompatibilité 
(MHC), et les présentent sous forme de complexe CMH- peptide à leur surface aux cellules 
du système immunitaire adaptatif et notamment les lymphocytes T. Les peptides associé au 
CMH de classe II sont présentés aux lymphocytes T CD4, dont le rôle est d’activer et 
moduler les lymphocytes T CD8 cytotoxiques : ce sont les T CD4 helper. Les peptides 
associé au CMH de classe I sont présentés aux lymphocytes T CD8, un processus nommé 
« cross-présentation », qui active directement et lymphocytes cytotoxiques, et serait 
particulièrement important dans l’immunité anti-tumorale (77), (223), (238).  
Les cellules dendritiques (CD) sont des cellules immunitaires qui ont été découvertes par 
Ralph Steinman en 1973 (41). Elles furent rapidement identifiées comme étant les cellules 
présentatrice d’antigène les plus efficaces pour activer le système immunitaire adaptatif (44). 
Cette activation des lymphocytes T nécessite 3 signaux complémentaires. Le signal 1 
correspond à la présentation du complexe CMH-peptide. Le signal 2 correspond à des 
molécules de costimulation membranaires qui vont interagir avec des récepteurs sur les 
lymphocytes T, tel que CD80/86 (CD) – CD28 (lymphocyte T). Le signal 3 correspond à des 
cytokines secrétées dans par les CD (45), (46).  
Les CD sont issues d’un progéniteur commun dans la moelle osseuse, circulent dans le 
sang, et infiltrent la plupart des tissus, notamment les muqueuses. Il existe plusieurs sous-
types de CD qui ont certaines divergences de fonction : les CD plasmacytoïdes « pDC », et 
les CD conventionnelles ou myéloïdes, elles même subdivisées en 3 sous-types principaux, 
les « cDC1 », « cDC2 », « cDC4 ».  Dans les tissues, il existe aussi des CD inflammatoires 
issues des monocytes, exprimant CD14, et appelées « Mo-DC » ou « CD14+DC ». Les pDC 
sont spécialisées dans la sécrétion d’interféron de type I en réponse à des stimuli viraux 
essentiellement. Les cDC1 sont BDCA3highBDCA1- et sont les CD les plus efficaces pour la 
« cross-présentation » (72), (73), (74). Les cDC2 sont BDCA3lowBDCA1+, activent 
préférentiellement les lymphocytes CD4+ et sont les plus nombreuses  (80). Les cDC4 sont 
BDCA3lowBDCA1- et ont moins été étudiées (64).  
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Les CD possèdent des récepteurs que l’on peut classer en 3 catégories : ceux qui détectent 
directement des pathogènes ou des signaux de danger, appelés « PRR », ceux détectant 
indirectement la présence d’une inflammation comme les récepteurs de cytokines et 
chemokines, et les récepteurs pour les autres fonctions des DC, notamment 
homéostatiques. Les « PRR » comprennent les récepteurs Toll-like « TLR », les récepteurs 
lectine de type C « CLR », les senseurs cytosoliques et les récepteurs de signaux de danger 
« DAMP ».  Les voies de signalisation intra-cellulaires aboutissent à l’activation des facteurs 
de transcriptions NFkb, AP1, CREB, IRF (102). Les récepteurs de cytokines signalent 
principalement par la voie Jak/STAT(122).  Même si les voies de signalisation sont très 
redondantes d’un récepteur à l’autre, et que le nombre de récepteurs différents est limité, 
chaque stimulus, présent à une dose et à une durée définie va engendrer une combinaison 
précise de niveau d’activation de chaque voie pour aboutir à une réponse cellulaire 
spécifique. Cette notion est importante pour le second article de cette thèse.  
 
La maturation des cellules dendritiques 
La liaison d’un ligand sur les récepteurs senseurs directs ou indirect de pathogènes, de 
danger et d’inflammation entraîne des modifications notables de la CD, regroupées sous le 
terme de maturation. Les principaux évènements sont : (i) l’augmentation de la présentation 
antigénique, allant de pair avec la diminution de capacité d’endocytose et de 
macropinocytose (156), (158) ; (ii) l’augmentation de l’expression de molécules de 
costimulation (45), (159), (160), (161); (iii) l’augmentation de la production de cytokines et 
chemokines (166) ; (iv) l’acquisition de la capacité de migration vers le ganglion drainant 
associée à l’expression du récepteur CCR7 (47); (v) l’augmentation en nombre et en taille 
des protrusions cellulaires ou « dendrites »  ayant donné leur nom à la cellule (181). Il faut 
noter que les CD peuvent également exprimer des molécules de surface et des cytokines à 
effet immunosuppresseurs pour les lymphocytes T, tels que PDL1 et IL-10 (159), (160), 
(161). 
Ainsi, selon la combinaison de molécules de surface et de cytokines produites, on distingue 
plusieurs nuances de maturation dénommées dans la littérature comme mature 
immunogéniques, matures tolérogéniques, semi-matures, immatures tolérogéniques, 
matures homéostatique, etc (187)… Grossièrement, les CD sont dites immunogéniques 
quand elles favorisent une réponse T cytotoxiques et tolérogéniques quand elles favorisent 
une immunosuppression et soit l’anergie des lymphocytes T, soit l’induction de lymphocytes 
T régulateurs. Les réponse immunogéniques sont elles-mêmes nuancées selon la 
polarisation des lymphocytes T CD4 (ex: Th1, Th2…) (54).  
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Les cellules dendritiques infiltrant les cancers 
Les CD sont des cellules clefs de la réponse immunitaire anti-tumorale. Les différents sous-
types de CD infiltrent les cancers (71).. Les CD sont recrutées à partir du sang en réponse 
aux signaux de dommages tissulaires issus de la destruction du tissu normal ou de la mort 
des cellules cancéreuses(230).  De nombreuses évidences supportent le rôle anti-tumoral 
des CD, notamment des cDC1 et de la « cross-présentation » (72), (77), (223), (238), mais 
aussi des cDC2 (237), (243), (244), (245), (246). Le rôle des pDC est présenté en annexe 
5.3 et ne sera pas détaillé.  Inversement, d’autres études relèvent le rôle pro-tumoral des CD  
infiltrant les tumeurs, qui seraient préférentiellement tolérogéniques (251), (252), (253). 
Finalement, des données de transcriptomique issues de CD humaines infiltrant  ses tumeurs 
du sein et de l’amygdale humaines ont noté une co-expression de molécules 
immunogéniques et immunosuppressives (71), (236).  
Les CD peuvent être utilisées comme immunothérapie anti-cancéreuse, en thérapie 
cellulaire après modulation in vitro de leur maturation (274), (287). Egalement, les CD intra-
tumorales ou du sang peuvent aussi être activées par le biais de stimuli administrés dans les 
tumeurs  ou en adjuvant de vaccins peptidiques (40), (207),  (278), (281). 
 
 
 
 
OBJECTIFS DE LA THESE 
La biologie des CD est un domaine de recherche relativement récent mais à présent très 
riche de connaissance. Cependant, il persiste certaines incertitudes concernant les états de 
maturation des CD, en particulier dans le contexte du cancer. Des données pré-cliniques et 
cliniques ont montré que les CD sont une cible intéressante pour l’immunothérapie et que les 
états de maturation sont la clef de l’efficacité de ces traitements. Les données sur les CD 
infiltrant les tumeurs ORL sont limitées et ne permettent pas d’anticiper comment moduler 
les CD intra-tumorales à des fins thérapeutiques.  
L’objectif de ma thèse était de décrire avec une résolution fine l’état moléculaire des CD 
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infiltrant les cancers ORL, et leur relation au microenvironnement tumoral. 
Nous voulions répondre à plusieurs questions :  - Quels sous-types de CD infiltrent les cancers ORL et dans quelles proportions ? - Quels marqueurs de maturation et molécules immunostimulatrices ou 
immunosuppressives expriment-elles ? - Quelle est la relation entre les CD et les autres cellules immunitaires infiltrant les 
tumeurs ? - Quels mécanismes influencent l’état des CD dans les tumeurs ? - Y-a-t-il des classes d’infiltration immunitaire tumorale ? - Quel est le lien entre l’infiltrat immunitaire tumoral et le microenvironnement soluble ? - Quels paramètres du microenvironnement sont associés au pronostique ? - Pouvons-nous identifier des cibles thérapeutiques et des biomarqueurs prédictifs ? 
 
 
 
RESULTATS 
PDL1 et ICOSL distinguent les CD humaines « sécrétantes » et « aidantes » 
En utilisant une large base de données de CD activées in vitro par 16 stimuli différents (130 
observations), nous avons pu décrire 2 états d’activation des CD humaines. Les CD 
« sécrétantes » PDL1fortICOSLfaible/nul produisaient de grandes quantités de cytokines et 
de chemokines, mais induisaient très peu de sécrétion de cytokines T helper après co-
culture avec les lymphocytes T CD4 naïfs ; inversement, les CD « aidantes » 
PDL1faibleICOSLfort sécrétaient peu elles-mêmes, mais induisaient une forte sécrétion de 
cytokines T helper, aussi bien Th1, Th2, Th9 et Treg. Par cytométrie en flux, puis par 
analyse transcriptomiques de CD infiltrant les cancers ORL, nous avons pu observer que 
celles infiltrant les tumeurs riches en lymphocytes T correspondaient au type de maturation 
« sécrétantes ». Elles exprimaient PDL1, mais aussi CD40, PVR, IL1B, TNF et CCL19. Les 
CD infiltrant les tumeurs pauvres en lymphocytes T étaient peu nombreuses et semblaient 
peu activées, proche des CD du sang. Nous proposons ainsi une nouvelle classification 
fonctionnelle des CD humaines avec un fort potentiel d’application en immunothérapie anti-
cancéreuse.  
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MMP2 est un biomarqueur pronostic indépendant des cancers de la cavité buccale. 
Nous avons observé dans l’article précédent que l’infiltrat lymphocytaire était associé à une 
plus forte infiltration de CD et un état d’activation spécifique. En étudiant le 
microenvironnement soluble de 18 cancers ORL, nous avons pu observer que CXCL9 et 
CXCL10 étaient fortement corrélées à l’infiltrat immunitaire. Dans une seconde cohorte de 37 
patients atteints de cancers de la cavité buccale traités par chirurgie première, CXCL9, 
CXCL10 et 27 autres molécules sur les 49 mesurées étaient différentiellement exprimées 
dans les tumeurs par rapport aux tissus sains périphériques pairés. Parmi ces molécules, 
seul MMP2 soluble, était prédictif de mauvais pronostic, ce qui suggère un rôle pronostique 
fort de cette métalloprotéinase et moindre de l’infiltrat immunitaire dans ce contexte clinique.  
Nous avons établi une cohorte de validation de 145 patients et analysé un panel de 30 
gènes par RTqPCR à partir d’ARN extrait d’échantillons tumoraux congelés : MMP1, MMP2, 
MMP9, une signature de 18 gènes prédictive de la réponse au Pembrolizumab (anticorps 
anti-PD1) (304), et d’autres gènes associés à l’infiltrat immunitaire. En analyse univariée, des 
taux élevés MMP2 et CD276, et des taux faibles de CXCL10 et STAT1 étaient associés à un 
mauvais pronostique. En analyse multivariée, MMP2 (p=0.001) et l’effraction extra-
capsulaire (EEC) (p=0.006) étaient des marqueurs indépendants de survie spécifique de la 
maladie (SSM). Ainsi, nous avons pu définir 4 groupes pronostiques avec des SSM à 5ans 
variant de 36% (MMP2fortEEC+) à 88% (MMP2faibleENE-). L’expression de la signature 
prédictive de réponse au pembrolizumab était similaire dans les différents groupes 
pronostiques, suggérant que les taux de réponse au traitement attendus devraient être 
similaires. 
Le statut MMP2 définit en pré-opératoire ou en post-opératoire pourrait être utilisé pour un 
réaliser un essai clinique d’intensification thérapeutique dirigé par biomarqueurs. Les 
patients à haut risque pourraient recevoir une immunothérapie ou une chimiothérapie 
néoadjuvante en sus du traitement standard par chirurgie puis radio-chimiothérapie. 
 
 
DISCUSSION 
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La maturation des cellules dendritiques : vers une nouvelle classification ? 
Dans notre étude, nous avons observé que la plupart des stimuli différents induisaient l’une 
ou l’autre des 2 catégories de CD : « sécrétantes » ou « aidantes », bien que la plupart de 
ces stimuli agissent sur des récepteurs différents. Cette observation pose la question de 
l’universalité de cette classification. Il serait intéressant de déterminer si : (i) cette 
classification s’applique à tous les sous-types de CD, (ii) PDL1 et ICOSL sont toujours les 
meilleurs marqueurs de surface pour discriminer les sous-types d’activation ; (iii) cette 
classification s’applique à tous les stimuli, y compris des senseurs cytosolic comme le 
cGAMP.  
De plus, les analyses transcriptomiques nous ont permis d’identifier les facteurs de 
transcription associés à l’un ou l’autre des types d’activation, mais le rôle des molécules 
mesurées (PDL1, ICOSL, IL12p40, IL10) ou non mesurées dans ce travail dans l’effet induit 
sur les lymphocytes T reste à éclaircir.  
 
Utilisation de la classification « sécrétante » versus « aidantes » des cellules 
dendritiques comme une base pour l’utilisation de modulateurs en cancérologie  
Les stimuli induisant des CD « sécrétantes » comme le R848 pourraient être utilisé pour 
augmenter le nombre de CD intra-tumorales dans les tumeurs peu infiltrées. On comprend 
cependant qu’il serait nécessaire d’y associer des anticorps anti-PD(L)1, voire un inhibiteur 
d’IL-10. Les essais cliniques en cours avec R848 n’ont pas prévu de telles combinaisons. 
Nous n’avons pas observé in vivo de CD « sécrétantes », il serait intéressant de déterminer 
si elles existent spontanément dans d’autres contextes comme les maladies allergiques, 
inflammatoires et auto-immunes, ou si on pourrait les induire dans les tumeurs en utilisant 
les stimuli identifiés (TSLP, GM-CSF). Enfin, l’impact sur les cellules T et le bénéfice 
thérapeutique resterait à déterminer. 
 
 
MMP2, vers un biomarqueur de routine pour les cancers de la cavité buccale ? 
Deux étapes seront nécessaires pour poursuivre le développement de MMP2 comme 
biomarqueur prédictif de cancers de la cavité buccale résécables : le choix d’une technologie 
de mesure et l’uniformisation de celle-ci dans les différents centres de soins, et la réalisation 
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d’un essai clinique randomisé montrant la supériorité de la prise en charge orientée par 
biomarqueur par rapport à la prise en charge standard.   
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Résumé : L’objectif de ce travail était de 
comprendre l’état moléculaire des cellules 
dendritiques (CD) dans le micro-
environnement tumoral. En intégrant l’analyse 
de tumeurs humaines par cytométrie en flux, 
de transcriptome, de secretome tumoral et 
l’analyse d’une base de données d’interaction 
CD-lymphocyte T générées in vitro, j’ai 
obtenu 2 résultats majeurs. Tout d’abord, 
nous proposons une nouvelle classification 
de CD activées humaines, qui sont soit 
« sécrétantes », c’est-à-dire spécialisées 
dans la production de cytokines et 
chemokines, soit « aidantes » c’est-à-dire 
spécialisées dans l’induction de la sécrétion 
de nombreuses cytokines T helper après co-
culture. Les CD infiltrant les tumeurs ORL 
inflammées correspondaient au type 
« sécrétantes ». 
Au-delà du nouveau concept biologique, cette 
classification est base théorique importante 
pour l’immunothérapie à base d’adjuvants. 
Deuxièmement, nous avons montré que 
l’inflammation tumorale n’était pas un facteur 
pronostic majeur des cancers ORL, mais que 
MMP2 et l’effraction extra-capsulaire étaient 
des facteurs pronostiques indépendants de la 
survie liée à la maladie. Nous avons pu 
classer les patients en 4 niveaux de risque et 
montré qu’ils avaient des chances 
équivalentes de réponse à l’immunothérapie. 
Nos données sont une base pour un essai 
clinique dirigé par biomarqueur, proposant de 
la chimiothérapie ou de l’immunothérapie 
néoadjuvantes, dans le but de diminuer le 
pourcentage de patients présentant des 
récidives sévères et précoces. 
 
 
Title: Dendritic cells in Head and Neck cancer microenvironment:  from mechanisms 
to biomarkers 
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Abstract: The objective of the thesis was to 
decipher the molecular state of tumor 
infiltrating dendritic cell (DC) and their 
relation to the tumor microenvironment. By 
combining the analysis of human tumor 
samples by flow cytometry and RNA 
sequencing, of tumor secretome and of a 
large dataset of in vitro DC- T cell 
interactions I obtained 2 main findings. First, 
we reported a novel classification of human 
activated DC, that are either “secretory” that 
is specialized in secreting cytokines and 
chemokines, or “helper” that is specialized at 
inducing the secretion of a broad range of T 
helper cytokines after cell co-culture. DC 
infiltrating inflamed human head and neck 
cancer matched the “secretory” phenotypic 
and transcriptomic signatures. Beyond this 
novel  
biological concept, this classification is of 
importance as a theoretical basis for 
adjuvant-based immunotherapy. Secondly, 
we showed that tumor inflammation was not 
the main prognostic factor for oral cavity 
cancer (OCC) patients, but that MMP2 and 
the presence of extra-nodal extension were 
independent predictors of reduced disease-
specific survival. We could stratify OCC into 
4 prognostic groups and showed that they 
had similar expected rates of response to 
immunotherapy. Our data may serve to 
design a biomarker-driven clinical trial 
proposing neoadjuvant chemotherapy or 
immunotherapy to high-risk patients, with the 
goal of reducing the percentage of OCC 
patients that will present with early and 
severe recurrences.  
  
 
 
 
